WorldWideScience

Sample records for actinium d

  1. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

    Energy Technology Data Exchange (ETDEWEB)

    Harvey, James T.; Nolen, Jerry; Vandergrift, George; Gomes, Itacil; Kroc, Tom; Horwitz, Phil; McAlister, Dan; Bowers, Del; Sullivan, Vivian; Greene, John

    2011-12-30

    The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces {approx}100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 Ge

  2. Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposes.

    Science.gov (United States)

    Radchenko, V; Engle, J W; Wilson, J J; Maassen, J R; Nortier, F M; Taylor, W A; Birnbaum, E R; Hudston, L A; John, K D; Fassbender, M E

    2015-02-06

    Actinium-225 (t1/2=9.92d) is an α-emitting radionuclide with nuclear properties well-suited for use in targeted alpha therapy (TAT), a powerful treatment method for malignant tumors. Actinium-225 can also be utilized as a generator for (213)Bi (t1/2 45.6 min), which is another valuable candidate for TAT. Actinium-225 can be produced via proton irradiation of thorium metal; however, long-lived (227)Ac (t1/2=21.8a, 99% β(-), 1% α) is co-produced during this process and will impact the quality of the final product. Thus, accurate assays are needed to determine the (225)Ac/(227)Ac ratio, which is dependent on beam energy, irradiation time and target design. Accurate actinium assays, in turn, require efficient separation of actinium isotopes from both the Th matrix and highly radioactive activation by-products, especially radiolanthanides formed from proton-induced fission. In this study, we introduce a novel, selective chromatographic technique for the recovery and purification of actinium isotopes from irradiated Th matrices. A two-step sequence of cation exchange and extraction chromatography was implemented. Radiolanthanides were quantitatively removed from Ac, and no non-Ac radionuclidic impurities were detected in the final Ac fraction. An (225)Ac spike added prior to separation was recovered at ≥ 98%, and Ac decontamination from Th was found to be ≥ 10(6). The purified actinium fraction allowed for highly accurate (227)Ac determination at analytical scales, i.e., at (227)Ac activities of 1-100 kBq (27 nCi to 2.7 μCi). Copyright © 2014 Elsevier B.V. All rights reserved.

  3. Spectroscopic and computational investigation of actinium coordination chemistry

    Science.gov (United States)

    Ferrier, Maryline G.; Batista, Enrique R.; Berg, John M.; Birnbaum, Eva R.; Cross, Justin N.; Engle, Jonathan W.; La Pierre, Henry S.; Kozimor, Stosh A.; Lezama Pacheco, Juan S.; Stein, Benjamin W.; Stieber, S. Chantal E.; Wilson, Justin J.

    2016-08-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, AcIII reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac-Cl and Ac-OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between AcIII and AmIII in HCl solutions indicate AcIII coordinates more inner-sphere Cl1- ligands (3.2+/-1.1) than AmIII (0.8+/-0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique AcIII chemical behaviour.

  4. Spectroscopic and computational investigation of actinium coordination chemistry

    Science.gov (United States)

    Ferrier, Maryline G.; Batista, Enrique R.; Berg, John M.; Birnbaum, Eva R.; Cross, Justin N.; Engle, Jonathan W.; La Pierre, Henry S.; Kozimor, Stosh A.; Lezama Pacheco, Juan S.; Stein, Benjamin W.; Stieber, S. Chantal E.; Wilson, Justin J.

    2016-01-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, AcIII reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac–Cl and Ac–OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between AcIII and AmIII in HCl solutions indicate AcIII coordinates more inner-sphere Cl1– ligands (3.2±1.1) than AmIII (0.8±0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique AcIII chemical behaviour. PMID:27531582

  5. Discovery of the actinium, thorium, protactinium, and uranium isotopes

    CERN Document Server

    Fry, C

    2012-01-01

    Currently, 31 actinium, 31 thorium, 28 protactinium, and 23 uranium isotopes have so far been observed; the discovery of these isotopes is discussed. For each isotope a brief summary of the first refereed publication, including the production and identification method, is presented.

  6. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources.

    Science.gov (United States)

    Soderquist, Chuck Z; McNamara, Bruce K; Fisher, Darrell R

    2012-07-01

    Radium-223 is a short-lived alpha-particle-emitting radionuclide with potential applications in cancer treatment. Research to develop new radiopharmaceuticals employing (223)Ra has been hindered by poor availability due to the small quantities of parent actinium-227 available world-wide. The purpose of this study was to develop innovative and cost-effective methods to obtain high-purity (223)Ra from (227)Ac. We obtained (227)Ac from two surplus actinium-beryllium neutron generators. We retrieved the actinium/beryllium buttons from the sources and dissolved them in a sulfuric-nitric acid solution. A crude actinium solid was recovered from the solution by coprecipitation with thorium fluoride, leaving beryllium in solution. The crude actinium was purified to provide about 40 milligrams of actinium nitrate using anion exchange in methanol-water-nitric acid solution. The purified actinium was then used to generate high-purity (223)Ra. We extracted (223)Ra using anion exchange in a methanol-water-nitric acid solution. After the radium was separated, actinium and thorium were then eluted from the column and dried for interim storage. This single-pass separation produces high purity, carrier-free (223)Ra product, and does not disturb the (227)Ac/(227)Th equilibrium. A high purity, carrier-free (227)Th was also obtained from the actinium using a similar anion exchange in nitric acid. These methods enable efficient production of (223)Ra for research and new alpha-emitter radiopharmaceutical development.

  7. Relativistic small-core pseudopotentials for actinium, thorium, and protactinium.

    Science.gov (United States)

    Weigand, Anna; Cao, Xiaoyan; Hangele, Tim; Dolg, Michael

    2014-04-03

    Small-core pseudopotentials for actinium, thorium, and protactinium have been energy-adjusted to multiconfiguration Dirac-Hartree-Fock reference data based on the Dirac-Coulomb-Breit Hamiltonian and the Fermi nucleus model. Corresponding optimized valence basis sets of polarized valence quadruple-ζ quality are presented. Atomic test calculations for the first four ionization potentials show satisfactory results at both the Hartree-Fock and the multireference averaged coupled-pair functional level. Highly correlated Fock-space coupled cluster calculations demonstrate that the new pseudopotentials yield ionization potentials, which are in excellent agreement with corresponding all-electron results and experimental data. The pseudopotentials and basis sets supplement a similar set previously published for uranium.

  8. Effects of spin-orbit coupling on actinium under pressure

    Energy Technology Data Exchange (ETDEWEB)

    Rubio-Ponce, A.; Rivera, J. [Departamento de Ciencias Basicas, Universidad Autonoma Metropolitana-Azcapotzalco, Mexico (Mexico); Olguin, D. [Departamento de Fi sica, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico (Mexico)

    2015-04-15

    Actinium (Ac) is a radioactive metal and the first element of the actinide series. At ambient conditions Ac crystallizes in the fcc lattice, however, up to date its phase diagram is unknown. In the present work, we have studied the structural and electronic properties of Ac under hydrostatic pressure assuming the fcc structure as well as three hypothetical structures, namely the hcp, bcc, and sc, and for pressures up to 100 GPa. From our calculations, we found only one structural transition allowed, from the fcc to hcp, our calculated pressure was 39.85 GPa. The calculations were performed by means of the full potential linearized augmented plane wave (FLAPW) method and the generalized gradient approximation (GGA) for the exchange-correlation energy, where we have included in our study the spin-orbit coupling which is important for heavy elements. The total energy results were fitted to the third order Birch-Murnaghan's equation of state. (copyright 2015 WILEY-VCH Verlag GmbH and Co. KGaA, Weinheim)

  9. Report for General Research September 18 to December 11, 1950 (Actinium Volume)

    Energy Technology Data Exchange (ETDEWEB)

    Haring, M.M.

    1951-01-15

    The purpose of the research work presented in this volume is to develop a process for the separation and purification of actinium-227 produced by neutron bombardment of radium-226 and to develop methods by which uniform films of actinium metal may be deposited on metallic surfaces. The design work on the cave structure and mechanical equipment used in the actinium separation is proceeding on schedule. As the mechanical design phase is nearing completion the emphasis is being directed toward processing equipment. The process as well as the mechanical equipment has been adapted from the research work of F. T. Hagemann and the Remote Control Group at Argonne National Laboratory. Consequently, one of the first objectives is to become familiary with the chemistry of the process and the operation of the mechanical equipment. Cold runs have been made on the T.T.A. benzene extraction using lanthanum and barium in place of actinium and radium. No difficulty with the operation was observed. The formation of precipitates was one of the difficulties encountered with the process as the precipitates carry radium. It has been found that metals such as nickel cause these precipitates to form and should, therefore, be avoided in the construction of equipment. it was also found that a T.T.A. solution exposed to 0.5 curie of polonium over a period of days develops a precipitate. Some new mechanical features hav eshown promise. The use of copper-coated glassware which will hold together even though the glass is cracked has made it possible to replace custom-built heaters with standard heating mantles. A new graphite, silicone grease mixture appears to hold up in stopcocks handling benzene and, as a result, may eliminate the necessary of entering the cave for regreasing. Tests on the preparation of dense concrete have given results which meet the shielding requirements for the cave. A strippable paint and tape combination has been studied and specified to provide for decontamination of

  10. Analysis of the gamma spectra of the uranium, actinium, and thorium decay series

    Energy Technology Data Exchange (ETDEWEB)

    Momeni, M.H.

    1981-09-01

    This report describes the identification of radionuclides in the uranium, actinium, and thorium series by analysis of gamma spectra in the energy range of 40 to 1400 keV. Energies and absolute efficiencies for each gamma line were measured by means of a high-resolution germanium detector and compared with those in the literature. A gamma spectroscopy method, which utilizes an on-line computer for deconvolution of spectra, search and identification of each line, and estimation of activity for each radionuclide, was used to analyze soil and uranium tailings, and ore.

  11. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.

    Science.gov (United States)

    Henriksen, Gjermund; Bruland, Oyvind S; Larsen, Roy H

    2004-01-01

    The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mice at four hours after injection. All three bone-seeking agents showed a high uptake in bone and a low uptake in soft tissues. Among the soft tissue organs, only kidney had a relatively high uptake. The femur/kidney ratios for 227Th-DTMP, 228-Ac-DOTMP and 227Th-DOTMP were 14.2, 7.6 and 6.0, respectively. A higher liver uptake of 228Ac-DOTMP was seen than for 227Th-DTMP and 227Th-DOTMP. This suggests that some demetallation of the 228Ac-DOTMP complex had occurred. The results indicate that 225Ac-DOTMP, 227Th-DOTMP and 227Th-DTMP have promising properties as potential therapeutic bone-seeking agents.

  12. Developments towards in-gas-jet laser spectroscopy studies of actinium isotopes at LISOL

    Energy Technology Data Exchange (ETDEWEB)

    Raeder, S., E-mail: s.raeder@gsi.de [KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, B-3001 Leuven (Belgium); Helmholtz-Institut Mainz, 55128 Mainz (Germany); GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt (Germany); Bastin, B. [GANIL, CEA/DSM-CNRS/IN2P3, B.P. 55027, 14076 Caen (France); Block, M. [Helmholtz-Institut Mainz, 55128 Mainz (Germany); GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt (Germany); Institut für Kernchemie, Johannes Gutenberg Universität, 55128 Mainz (Germany); Creemers, P. [KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, B-3001 Leuven (Belgium); Delahaye, P. [GANIL, CEA/DSM-CNRS/IN2P3, B.P. 55027, 14076 Caen (France); Ferrer, R. [KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, B-3001 Leuven (Belgium); Fléchard, X. [LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, Caen (France); Franchoo, S. [Institute de Physique Nucléaire (IPN) d’Orsay, 91406 Orsay, Cedex (France); Ghys, L. [KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, B-3001 Leuven (Belgium); SCK-CEN, Belgian Nuclear Research Center, Boeretang 200, 2400 Mol (Belgium); Gaffney, L.P.; Granados, C. [KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, B-3001 Leuven (Belgium); Heinke, R. [Institut für Physik, Johannes Gutenberg Universität, 55128 Mainz (Germany); Hijazi, L. [GANIL, CEA/DSM-CNRS/IN2P3, B.P. 55027, 14076 Caen (France); and others

    2016-06-01

    To study exotic nuclides at the borders of stability with laser ionization and spectroscopy techniques, highest efficiencies in combination with a high spectral resolution are required. These usually opposing requirements are reconciled by applying the in-gas-laser ionization and spectroscopy (IGLIS) technique in the supersonic gas jet produced by a de Laval nozzle installed at the exit of the stopping gas cell. Carrying out laser ionization in the low-temperature and low density supersonic gas jet eliminates pressure broadening, which will significantly improve the spectral resolution. This article presents the required modifications at the Leuven Isotope Separator On-Line (LISOL) facility that are needed for the first on-line studies of in-gas-jet laser spectroscopy. Different geometries for the gas outlet and extraction ion guides have been tested for their performance regarding the acceptance of laser ionized species as well as for their differential pumping capacities. The specifications and performance of the temporarily installed high repetition rate laser system, including a narrow bandwidth injection-locked Ti:sapphire laser, are discussed and first preliminary results on neutron-deficient actinium isotopes are presented indicating the high capability of this novel technique.

  13. Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141 MeV

    Energy Technology Data Exchange (ETDEWEB)

    Ermolaev, S.V.; Zhuikov, B.L.; Kokhanyuk, V.M.; Matushko, V.L. [Russian Academy of Sciences, Moscow (Russian Federation). Inst. of Nuclear Research; Kalmykov, S.N. [Lomonosov Moscow State Univ., Moscow (Russian Federation). Chemistry Dept.; Aliev, R.A. [Lomonosov Moscow State Univ., Moscow (Russian Federation). Skobeltsyn Inst. of Nuclear Physics; Tananaev, I.G.; Myasoedov, B.F. [Russian Academy of Sciences, Moscow (Russian Federation). A.N. Frumkin Inst. of Physical Chemistry and Electrochemistry

    2012-07-01

    Cross sections of {sup 225}Ac, {sup 227}Ac, {sup 227}Th and {sup 228}Th in thorium-232 targets irradiated with protons in the energy range 21-141 MeV have been measured. Based on these data, production yields of {sup 225}Ac and {sup 223}Ra in thick thorium targets have been calculated. It is possible to produce in proton energy range 60-140 MeV about 96 GBq (2.6 Ci) {sup 225}Ac per 10-d irradiation with 100 {mu}A proton beam current and 10-d decay, and much higher amount of {sup 223}Ra. The impurities of {sup 227}Ac and {sup 224}Ra are important and need to be assessed for further medical applications. (orig.)

  14. D

    African Journals Online (AJOL)

    that the State is confronted with second order constraints in its relations with both national and ... Assiga Ateba: La nouvelle économie politique en Afrique 91 ...... Pour Jonhson (1997) par exemple Je gouvernement aux affaires est dans ..... nes telles que le respect des règles et du droit d'aînesse, l'importance de la.

  15. Origin of elements of the Uranium-235 family observed in the Ellez river near the EL-4 experimental nuclear reactor in dismantling (Monts d'Arree- Finistere department); Origine des elements de la famille de l'uranium-235 observes dans la riviere Ellez a proximite du reacteur nucleaire experimental EL4 en cours de demantelement (Mont d'Arree - departement du Finistere). Resultats et premiers constats annee 2006

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2006-07-01

    In a previous study which concerned the catchment basin of the harbour of Brest, the A.C.R.O. put in evidence a marking by artificial radioelements around the power plant of Brennilis which can be imputed without ambiguities to the nuclear installation. It also put in evidence abnormalities concerning the natural radioactivity which justifies this new study. In the area of the Monts d'Arree, actinium 227 ({sup 227}Ac), non born by its ascendents which are {sup 235}U and {sup 231}Pa is observed. This phenomenon is characterized by mass activities superior to these ones of {sup 235}U and able to reach these ones of {sup 238}U. Its presence corresponds with the drainage of the Ellez river since the former channel of radioactive effluents releases from the nuclear power plant EL-4 up to the reservoir Saint-Herblot situated 6 km downstream. The strongest values of radioactivity are registered near the disused power plant, at this place a relationship exists between the level of actinium 227 and this one of the artificial radioactivity as it exists a relationship with the decay products of radon exhaled from the subsoil ({sup 210}Pb). But its presence is not limited to a part of the Ellez river, it is equally observed in terrestrial medium, in places in priori not influenced by the direct liquid effluents of the power plant. This place is situated at more than 4 km and without any connection with the Ellez waters. At this stage of the study, it is not possible to answer with certainty the question of the origin of this phenomenon. A new reorientation is considered indispensable to clarify definitively the origin of this unknown phenomenon in the scientific publications and the environmental monitoring. (N.C.)

  16. Production of actinium-225 for alpha particle mediated radioimmunotherapy.

    Science.gov (United States)

    Boll, Rose A; Malkemus, Dairin; Mirzadeh, Saed

    2005-05-01

    The initial clinical trials for treatment of acute myeloid leukemia have demonstrated the effectiveness of the alpha emitter (213)Bi in killing cancer cells. Bismuth-213 is obtained from a radionuclide generator system from decay of 10-days (225)Ac parent. Recent pre-clinical studies have also shown the potential application of both (213)Bi, and the (225)Ac parent radionuclide in a variety of cancer systems and targeted radiotherapy. This paper describes our five years of experience in production of (225)Ac in partial support of the on-going clinical trials. A four-step chemical process, consisting of both anion and cation exchange chromatography, is utilized for routine separation of carrier-free (225)Ac from a mixture of (228)Th, (229)Th and (232)Th. The separation of Ra and Ac from Th is achieved using the marcoporous anion exchange resin MP1 in 8M HNO(3) media. Two sequential MP1/NO(3) columns provide a separation factor of approximately 10(6) for Ra and Ac from Th. The separation of Ac from Ra is accomplished on a low cross-linking cation exchange resin AG50-X4 using 1.2M HNO(3) as eluant. Two sequential AG50/NO(3) columns provide a separation factor of approximately 10(2) for Ac from Ra. A 60-day processing schedule has been adopted in order to reduce the processing cost and to provide the highest levels of (225)Ac possible. Over an 8-week campaign, a total of approximately 100 mCi of (225)Ac (approximately 80% of the theoretical yield) is shipped in 5-6 batches, with the first batch typically consisting of approximately 50 mCi. After the initial separation and purification of Ac, the Ra pool is re-processed on a bi-weekly schedule or as needed to provide smaller batches of (225)Ac. The averaged radioisotopic purity of the (225)Ac was 99.6 +/- 0.7% with a (225)Ra content of < or =0.6%, and an average (229)Th content of (4(-4)(+5)) x 10(-5)%.

  17. Isolation of Actinium from Neutron-irradiated Thorium-I

    Institute of Scientific and Technical Information of China (English)

    1994-01-01

    Isolation of Actinium from Neutron-irradiated Thorium-I¥YangWeifan;YuanShuanggui;MuWantong;ZhangXueqian;LiZhongweiandZhaoLili...

  18. Runco D-113d

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    Runco最新的D-113d3D投影机系统,一体化的机身设计,搭配先进的CSV(Constant Stereoscopic Video)技术和Panavision 3D System光学滤镜技术,能实现超高亮度的输出,最高可在400英寸的超大银幕上投射出卓越的3D及2D画面。

  19. Vitamin D

    Science.gov (United States)

    ... body needs to grow and develop normally. Vitamin D helps your body absorb calcium. Calcium is one ... building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis ...

  20. Vitamin D

    Science.gov (United States)

    ... thin, and brittle bones, a condition known as rickets in children and osteomalacia in adults. Vitamin D ... the body. In children, vitamin D deficiency causes rickets, where the bones become soft and bend. It's ...

  1. Hipovitaminosis D

    Directory of Open Access Journals (Sweden)

    M. Patricio Trincado, Dr.

    2013-09-01

    Full Text Available La vitamina D es estructuralmente una hormona producida por la piel cuya función es captar calcio desde el medio externo. Se revisa brevemente su metabolismo y las consecuencias de la hipovitaminosis D. Se describe ostemalacia y miopatia por hipovitaminosis D y su tratamiento al igual que las recomendaciones actuales de aporte de vitamina D en diferentes grupos etarios. Dado que el objetivo principal es referirse a las acciones clásicas, se resumen las no clásicas en tabla al final del artículo.

  2. Hadronic production of D (2550 ) , D*(2600 ) , D (2750 ) , D1*(2760 ) , and D3*(2760 )

    Science.gov (United States)

    Zhao, Ze; Tian, Yu; Zhang, Ailin

    2016-12-01

    Hadronic decays of radially excited 2 D D (2 3D1) , D (2 3D3) , D (2 D2) , and D (2 D2') have been studied in a 3P0 model. All Okubo-Zweig-Iizuka-allowed decay channels of these 2 D D resonances have been given, and relevant decay widths have been calculated. D (2550 ), D*(2600 ), D (2750 ), D1*(2760 ), and D3*(2760 ) can be produced in hadronic decays of D (2 3D1) , D (2 3D3) , D (2 D2), and D (2 D2'). In different assignments, hadronic decay widths and some relevant ratios from the 2 D D resonances to D (2550 ), D*(2600 ), D (2750 ), D1*(2760 ), or D3*(2760 ) final states have been predicted, which may provide more information to identify these resonances in forthcoming experiments.

  3. Hadronic production of $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ and $D^*_3(2760)$

    CERN Document Server

    Zhao, Ze; Zhang, Ailin

    2016-01-01

    Hadronic decays of radially excited $2D$ $D(2^3D_1)$, $D(2^3D_3)$, $D(2D_2)$ and $D(2D^\\prime_2)$ have been studied in a $^3P_0$ model. All OZI-allowed decay channels of these $2D$ $D$ resonances have been given, and relevant decay widths have been calculated. $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ and $D^*_3(2760)$ can be produced in hadronic decays of $D(2^3D_1)$, $D(2^3D_3)$, $D(2D_2)$ and $D(2D^\\prime_2)$. In different assignments, hadronic decay widths and some relevant ratios from the $2D$ $D$ resonances to $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ or $D^*_3(2760)$ final states have been predicted, which may provide some more information to identify these resonances in forthcoming experiments.

  4. Vitamin D

    Science.gov (United States)

    ... Because exposure to sunlight is a risk for skin cancer, you should use sunscreen after a few minutes in the sun. People who do not live in sunny places may not make enough vitamin D. Skin that is exposed to sunshine indoors through a ...

  5. Vitamine D2 ou vitamine D3?

    OpenAIRE

    MISTRETTA, Virginie; Delanaye, Pierre; Chapelle, Jean-Paul; Souberbielle, Jean-Claude; Cavalier, Etienne

    2008-01-01

    PURPOSE: Nearly one billion people around the world are deficient in vitamin D and need to be supplemented. Vitamin D is available in medicines and fortified foods. It is available in two forms: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). KEY POINTS: The pharmacopeiae consider these steroid hormones as equivalent and interchangeable. However, several studies have showed that serum level of 25(OH)D is increased more effectively with vitamin D3 than vitamin D2. Vitamin D2 has ...

  6. D2 to D2

    Science.gov (United States)

    Ezhuthachan, Bobby; Mukhi, Sunil; Papageorgakis, Constantinos

    2008-07-01

    Starting from maximally supersymmetric (2+1)d Yang-Mills theory and using a duality transformation due to de Wit, Nicolai and Samtleben, we obtain the ghost-free Lorentzian 3-algebra theory that has recently been proposed to describe M2-branes. Our derivation does not invoke any properties of 3-algebras. Being derivable from SYM, the final theory is manifestly equivalent to it on-shell and should not be thought of as the IR limit that describes M2-branes, though it does have enhanced R-symmetry as well as superconformal symmetry off-shell.

  7. D2 to D2

    CERN Document Server

    Ezhuthachan, Bobby; Papageorgakis, Constantinos

    2008-01-01

    Starting from maximally supersymmetric (2+1)d Yang-Mills theory and using a duality transformation due to de Wit, Nicolai and Samtleben, we obtain the ghost-free Lorentzian 3-algebra theory that has recently been proposed to describe M2-branes. Our derivation does not invoke any properties of 3-algebras. Being derivable from SYM, the final theory is manifestly equivalent to it on-shell and should not be thought of as the IR limit that describes M2-branes, though it does have enhanced R-symmetry as well as superconformal symmetry off-shell.

  8. Color suppressed contributions to the decay modes B_{d,s} -> D_{s,d} D_{s,d}, B_{d,s} -> D_{s,d} D^*_{s,d}, and B_{d,s} -> D^*_{s,d} D^*_{s,d}

    OpenAIRE

    Eeg, Jan O.; Fajfer, Svjetlana; Prapotnik, Anita

    2005-01-01

    The amplitudes for decays of the type $B_{d,s} \\to D_{s,d} D_{s,d}$, have no factorizable contributions, while $B_{d,s} \\to D_{s,d} D^*_{s,d}$, and $B_{d,s} \\to D^*_{s,d} D^*_{s,d}$ have relatively small factorizable contributions through the annihilation mechanism. The dominant contributions to the decay amplitudes arise from chiral loop contributions and tree level amplitudes which can be obtained in terms of soft gluon emissions forming a gluon condensate. We predict that the branching rat...

  9. Color suppressed contributions to the decay modes B_{d,s} -> D_{s,d} D_{s,d}, B_{d,s} -> D_{s,d} D^*_{s,d}, and B_{d,s} -> D^*_{s,d} D^*_{s,d}

    OpenAIRE

    Eeg, Jan O.; Fajfer, Svjetlana; Prapotnik, Anita

    2005-01-01

    The amplitudes for decays of the type $B_{d,s} \\to D_{s,d} D_{s,d}$, have no factorizable contributions, while $B_{d,s} \\to D_{s,d} D^*_{s,d}$, and $B_{d,s} \\to D^*_{s,d} D^*_{s,d}$ have relatively small factorizable contributions through the annihilation mechanism. The dominant contributions to the decay amplitudes arise from chiral loop contributions and tree level amplitudes which can be obtained in terms of soft gluon emissions forming a gluon condensate. We predict that the branching rat...

  10. Radium-228 analysis of natural waters by Cherenkov counting of Actinium-228

    Energy Technology Data Exchange (ETDEWEB)

    Aleissa, Khalid A.; Almasoud, Fahad I.; Islam, Mohammed S. [Atomic Energy Research Institute, King Abdul Aziz City for Science and Technology, P.O. Box 6086, Riyadh 11442 (Saudi Arabia); L' Annunziata, Michael F. [IAEA Expert, Montague Group, P.O. Box 5033, Oceanside, CA 92052-5033 (United States)], E-mail: mlannunziata@cox.net

    2008-12-15

    The activities of {sup 228}Ra in natural waters were determined by the Cherenkov counting of the daughter nuclide {sup 228}Ac. The radium was pre-concentrated on MnO{sub 2} and the radium purified via ion exchange and, after a 2-day period of incubation to allow for secular equilibrium between the parent-daughter {sup 228}Ra({sup 228}Ac), the daughter nuclide {sup 228}Ac was isolated by ion exchange according to the method of Nour et al. [2004. Radium-228 determination of natural waters via concentration on manganese dioxide and separation using Diphonix ion exchange resin. Appl. Radiat. Isot. 61, 1173-1178]. The Cherenkov photons produced by {sup 228}Ac were counted directly without the addition of any scintillation reagents. The optimum Cherenkov counting window, sample volume, and vial type were determined experimentally to achieve optimum Cherenkov photon detection efficiency and lowest background count rates. An optimum detection efficiency of 10.9{+-}0.1% was measured for {sup 228}Ac by Cherenkov counting with a very low Cherenkov photon background of 0.317{+-}0.013 cpm. The addition of sodium salicylate into the sample counting vial at a concentration of 0.1 g/mL yielded a more than 3-fold increase in the Cherenkov detection efficiency of {sup 228}Ac to 38%. Tests of the Cherenkov counting technique were conducted with several water standards of known activity and the results obtained compared closely with a conventional liquid scintillation counting technique. The advantages and disadvantages of Cherenkov counting compared to liquid scintillation counting methods are discussed. Advantages include much lower Cherenkov background count rates and consequently lower minimal detectable activities for {sup 228}Ra and no need for expensive environmentally unfriendly liquid scintillation cocktails. The disadvantages of the Cherenkov counting method include the need to measure {sup 228}Ac Cherenkov photon detection efficiency and optimum Cherenkov counting volume, which are not at all required when liquid scintillation analysis is used.

  11. Radium-228 analysis of natural waters by Cherenkov counting of Actinium-228.

    Science.gov (United States)

    Aleissa, Khalid A; Almasoud, Fahad I; Islam, Mohammed S; L'Annunziata, Michael F

    2008-12-01

    The activities of (228)Ra in natural waters were determined by the Cherenkov counting of the daughter nuclide (228)Ac. The radium was pre-concentrated on MnO(2) and the radium purified via ion exchange and, after a 2-day period of incubation to allow for secular equilibrium between the parent-daughter (228)Ra((228)Ac), the daughter nuclide (228)Ac was isolated by ion exchange according to the method of Nour et al. [2004. Radium-228 determination of natural waters via concentration on manganese dioxide and separation using Diphonix ion exchange resin. Appl. Radiat. Isot. 61, 1173-1178]. The Cherenkov photons produced by (228)Ac were counted directly without the addition of any scintillation reagents. The optimum Cherenkov counting window, sample volume, and vial type were determined experimentally to achieve optimum Cherenkov photon detection efficiency and lowest background count rates. An optimum detection efficiency of 10.9+/-0.1% was measured for (228)Ac by Cherenkov counting with a very low Cherenkov photon background of 0.317+/-0.013cpm. The addition of sodium salicylate into the sample counting vial at a concentration of 0.1g/mL yielded a more than 3-fold increase in the Cherenkov detection efficiency of (228)Ac to 38%. Tests of the Cherenkov counting technique were conducted with several water standards of known activity and the results obtained compared closely with a conventional liquid scintillation counting technique. The advantages and disadvantages of Cherenkov counting compared to liquid scintillation counting methods are discussed. Advantages include much lower Cherenkov background count rates and consequently lower minimal detectable activities for (228)Ra and no need for expensive environmentally unfriendly liquid scintillation cocktails. The disadvantages of the Cherenkov counting method include the need to measure (228)Ac Cherenkov photon detection efficiency and optimum Cherenkov counting volume, which are not at all required when liquid scintillation analysis is used.

  12. Purification of selenium from thorium, uranium, radium, actinium and potassium impurities for low background measurements

    Energy Technology Data Exchange (ETDEWEB)

    Rakhimov, A.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz); Warot, G. [CEA-CNRS, Modane (France). Laboratoire Souterrain de Modane (LSM); Karaivanov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Institute for Nuclear Research and Nuclear Energy (INRNE), Sofia (Bulgaria); Kochetov, O.I.; Lebedev, N.A.; Filosofov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Mukhamedshina, N.M.; Sadikov, I.I. [Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz)

    2013-07-01

    A technique of selenium purification from {sup 232}Th, {sup 238}U, {sup 226,228}Ra, {sup 227}Ac and {sup 40}K was developed. This technique is simple to perform and employs a minimum number of highly pure reagents (bidistilled water, nitric acid). Operations carried out during purification (elution, evaporation) practically exclude losses of the target product (chemical yields of Se > 99%). A test purification of 100 g of selenium was carried out using this technique. The efficiency of this technique was confirmed by low background gamma spectrometry of the purified selenium sample. Distribution coefficients of Th, U, Ra and Ac on DOWEX 50W- x 8 cation-exchange resin at different concentrations of selenium and nitric acid were experimentally determinated. Instrumental neutron activation analysis of bidistilled water, deionized water and nitric acid was performed. (orig.)

  13. The release of dissolved actinium to the ocean: A global comparison of different end-members

    Science.gov (United States)

    Geibert, W.; Charette, M.; Kim, G.; Moore, W.S.; Street, J.; Young, M.; Paytan, A.

    2008-01-01

    The measurement of short-lived 223Ra often involves a second measurement for supported activities, which represents 227Ac in the sample. Here we exploit this fact, presenting a set of 284 values on the oceanic distribution of 227Ac, which was collected when analyzing water samples for short-lived radium isotopes by the radium delayed coincidence counting system. The present work compiles 227Ac data from coastal regions all over the northern hemisphere, including values from ground water, from estuaries and lagoons, and from marine end-members. Deep-sea samples from a continental slope off Puerto Rico and from an active vent site near Hawaii complete the overview of 227Ac near its potential sources. The average 227Ac activities of nearshore marine end-members range from 0.4??dpm m- 3 at the Gulf of Mexico to 3.0??dpm m- 3 in the coastal waters of the Korean Strait. In analogy to 228Ra, we find the extension of adjacent shelf regions to play a substantial role for 227Ac activities, although less pronounced than for radium, due to its weaker shelf source. Based on previously published values, we calculate an open ocean 227Ac inventory of 1.35 * 1018??dpm 227Acex in the ocean, which corresponds to 37??moles, or 8.4??kg. This implies a flux of 127??dpm m-2 y- 1 from the deep-sea floor. For the shelf regions, we obtain a global inventory of 227Ac of 4.5 * 1015??dpm, which cannot be converted directly into a flux value, as the regional loss term of 227Ac to the open ocean would have to be included. Ac has so far been considered to behave similarly to Ra in the marine environment, with the exception of a strong Ac source in the deep-sea due to 231Paex. Here, we present evidence of geochemical differences between Ac, which is retained in a warm vent system, and Ra, which is readily released [Moore, W.S., Ussler, W. and Paull, C.K., 2008-this issue. Short-lived radium isotopes in the Hawaiian margin: Evidence for large fluid fluxes through the Puna Ridge. Marine Chemistry]. Another potential mechanism of producing deviations in 227Ac/228Ra and daughter isotope ratios from the expected production value of lithogenic material is observed at reducing environments, where enrichment in uranium may occur. The presented data here may serve as a reference for including 227Ac in circulation models, and the overview provides values for some end-members that contribute to the global Ac distribution. ?? 2007 Elsevier B.V. All rights reserved.

  14. D-D tokamak reactor studies

    Energy Technology Data Exchange (ETDEWEB)

    Evans, K.E. Jr.; Baker, C.C.; Brooks, J.N.; Ehst, D.A.; Finn, P.A.; Jung, J.; Mattas, R.F.; Misra, B.; Smith, D.L.; Stevens, H.C.

    1980-11-01

    A tokamak D-D reactor design, utilizing the advantages of a deuterium-fueled reactor but with parameters not unnecessarily extended from existing D-T designs, is presented. Studies leading to the choice of a design and initial studies of the design are described. The studies are in the areas of plasma engineering, first-wall/blanket/shield design, magnet design, and tritium/fuel/vacuum requirements. Conclusions concerning D-D tokamak reactors are stated.

  15. Unsuccessful vitamin D treatment

    DEFF Research Database (Denmark)

    Schmedes, Anne; Hey, Henrik; Larsson, Iben

    2012-01-01

    Vitamin D3 (25-OHD3) analyses have increased exponentially and vitamin D deficiency (vitamin D2). Lack of effect of treatment can be due to: 1......) too low dose, 2) incorrect analytical methods when injection treatment (vitamin D2) is used, 3) obesity, 4) seasonal variations, and 5) poor compliance. Treatment is mandatory in order to prevent osteopenia and osteoporosis. Vitamin D3 is more potent than vitamin D2. Injections with vitamin D2 should...... be replaced by vitamin D3....

  16. Vitamin D and diabetes

    DEFF Research Database (Denmark)

    Wolden-Kirk, Heidi; Overbergh, Lut; Christesen, Henrik Thybo

    2011-01-01

    Experimental evidence indicates that vitamin D may play a role in the defense against type 1 diabetes (T1D) as well as type 2 diabetes (T2D). Epidemiological data have established a link between vitamin D deficiency and an increased incidence of both T1D and T2D, whereas early and long-term vitamin...

  17. 6D Interpretation of 3D Gravity

    Science.gov (United States)

    Herfray, Yannick; Krasnov, Kirill; Scarinci, Carlos

    2017-02-01

    We show that 3D gravity, in its pure connection formulation, admits a natural 6D interpretation. The 3D field equations for the connection are equivalent to 6D Hitchin equations for the Chern–Simons 3-form in the total space of the principal bundle over the 3-dimensional base. Turning this construction around one gets an explanation of why the pure connection formulation of 3D gravity exists. More generally, we interpret 3D gravity as the dimensional reduction of the 6D Hitchin theory. To this end, we show that any \\text{SU}(2) invariant closed 3-form in the total space of the principal \\text{SU}(2) bundle can be parametrised by a connection together with a 2-form field on the base. The dimensional reduction of the 6D Hitchin theory then gives rise to 3D gravity coupled to a topological 2-form field.

  18. 6D Interpretation of 3D Gravity

    CERN Document Server

    Herfray, Yannick; Scarinci, Carlos

    2016-01-01

    We show that 3D gravity, in its pure connection formulation, admits a natural 6D interpretation. The 3D field equations for the connection are equivalent to 6D Hitchin equations for the Chern-Simons 3-form in the total space of the principal bundle over the 3-dimensional base. Turning this construction around one gets an explanation of why the pure connection formulation of 3D gravity exists. More generally, we interpret 3D gravity as the dimensional reduction of the 6D Hitchin theory. To this end, we show that any SU(2) invariant closed 3-form in the total space of the principal SU(2) bundle can be parametrised by a connection together with a 2-form field on the base. The dimensional reduction of the 6D Hitchin theory then gives rise to 3D gravity coupled to a topological 2-form field.

  19. 2D/3D switchable displays

    Science.gov (United States)

    Dekker, T.; de Zwart, S. T.; Willemsen, O. H.; Hiddink, M. G. H.; IJzerman, W. L.

    2006-02-01

    A prerequisite for a wide market acceptance of 3D displays is the ability to switch between 3D and full resolution 2D. In this paper we present a robust and cost effective concept for an auto-stereoscopic switchable 2D/3D display. The display is based on an LCD panel, equipped with switchable LC-filled lenticular lenses. We will discuss 3D image quality, with the focus on display uniformity. We show that slanting the lenticulars in combination with a good lens design can minimize non-uniformities in our 20" 2D/3D monitors. Furthermore, we introduce fractional viewing systems as a very robust concept to further improve uniformity in the case slanting the lenticulars and optimizing the lens design are not sufficient. We will discuss measurements and numerical simulations of the key optical characteristics of this display. Finally, we discuss 2D image quality, the switching characteristics and the residual lens effect.

  20. A note on the B*(B),B*(B)*,D*(D),D*(D)* molecular states

    Institute of Scientific and Technical Information of China (English)

    SUN Zhi-Feng; LUO Zhi-Gang; HE Jun; LIU Xiang; ZHU Shi-Lin

    2012-01-01

    In the framework of the one-boson-exchange model,we have performed an extensive study of the possible B*(B),B*(B)*,D*(D),D*(D)* molecular states with various quantum numbers after considering the S-wave and D-wave mixing.We also discuss the possible experimental research of these interesting states.

  1. Drug: D08227 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Co...rticosteroids, potent (group III) D07AC13 Mometasone D08227 Mometasone (INN) D07X CORTICOSTEROIDS, OTHER COM

  2. Drug: D03813 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids... (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC04 D

  3. Vitamin D Test

    Science.gov (United States)

    ... products and services. Advertising & Sponsorship: Policy | Opportunities Vitamin D Tests Share this page: Was this page helpful? Also known as: Ergocalciferol (Vitamin D 2 ); Cholecalciferol (Vitamin D 3 ); Calcidiol (25-hydroxyvitamin ...

  4. Delta agent (Hepatitis D)

    Science.gov (United States)

    Hepatitis D virus ... Hepatitis D virus (HDV) is found only in people who carry the hepatitis B virus. HDV may make liver ... B virus but who never had symptoms. Hepatitis D infects about 15 million people worldwide. It occurs ...

  5. Vitamin D and Health

    Science.gov (United States)

    ... Service Resources Additional Resources About FAQ Contact Vitamin D and Health Table of Contents Vitamin D Deficiency: ... and Colds Risk of Premature Death References Vitamin D Deficiency: A Global Concern If you live north ...

  6. Calcium D-saccharate

    DEFF Research Database (Denmark)

    Garcia, André Castilho; Hedegaard, Martina Vavrusova; Skibsted, Leif Horsfelt

    2016-01-01

    K-1. Equilibria in supersaturated solutions of calcium d-saccharate seem only to adjust slowly, as seen from calcium activity measurements in calcium d-saccharate solutions made supersaturated by cooling. Solutions formed by isothermal dissolution of calcium d-gluconate in aqueous potassium d......-saccharate becomes spontaneously supersaturated with both d-gluconate and d-saccharate calcium salts, from which only calcium d-saccharate slowly precipitates. Calcium d-saccharate is suggested to act as a stabilizer of supersaturated solutions of other calcium hydroxycarboxylates with endothermic complex formation...

  7. 3D video

    CERN Document Server

    Lucas, Laurent; Loscos, Céline

    2013-01-01

    While 3D vision has existed for many years, the use of 3D cameras and video-based modeling by the film industry has induced an explosion of interest for 3D acquisition technology, 3D content and 3D displays. As such, 3D video has become one of the new technology trends of this century.The chapters in this book cover a large spectrum of areas connected to 3D video, which are presented both theoretically and technologically, while taking into account both physiological and perceptual aspects. Stepping away from traditional 3D vision, the authors, all currently involved in these areas, provide th

  8. 3D Animation Essentials

    CERN Document Server

    Beane, Andy

    2012-01-01

    The essential fundamentals of 3D animation for aspiring 3D artists 3D is everywhere--video games, movie and television special effects, mobile devices, etc. Many aspiring artists and animators have grown up with 3D and computers, and naturally gravitate to this field as their area of interest. Bringing a blend of studio and classroom experience to offer you thorough coverage of the 3D animation industry, this must-have book shows you what it takes to create compelling and realistic 3D imagery. Serves as the first step to understanding the language of 3D and computer graphics (CG)Covers 3D anim

  9. The dS/dS Correspondence

    CERN Document Server

    Alishahiha, M; Silverstein, E; Tong, D; Alishahiha, Mohsen; Karch, Andreas; Silverstein, Eva; Tong, David

    2004-01-01

    We present a holographic duality for the de Sitter static patch which consolidates basic features of its geometry and the behavior of gravity and brane probes, valid on timescales short compared to the decay or Poincare recurrence times. Namely de Sitter spacetime $dS_d(R)$ in $d$ dimensions with curvature radius $R$ is holographically dual to two conformal field theories on $dS_{d-1}(R)$, cut off at an energy scale 1/R where they couple to each other and to $d-1$ dimensional gravity. As part of our analysis, we study brane probes in de Sitter and thermal Anti de Sitter spaces, and interpret the terms in the corresponding DBI action via strongly coupled thermal field theory. This provides a dual field theoretic interpretation of the fact that probes take forever to reach a horizon in general relativity.

  10. Axionic D3-D7 Inflation

    CERN Document Server

    Burgess, C P; Postma, M

    2009-01-01

    We study the motion of a D3 brane moving within a Type IIB string vacuum compactified to 4D on K3 x T_2/Z_2 in the presence of D7 and O7 planes. We work within the effective 4D supergravity describing how the mobile D3 interacts with the lightest bulk moduli of the compactification, including the effects of modulus-stabilizing fluxes. We seek inflationary solutions to the resulting equations, performing our search numerically in order to avoid resorting to approximate parameterizations of the low-energy potential. We consider uplifting from D-terms and from the supersymmetry-breaking effects of anti-D3 branes. We find examples of slow-roll inflation (with anti-brane uplifting) with the mobile D3 moving along the toroidal directions, falling towards a D7-O7 stack starting from the antipodal point. The inflaton turns out to be a linear combination of the brane position and the axionic partner of the K3 volume modulus, and the similarity of the potential along the inflaton direction with that of racetrack inflat...

  11. Disseny d'un amplificador classe D

    OpenAIRE

    Sangüesa Cremades, Kevin

    2010-01-01

    Diseny i muntatge en circuit imprés d'un amplificador commutat classe D. Disseny i testeig dels subsistemes i muntatge i verificació final. Permet treballar amb electrònica analògica i amb commutada, i amb dispositius de potencia mitjana. Potencia de sortida (aprox): 5 - 10 W.

  12. Drug: D01248 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 05CA08 Ethacridine lactate D01248 Acrinol hydrate (JP16) D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AA Acridine derivatives D08AA01 Ethacridin

  13. Drug: D04926 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ion [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other dermatolo...gicals D11AX06 Mequinol D04926 Mequinol (USAN/INN) CAS:

  14. Drug: D00904 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available atologicals D11AX18 Diclofenac D00904 Diclofenac sodium ...fication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other derm

  15. Drug: D08510 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available azole derivatives D01AC14 Sertaconazole D08510 Sertacona...cation [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tri

  16. Drug: D04208 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ssification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST...ne D04208 Flumethasone (USAN); Flumetasone (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticostero

  17. Drug: D06222 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06222 Mixture, Drug Tricitrates (USP) Sodium citrate [DR:D01781 D05855], Potassium citrate [DR:D05578], Cit...ric acid [DR:D00037 D01222] Alkalizer [systemic]; Alkalizer [urinary]; Anti-urolith

  18. Drug: D01711 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iseptics and disinfectants D08AX07 Sodium hypochlorite D...C) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AX Other ant

  19. Drug: D08714 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08714 Mixture, Drug d-Camphor - mentha oil mixt d-Camphor [DR:D06392], Mentha oil ... Peppermint rubber and camphor peppermint D08714 d-Camphor - mentha oil mixt PubChem: 96025397 ...

  20. Drug: D03812 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, ...COSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC04 Diflucortolone D038

  1. EUROPEANA AND 3D

    Directory of Open Access Journals (Sweden)

    D. Pletinckx

    2012-09-01

    Full Text Available The current 3D hype creates a lot of interest in 3D. People go to 3D movies, but are we ready to use 3D in our homes, in our offices, in our communication? Are we ready to deliver real 3D to a general public and use interactive 3D in a meaningful way to enjoy, learn, communicate? The CARARE project is realising this for the moment in the domain of monuments and archaeology, so that real 3D of archaeological sites and European monuments will be available to the general public by 2012. There are several aspects to this endeavour. First of all is the technical aspect of flawlessly delivering 3D content over all platforms and operating systems, without installing software. We have currently a working solution in PDF, but HTML5 will probably be the future. Secondly, there is still little knowledge on how to create 3D learning objects, 3D tourist information or 3D scholarly communication. We are still in a prototype phase when it comes to integrate 3D objects in physical or virtual museums. Nevertheless, Europeana has a tremendous potential as a multi-facetted virtual museum. Finally, 3D has a large potential to act as a hub of information, linking to related 2D imagery, texts, video, sound. We describe how to create such rich, explorable 3D objects that can be used intuitively by the generic Europeana user and what metadata is needed to support the semantic linking.

  2. Drug: D05815 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fungal; Antiseborrheic ATC code: D01AE13 D11AC03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGIC...ALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other... antifungals for topical use D01AE13 Selenium sulfide D05815 Selenium sulfide (USP) D11 OTHER DERMATOLOGIC...AL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AC Medicated shampoos D11

  3. Drug: D09058 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09058 Formula, Drug Kamigedokuto Coptis rhizome [DR:D00092], Scutellaria root [DR:...D06688], Phellodendron bark [DR:D06689], Gardenia fruit [DR:D06731], Bupleurum root [DR:D06727], Artemisia c...:D06895], Cimicifuga rhizome [DR:D06745], Glycyrrhiza [DR:D04365], Rush [ED:E0029

  4. Vitamin D and allergies

    Directory of Open Access Journals (Sweden)

    Gafvelin Guro

    2013-01-01

    Full Text Available An increasing amount of evidence has established that the biologically active form of vitamin D, 1,25-dihydroxy vitamin D3, possesses immunoregulatory properties. Vitamin D exerts its effects through binding to the nuclear vitamin D receptor (VDR, which is expressed by cells of the immune system. Most of the immunological effects mediated by vitamin D-VDR are regulatory, inhibiting adaptive immune responses. It has become apparent that the incidence of vitamin D insufficiency is surprisingly high in the general population. A link between low vitamin D serum levels and the increased prevalence of allergic diseases has been proposed. This possible connection has been investigated in numerous studies on associations between vitamin D serum concentrations and different allergic conditions, as well as studies on the effect of vitamin D supplementation. Although there is some evidence for a protective role of vitamin D in asthma, no consensus on the role of vitamin D in allergic disease has yet been reached. Still, treatment strategies involving vitamin D supplementation to risk groups, combinatorial corticosteroid and vitamin D treatment in asthma and vitamin D as an immunomodulator in allergen specific immunotherapy show promise for the future.

  5. First observations of $\\bar{B}_s^0\\to D^+D^-$, $D_s^+D^-$ and $D^0\\bar{D}^0$ decays

    CERN Document Server

    Aaij, R; Adeva, B; Adinolfi, M; Adrover, C; Affolder, A; Ajaltouni, Z; Albrecht, J; Alessio, F; Alexander, M; Ali, S; Alkhazov, G; Alvarez Cartelle, P; Alves Jr, A A; Amato, S; Amerio, S; Amhis, Y; Anderlini, L; Anderson, J; Andreassen, R; Appleby, R B; Aquines Gutierrez, O; Archilli, F; Artamonov, A; Artuso, M; Aslanides, E; Auriemma, G; Bachmann, S; Back, J J; Baesso, C; Balagura, V; Baldini, W; Barlow, R J; Barschel, C; Barsuk, S; Barter, W; Bauer, Th; Bay, A; Beddow, J; Bedeschi, F; Bediaga, I; Belogurov, S; Belous, K; Belyaev, I; Ben-Haim, E; Benayoun, M; Bencivenni, G; Benson, S; Benton, J; Berezhnoy, A; Bernet, R; Bettler, M -O; van Beuzekom, M; Bien, A; Bifani, S; Bird, T; Bizzeti, A; Bjørnstad, P M; Blake, T; Blanc, F; Blouw, J; Blusk, S; Bocci, V; Bondar, A; Bondar, N; Bonivento, W; Borghi, S; Borgia, A; Bowcock, T J V; Bowen, E; Bozzi, C; Brambach, T; van den Brand, J; Bressieux, J; Brett, D; Britsch, M; Britton, T; Brook, N H; Brown, H; Burducea, I; Bursche, A; Busetto, G; Buytaert, J; Cadeddu, S; Callot, O; Calvi, M; Calvo Gomez, M; Camboni, A; Campana, P; Carbone, A; Carboni, G; Cardinale, R; Cardini, A; Carranza-Mejia, H; Carson, L; Carvalho Akiba, K; Casse, G; Cattaneo, M; Cauet, Ch; Charles, M; Charpentier, Ph; Chen, P; Chiapolini, N; Chrzaszcz, M; Ciba, K; Cid Vidal, X; Ciezarek, G; Clarke, P E L; Clemencic, M; Cliff, H V; Closier, J; Coca, C; Coco, V; Cogan, J; Cogneras, E; Collins, P; Comerma-Montells, A; Contu, A; Cook, A; Coombes, M; Coquereau, S; Corti, G; Couturier, B; Cowan, G A; Craik, D; Cunliffe, S; Currie, R; D'Ambrosio, C; David, P; David, P N Y; De Bonis, I; De Bruyn, K; De Capua, S; De Cian, M; De Miranda, J M; De Oyanguren Campos, M; De Paula, L; De Silva, W; De Simone, P; Decamp, D; Deckenhoff, M; Del Buono, L; Derkach, D; Deschamps, O; Dettori, F; Di Canto, A; Dijkstra, H; Dogaru, M; Donleavy, S; Dordei, F; Dosil Suárez, A; Dossett, D; Dovbnya, A; Dupertuis, F; Dzhelyadin, R; Dziurda, A; Dzyuba, A; Easo, S; Egede, U; Egorychev, V; Eidelman, S; van Eijk, D; Eisenhardt, S; Eitschberger, U; Ekelhof, R; Eklund, L; El Rifai, I; Elsasser, Ch; Elsby, D; Falabella, A; Färber, C; Fardell, G; Farinelli, C; Farry, S; Fave, V; Ferguson, D; Fernandez Albor, V; Ferreira Rodrigues, F; Ferro-Luzzi, M; Filippov, S; Fitzpatrick, C; Fontana, M; Fontanelli, F; Forty, R; Francisco, O; Frank, M; Frei, C; Frosini, M; Furcas, S; Furfaro, E; Gallas Torreira, A; Galli, D; Gandelman, M; Gandini, P; Gao, Y; Garofoli, J; Garosi, P; Garra Tico, J; Garrido, L; Gaspar, C; Gauld, R; Gersabeck, E; Gersabeck, M; Gershon, T; Ghez, Ph; Gibson, V; Gligorov, V V; Göbel, C; Golubkov, D; Golutvin, A; Gomes, A; Gordon, H; Grabalosa Gándara, M; Graciani Diaz, R; Granado Cardoso, L A; Graugés, E; Graziani, G; Grecu, A; Greening, E; Gregson, S; Grünberg, O; Gui, B; Gushchin, E; Guz, Yu; Gys, T; Hadjivasiliou, C; Haefeli, G; Haen, C; Haines, S C; Hall, S; Hampson, T; Hansmann-Menzemer, S; Harnew, N; Harnew, S T; Harrison, J; Hartmann, T; He, J; Heijne, V; Hennessy, K; Henrard, P; Hernando Morata, J A; van Herwijnen, E; Hicks, E; Hill, D; Hoballah, M; Hombach, C; Hopchev, P; Hulsbergen, W; Hunt, P; Huse, T; Hussain, N; Hutchcroft, D; Hynds, D; Iakovenko, V; Idzik, M; Ilten, P; Jacobsson, R; Jaeger, A; Jans, E; Jaton, P; Jing, F; John, M; Johnson, D; Jones, C R; Jost, B; Kaballo, M; Kandybei, S; Karacson, M; Karbach, T M; Kenyon, I R; Kerzel, U; Ketel, T; Keune, A; Khanji, B; Kochebina, O; Komarov, I; Koopman, R F; Koppenburg, P; Korolev, M; Kozlinskiy, A; Kravchuk, L; Kreplin, K; Kreps, M; Krocker, G; Krokovny, P; Kruse, F; Kucharczyk, M; Kudryavtsev, V; Kvaratskheliya, T; La Thi, V N; Lacarrere, D; Lafferty, G; Lai, A; Lambert, D; Lambert, R W; Lanciotti, E; Lanfranchi, G; Langenbruch, C; Latham, T; Lazzeroni, C; Le Gac, R; van Leerdam, J; Lees, J -P; Lefèvre, R; Leflat, A; Lefrançois, J; Leo, S; Leroy, O; Leverington, B; Li, Y; Li Gioi, L; Liles, M; Lindner, R; Linn, C; Liu, B; Liu, G; von Loeben, J; Lohn, S; Lopes, J H; Lopez Asamar, E; Lopez-March, N; Lu, H; Lucchesi, D; Luisier, J; Luo, H; Machefert, F; Machikhiliyan, I V; Maciuc, F; Maev, O; Malde, S; Manca, G; Mancinelli, G; Marconi, U; Märki, R; Marks, J; Martellotti, G; Martens, A; Martin, L; Martín Sánchez, A; Martinelli, M; Martinez Santos, D; Martins Tostes, D; Massafferri, A; Matev, R; Mathe, Z; Matteuzzi, C; Maurice, E; Mazurov, A; McCarthy, J; McNulty, R; Mcnab, A; Meadows, B; Meier, F; Meissner, M; Merk, M; Milanes, D A; Minard, M -N; Molina Rodriguez, J; Monteil, S; Moran, D; Morawski, P; Morello, M J; Mountain, R; Mous, I; Muheim, F; Müller, K; Muresan, R; Muryn, B; Muster, B; Naik, P; Nakada, T; Nandakumar, R; Nasteva, I; Needham, M; Neufeld, N; Nguyen, A D; Nguyen, T D; Nguyen-Mau, C; Nicol, M; Niess, V; Niet, R; Nikitin, N; Nikodem, T; Nomerotski, A; Novoselov, A; Oblakowska-Mucha, A; Obraztsov, V; Oggero, S; Ogilvy, S; Okhrimenko, O; Oldeman, R; Orlandea, M; Otalora Goicochea, J M; Owen, P; Pal, B K; Palano, A; Palutan, M; Panman, J; Papanestis, A; Pappagallo, M; Parkes, C; Parkinson, C J; Passaleva, G; Patel, G D; Patel, M; Patrick, G N; Patrignani, C; Pavel-Nicorescu, C; Pazos Alvarez, A; Pellegrino, A; Penso, G; Pepe Altarelli, M; Perazzini, S; Perego, D L; Perez Trigo, E; Pérez-Calero Yzquierdo, A; Perret, P; Perrin-Terrin, M; Pessina, G; Petridis, K; Petrolini, A; Phan, A; Picatoste Olloqui, E; Pietrzyk, B; Pilař, T; Pinci, D; Playfer, S; Plo Casasus, M; Polci, F; Polok, G; Poluektov, A; Polycarpo, E; Popov, D; Popovici, B; Potterat, C; Powell, A; Prisciandaro, J; Pugatch, V; Puig Navarro, A; Punzi, G; Qian, W; Rademacker, J H; Rakotomiaramanana, B; Rangel, M S; Raniuk, I; Rauschmayr, N; Raven, G; Redford, S; Reid, M M; dos Reis, A C; Ricciardi, S; Richards, A; Rinnert, K; Rives Molina, V; Roa Romero, D A; Robbe, P; Rodrigues, E; Rodriguez Perez, P; Roiser, S; Romanovsky, V; Romero Vidal, A; Rouvinet, J; Ruf, T; Ruffini, F; Ruiz, H; Ruiz Valls, P; Sabatino, G; Saborido Silva, J J; Sagidova, N; Sail, P; Saitta, B; Salzmann, C; Sanmartin Sedes, B; Sannino, M; Santacesaria, R; Santamarina Rios, C; Santovetti, E; Sapunov, M; Sarti, A; Satriano, C; Satta, A; Savrie, M; Savrina, D; Schaack, P; Schiller, M; Schindler, H; Schlupp, M; Schmelling, M; Schmidt, B; Schneider, O; Schopper, A; Schune, M -H; Schwemmer, R; Sciascia, B; Sciubba, A; Seco, M; Semennikov, A; Senderowska, K; Sepp, I; Serra, N; Serrano, J; Seyfert, P; Shapkin, M; Shapoval, I; Shatalov, P; Shcheglov, Y; Shears, T; Shekhtman, L; Shevchenko, O; Shevchenko, V; Shires, A; Silva Coutinho, R; Skwarnicki, T; Smith, N A; Smith, E; Smith, M; Sokoloff, M D; Soler, F J P; Soomro, F; Souza, D; Souza De Paula, B; Spaan, B; Sparkes, A; Spradlin, P; Stagni, F; Stahl, S; Steinkamp, O; Stoica, S; Stone, S; Storaci, B; Straticiuc, M; Straumann, U; Subbiah, V K; Swientek, S; Syropoulos, V; Szczekowski, M; Szczypka, P; Szumlak, T; T'Jampens, S; Teklishyn, M; Teodorescu, E; Teubert, F; Thomas, C; Thomas, E; van Tilburg, J; Tisserand, V; Tobin, M; Tolk, S; Tonelli, D; Topp-Joergensen, S; Torr, N; Tournefier, E; Tourneur, S; Tran, M T; Tresch, M; Tsaregorodtsev, A; Tsopelas, P; Tuning, N; Ubeda Garcia, M; Ukleja, A; Urner, D; Uwer, U; Vagnoni, V; Valenti, G; Vazquez Gomez, R; Vazquez Regueiro, P; Vecchi, S; Velthuis, J J; Veltri, M; Veneziano, G; Vesterinen, M; Viaud, B; Vieira, D; Vilasis-Cardona, X; Vollhardt, A; Volyanskyy, D; Voong, D; Vorobyev, A; Vorobyev, V; Voß, C; Voss, H; Waldi, R; Wallace, R; Wandernoth, S; Wang, J; Ward, D R; Watson, N K; Webber, A D; Websdale, D; Whitehead, M; Wicht, J; Wiechczynski, J; Wiedner, D; Wiggers, L; Wilkinson, G; Williams, M P; Williams, M; Wilson, F F; Wishahi, J; Witek, M; Wotton, S A; Wright, S; Wu, S; Wyllie, K; Xie, Y; Xing, F; Xing, Z; Yang, Z; Young, R; Yuan, X; Yushchenko, O; Zangoli, M; Zavertyaev, M; Zhang, F; Zhang, L; Zhang, W C; Zhang, Y; Zhelezov, A; Zhokhov, A; Zhong, L; Zvyagin, A

    2013-01-01

    First observations and measurements of the branching fractions of the $\\bar{B}_s^0\\to D^+D^-$, $\\bar{B}_s^0\\to D_s^+D^-$ and $\\bar{B}_s^0\\to D^0\\bar{D}^0$ decays are presented using $1.0$~fb$^{-1}$ of data collected by the LHCb experiment. These branching fractions are normalized to those of $\\bar{B}^0\\to D^+D^-$, $B^0\\to D_s^+D^-$ and $B^-\\to D^0D_s^-$, respectively. An excess of events consistent with the decay $\\bar{B}^0\\to D^0\\bar{D}^0$ is also seen, and its branching fraction is measured relative to that of $B^-\\to D^0D_s^-$. Improved measurements of the branching fractions ${\\cal{B}}(\\bar{B}_s^0\\to D_s^+D_s^-)$ and ${\\cal{B}}(B^-\\to D^0D_s^-)$ are reported, each relative to ${\\cal{B}}(B^0\\to D_s^+D^-)$. The ratios of branching fractions are \\begin{align*} {{\\cal{B}}(\\bar{B}_s^0\\to D^+D^-)\\over {\\cal{B}}(\\bar{B}^0\\to D^+D^-)} &= 1.08\\pm 0.20\\pm0.10, \

  6. Sunlight and Vitamin D

    Science.gov (United States)

    Wacker, Matthias; Holick, Michael F.

    2013-01-01

    Vitamin D is the sunshine vitamin that has been produced on this earth for more than 500 million years. During exposure to sunlight 7-dehydrocholesterol in the skin absorbs UV B radiation and is converted to previtamin D3 which in turn isomerizes into vitamin D3. Previtamin D3 and vitamin D3 also absorb UV B radiation and are converted into a variety of photoproducts some of which have unique biologic properties. Sun induced vitamin D synthesis is greatly influenced by season, time of day, latitude, altitude, air pollution, skin pigmentation, sunscreen use, passing through glass and plastic, and aging. Vitamin D is metabolized sequentially in the liver and kidneys into 25-hydroxyvitamin D which is a major circulating form and 1,25-dihydroxyvitamin D which is the biologically active form respectively. 1,25-dihydroxyvitamin D plays an important role in regulating calcium and phosphate metabolism for maintenance of metabolic functions and for skeletal health. Most cells and organs in the body have a vitamin D receptor and many cells and organs are able to produce 1,25-dihydroxyvitamin D. As a result 1,25-dihydroxyvitamin D influences a large number of biologic pathways which may help explain association studies relating vitamin D deficiency and living at higher latitudes with increased risk for many chronic diseases including autoimmune diseases, some cancers, cardiovascular disease, infectious disease, schizophrenia and type 2 diabetes. A three-part strategy of increasing food fortification programs with vitamin D, sensible sun exposure recommendations and encouraging ingestion of a vitamin D supplement when needed should be implemented to prevent global vitamin D deficiency and its negative health consequences. PMID:24494042

  7. Evidence for D0-D0 mixing.

    Science.gov (United States)

    Aubert, B; Bona, M; Boutigny, D; Karyotakis, Y; Lees, J P; Poireau, V; Prudent, X; Tisserand, V; Zghiche, A; Garra Tico, J; Grauges, E; Lopez, L; Palano, A; Eigen, G; Stugu, B; Sun, L; Abrams, G S; Battaglia, M; Brown, D N; Button-Shafer, J; Cahn, R N; Groysman, Y; Jacobsen, R G; Kadyk, J A; Kerth, L T; Kolomensky, Yu G; Kukartsev, G; Lopes Pegna, D; Lynch, G; Mir, L M; Orimoto, T J; Ronan, M T; Tackmann, K; Wenzel, W A; Del Amo Sanchez, P; Hawkes, C M; Watson, A T; Held, T; Koch, H; Lewandowski, B; Pelizaeus, M; Schroeder, T; Steinke, M; Walker, D; Asgeirsson, D J; Cuhadar-Donszelmann, T; Fulsom, B G; Hearty, C; Knecht, N S; Mattison, T S; McKenna, J A; Khan, A; Saleem, M; Teodorescu, L; Blinov, V E; Bukin, A D; Druzhinin, V P; Golubev, V B; Onuchin, A P; Serednyakov, S I; Skovpen, Yu I; Solodov, E P; Todyshev, K Yu; Bondioli, M; Curry, S; Eschrich, I; Kirkby, D; Lankford, A J; Lund, P; Mandelkern, M; Martin, E C; Stoker, D P; Abachi, S; Buchanan, C; Foulkes, S D; Gary, J W; Liu, F; Long, O; Shen, B C; Zhang, L; Paar, H P; Rahatlou, S; Sharma, V; Berryhill, J W; Campagnari, C; Cunha, A; Dahmes, B; Hong, T M; Kovalskyi, D; Richman, J D; Beck, T W; Eisner, A M; Flacco, C J; Heusch, C A; Kroseberg, J; Lockman, W S; Schalk, T; Schumm, B A; Seiden, A; Williams, D C; Wilson, M G; Winstrom, L O; Chen, E; Cheng, C H; Fang, F; Hitlin, D G; Narsky, I; Piatenko, T; Porter, F C; Mancinelli, G; Meadows, B T; Mishra, K; Sokoloff, M D; Blanc, F; Bloom, P C; Chen, S; Ford, W T; Hirschauer, J F; Kreisel, A; Nagel, M; Nauenberg, U; Olivas, A; Smith, J G; Ulmer, K A; Wagner, S R; Zhang, J; Gabareen, A M; Soffer, A; Toki, W H; Wilson, R J; Winklmeier, F; Zeng, Q; Altenburg, D D; Feltresi, E; Hauke, A; Jasper, H; Merkel, J; Petzold, A; Spaan, B; Wacker, K; Brandt, T; Klose, V; Kobel, M J; Lacker, H M; Mader, W F; Nogowski, R; Schubert, J; Schubert, K R; Schwierz, R; Sundermann, J E; Volk, A; Bernard, D; Bonneaud, G R; Latour, E; Lombardo, V; Thiebaux, Ch; Verderi, M; Clark, P J; Gradl, W; Muheim, F; Playfer, S; Robertson, A I; Xie, Y; Andreotti, M; Bettoni, D; Bozzi, C; Calabrese, R; Cecchi, A; Cibinetto, G; Franchini, P; Luppi, E; Negrini, M; Petrella, A; Piemontese, L; Prencipe, E; Santoro, V; Anulli, F; Baldini-Ferroli, R; Calcaterra, A; de Sangro, R; Finocchiaro, G; Pacetti, S; Patteri, P; Peruzzi, I M; Piccolo, M; Rama, M; Zallo, A; Buzzo, A; Contri, R; Lo Vetere, M; Macri, M M; Monge, M R; Passaggio, S; Patrignani, C; Robutti, E; Santroni, A; Tosi, S; Chaisanguanthum, K S; Morii, M; Wu, J; Dubitzky, R S; Marks, J; Schenk, S; Uwer, U; Bard, D J; Dauncey, P D; Flack, R L; Nash, J A; Nikolich, M B; Panduro Vazquez, W; Behera, P K; Chai, X; Charles, M J; Mallik, U; Meyer, N T; Ziegler, V; Cochran, J; Crawley, H B; Dong, L; Eyges, V; Meyer, W T; Prell, S; Rosenberg, E I; Rubin, A E; Gritsan, A V; Guo, Z J; Lae, C K; Denig, A G; Fritsch, M; Schott, G; Arnaud, N; Béquilleux, J; Davier, M; Grosdidier, G; Höcker, A; Lepeltier, V; Le Diberder, F; Lutz, A M; Pruvot, S; Rodier, S; Roudeau, P; Schune, M H; Serrano, J; Sordini, V; Stocchi, A; Wang, W F; Wormser, G; Lange, D J; Wright, D M; Chavez, C A; Forster, I J; Fry, J R; Gabathuler, E; Gamet, R; Hutchcroft, D E; Payne, D J; Schofield, K C; Touramanis, C; Bevan, A J; George, K A; Di Lodovico, F; Menges, W; Sacco, R; Cowan, G; Flaecher, H U; Hopkins, D A; Jackson, P S; McMahon, T R; Salvatore, F; Wren, A C; Brown, D N; Davis, C L; Allison, J; Barlow, N R; Barlow, R J; Chia, Y M; Edgar, C L; Lafferty, G D; West, T J; Yi, J I; Anderson, J; Chen, C; Jawahery, A; Roberts, D A; Simi, G; Tuggle, J M; Blaylock, G; Dallapiccola, C; Hertzbach, S S; Li, X; Moore, T B; Salvati, E; Saremi, S; Cowan, R; Fisher, P H; Sciolla, G; Sekula, S J; Spitznagel, M; Taylor, F; Yamamoto, R K; McLachlin, S E; Patel, P M; Robertson, S H; Lazzaro, A; Palombo, F; Bauer, J M; Cremaldi, L; Eschenburg, V; Godang, R; Kroeger, R; Sanders, D A; Summers, D J; Zhao, H W; Brunet, S; Côté, D; Simard, M; Taras, P; Viaud, F B; Nicholson, H; De Nardo, G; Fabozzi, F; Lista, L; Monorchio, D; Sciacca, C; Baak, M A; Raven, G; Snoek, H L; Jessop, C P; LoSecco, J M; Benelli, G; Corwin, L A; Gan, K K; Honscheid, K; Hufnagel, D; Kagan, H; Kass, R; Morris, J P; Rahimi, A M; Regensburger, J J; Ter-Antonyan, R; Wong, Q K; Blount, N L; Brau, J; Frey, R; Igonkina, O; Kolb, J A; Lu, M; Rahmat, R; Sinev, N B; Strom, D; Strube, J; Torrence, E; Gagliardi, N; Gaz, A; Margoni, M; Morandin, M; Pompili, A; Posocco, M; Rotondo, M; Simonetto, F; Stroili, R; Voci, C; Ben-Haim, E; Briand, H; Calderini, G; Chauveau, J; David, P; Del Buono, L; de la Vaissière, Ch; Hamon, O; Leruste, Ph; Malclès, J; Ocariz, J; Perez, A; Gladney, L; Biasini, M; Covarelli, R; Manoni, E; Angelini, C; Batignani, G; Bettarini, S; Carpinelli, M; Cenci, R; Cervelli, A; Forti, F; Giorgi, M A; Lusiani, A; Marchiori, G; Mazur, M A; Morganti, M; Neri, N; Paoloni, E; Rizzo, G; Walsh, J J; Haire, M; Biesiada, J; Elmer, P; Lau, Y P; Lu, C; Olsen, J; Smith, A J S; Telnov, A V; Baracchini, E; Bellini, F; Cavoto, G; D'Orazio, A; del Re, D; Di Marco, E; Faccini, R; Ferrarotto, F; Ferroni, F; Gaspero, M; Jackson, P D; Li Gioi, L; Mazzoni, M A; Morganti, S; Piredda, G; Polci, F; Renga, F; Voena, C; Ebert, M; Schröder, H; Waldi, R; Adye, T; Castelli, G; Franek, B; Olaiya, E O; Ricciardi, S; Roethel, W; Wilson, F F; Aleksan, R; Emery, S; Escalier, M; Gaidot, A; Ganzhur, S F; Hamel de Monchenault, G; Kozanecki, W; Legendre, M; Vasseur, G; Yèche, Ch; Zito, M; Chen, X R; Liu, H; Park, W; Purohit, M V; Wilson, J R; Allen, M T; Aston, D; Bartoldus, R; Bechtle, P; Berger, N; Claus, R; Coleman, J P; Convery, M R; Dingfelder, J C; Dorfan, J; Dubois-Felsmann, G P; Dujmic, D; Dunwoodie, W; Field, R C; Glanzman, T; Gowdy, S J; Graham, M T; Grenier, P; Hast, C; Hryn'ova, T; Innes, W R; Kaminski, J; Kelsey, M H; Kim, H; Kim, P; Kocian, M L; Leith, D W G S; Li, S; Luitz, S; Luth, V; Lynch, H L; MacFarlane, D B; Marsiske, H; Messner, R; Muller, D R; O'Grady, C P; Ofte, I; Perazzo, A; Perl, M; Pulliam, T; Ratcliff, B N; Roodman, A; Salnikov, A A; Schindler, R H; Schwiening, J; Snyder, A; Stelzer, J; Su, D; Sullivan, M K; Suzuki, K; Swain, S K; Thompson, J M; Va'vra, J; van Bakel, N; Wagner, A P; Weaver, M; Wisniewski, W J; Wittgen, M; Wright, D H; Yarritu, A K; Yi, K; Young, C C; Burchat, P R; Edwards, A J; Majewski, S A; Petersen, B A; Wilden, L; Ahmed, S; Alam, M S; Bula, R; Ernst, J A; Jain, V; Pan, B; Saeed, M A; Wappler, F R; Zain, S B; Bugg, W; Krishnamurthy, M; Spanier, S M; Eckmann, R; Ritchie, J L; Ruland, A M; Schilling, C J; Schwitters, R F; Izen, J M; Lou, X C; Ye, S; Bianchi, F; Gallo, F; Gamba, D; Pelliccioni, M; Bomben, M; Bosisio, L; Cartaro, C; Cossutti, F; Della Ricca, G; Lanceri, L; Vitale, L; Azzolini, V; Lopez-March, N; Martinez-Vidal, F; Milanes, D A; Oyanguren, A; Albert, J; Banerjee, Sw; Bhuyan, B; Hamano, K; Kowalewski, R; Nugent, I M; Roney, J M; Sobie, R J; Back, J J; Harrison, P F; Latham, T E; Mohanty, G B; Pappagallo, M; Band, H R; Chen, X; Dasu, S; Flood, K T; Hollar, J J; Kutter, P E; Pan, Y; Pierini, M; Prepost, R; Wu, S L; Yu, Z; Neal, H

    2007-05-25

    We present evidence for D0-D(0) mixing in D(0)-->K(+)pi(-) decays from 384 fb(-1) of e(+)e(-) colliding-beam data recorded near square root s=10.6 GeV with the BABAR detector at the PEP-II storage rings at the Stanford Linear Accelerator Center. We find the mixing parameters x('2)=[-0.22+/-0.30(stat)+/-0.21(syst)] x 10(-3) and y(')=[9.7+/-4.4(stat)+/-3.1(syst)] x 10(-3) and a correlation between them of -0.95. This result is inconsistent with the no-mixing hypothesis with a significance of 3.9 standard deviations. We measure R(D), the ratio of doubly Cabibbo-suppressed to Cabibbo-favored decay rates, to be [0.303+/-0.016(stat)+/-0.010(syst)]%. We find no evidence for CP violation.

  8. The dS/dS Correspondence

    Science.gov (United States)

    Alishahiha, Mohsen; Karch, Andreas; Silverstein, Eva; Tong, David

    2004-12-01

    We present a holographic duality for the de Sitter static patch which consolidates basic features of its geometry and the behavior of gravity and brane probes, valid on timescales short compared to the decay or Poincare recurrence times. Namely de Sitter spacetime dSd(R) in d dimensions with curvature radius R is holographically dual to two conformal field theories on dSd-1(R), cut off at an energy scale 1/R where they couple to each other and to d - 1 dimensional gravity. As part of our analysis, we study brane probes in de Sitter and thermal Anti de Sitter spaces, and interpret the terms in the corresponding DBI action via strongly coupled thermal field theory. This provides a dual field theoretic interpretation of the fact that probes take forever to reach a horizon in general relativity.

  9. D-xylose absorption

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/article/003606.htm D-xylose absorption To use the sharing features on this page, please enable JavaScript. D-xylose absorption is a laboratory test to determine ...

  10. Drug Coverage (Part D)

    Science.gov (United States)

    ... insurance Find health & drug plans Drug coverage (Part D) How to get drug coverage Get Medicare prescription drug coverage either from a Part D plan or a Medicare Advantage Plan offering Medicare ...

  11. Breastfeeding: Vitamin D Supplementation

    Science.gov (United States)

    ... Weight Breastfeeding Micronutrient Malnutrition State and Local Programs Vitamin D Supplementation Recommend on Facebook Tweet Share Compartir ... not provide infants with an adequate intake of vitamin D. Most breastfed infants are able to synthesize ...

  12. Vitamin D Pooling Project

    Science.gov (United States)

    The Vitamin D Pooling Project of Rarer Cancers brought together investigators from 10 cohorts to conduct a large prospective epidemiologic study of the association between vitamin D status and seven rarer cancers.

  13. D and DR Reactors

    Data.gov (United States)

    Federal Laboratory Consortium — The world's second full-scale nuclear reactor was the D Reactor at Hanford which was built in the early 1940's and went operational in December of 1944.D Reactor ran...

  14. [VITAMIN D AND PREGNANCY].

    Science.gov (United States)

    Hitrova-Nikolova, St; Nikolov, A

    2015-01-01

    This arcicle reviews the role of vitimin D during pregnancy. Adequate intake of vitamin D during pregnancy is very important for the health of mother and infant. A number of epidemiological data worldwide show widespread suboptimal levels of vitamin D in pregnant women. Vitamin D deficiency may be associated with an increased risk of infection, bacterial vaginosis, pre-eclampsia, low serum vitamin D levels in the newborn and others. There are not universal recommendations for dosage and intake of vitamin D for pregnant women in the world. It is recommended that serum level of vitamin D in all pregnant women and its adequate supplementation. Normal maternal vitamin D levels would provide sufficient its accumulation in the fetus.

  15. Study of the Decays $B^{0} \\to D^{(*)+}D^{(*)-}$

    CERN Document Server

    Lipeles, E; Shapiro, A; Sun, W M; Weinstein, A J; Würthwein, F; Jaffe, D E; Masek, G E; Paar, H P; Potter, E M; Prell, S; Sharma, V; Asner, D M; Eppich, A; Hill, T S; Morrison, R J; Nelson, H N; Briere, R A; Behrens, B H; Ford, W T; Gritsan, A; Roy, J D; Smith, J G; Alexander, J P; Baker, R; Bebek, C; Berger, B E; Berkelman, K; Blanc, F; Boisvert, V; Cassel, David G; Dickson, M; Drell, P S; Ecklund, K M; Ehrlich, R; Foland, A D; Gaidarev, P B; Gibbons, L K; Gittelman, B; Gray, S W; Hartill, D L; Heltsley, B K; Hopman, P I; Jones, C D; Kreinick, D L; Lohner, M; Magerkurth, A; Meyer, T O; Mistry, N B; Nordberg, E; Patterson, J R; Peterson, D; Riley, D; Thayer, J G; Thies, P G; Valant-Spaight, B L; Warburton, A; Avery, P; Prescott, C; Rubiera, A I; Yelton, J; Zheng, J; Brandenburg, G; Ershov, A; Gao, Y S; Kim, D Y J; Wilson, R; Browder, T E; Li, Y; Rodríguez, J L; Yamamoto, H; Bergfeld, T; Eisenstein, B I; Ernst, J; Gladding, G E; Gollin, G D; Hans, R M; Johnson, E; Karliner, I; Marsh, M A; Palmer, M; Plager, C; Sedlack, C; Selen, M; Thaler, J J; Williams1, J; Edwards, K W; Patel, R; Janicek, P M; Sadoff, A J; Ammar, R; Bean, A; Besson, D; Davis, R; Kwak, N; Zhao, X; Anderson, S; Frolov, V V; Kubota, Y; Lee, S J; Mahapatra, R; O'Neill, J J; Poling, R A; Riehle, T; Smith, A; Urheim, J; Ahmed, S; Alam, M S; Athar, S B; Jian, L; Ling, L; Mahmood, A H; Saleem, M; Timm, S; Wappler, F; Anastassov, A; Duboscq, J E; Gan, K K; Gwon, C; Hart, T; Honscheid, K; Hufnagel, D; Kagan, H; Kass, R; Pedlar, T K; Schwarthoff, H; Thayer, J B; Von Törne, E; Zoeller, M M; Richichi, S J; Severini, H; Skubic, P L; Undrus, A; Chen, S; Fast, J; Hinson, J W; Lee, J; Menon, N; Miller, D H; Shibata, E I; Shipsey, I P J; Pavlunin, V; Cronin-Hennessy, D; Kwon, Y; Lyon, A L; Thorndike, E H; Jessop, C P; Marsiske, H; Perl, Martin Lewis; Savinov, V; Ugolini, D W; Zhou, X; Coan, T E; Fadeev, V; Maravin, Y; Narsky, I; Stroynowski, R; Ye, J; Wlodek, T; Artuso, M; Ayad, R; Boulahouache, C; Bukin, K; Dambasuren, E; Karamov, S; Majumder, G; Moneti, G C; Mountain, R; Schuh, S; Skwarnicki, T; Stone, S; Viehhauser, G; Wang, J C; Wolf, A; Wu, J; Kopp, S E; Csorna, S E; Danko, I; McLean, K W; Marka, S; Xu, Z; Godang, R; Kinoshita, K; Lai, I C; Schrenk, S; Bonvicini, G; Cinabro, D; McGee, S; Perera, L P; Zhou, G J

    2000-01-01

    The decays B0 --> D*+D*-, B0 --> D*+D- and B0 --> D+D- are studied in 9.7million Y(4S) --> BBbar decays accumulated with the CLEO detector. We determineBr(B0 --> D*+D*-) = (9.9+4.2-3.3+-1.2)e-4 and limit Br(B0 --> D*+D-) D+D-) D*+D*- decay and determine that theCP-even fraction of the final state is greater than 0.11 at 90L. Futuremeasurements of the time dependence of these decays may be useful for theinvestigation of CP violation in neutral B meson decays.

  16. 4D Electron Tomography

    OpenAIRE

    Kwon, Oh-Hoon; Zewail, Ahmed H.

    2010-01-01

    Electron tomography provides three-dimensional (3D) imaging of noncrystalline and crystalline equilibrium structures, as well as elemental volume composition, of materials and biological specimens, including those of viruses and cells. We report the development of 4D electron tomography by integrating the fourth dimension (time resolution) with the 3D spatial resolution obtained from a complete tilt series of 2D projections of an object. The different time frames of tomograms constitute a mov...

  17. Enterovirus D68 Infection

    NARCIS (Netherlands)

    Esposito, Susanna; Bosis, Samantha; Niesters, Hubert; Principi, Nicola

    2015-01-01

    First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68) is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many repor

  18. D and C - slideshow

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/presentations/100013.htm D and C - series—Normal anatomy To use the ... MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team. Related MedlinePlus Health Topics ...

  19. Facts about Vitamin D

    Science.gov (United States)

    ... Gorse/iStock/Thinkstock.com Food Eggs, sardines, and salmon contain vitamin D. Most fluid milk and some brands of ... 2. Typical Vitamin D Content in Food Food Vitamin D in IU (mcg) Salmon, cooked, 3 oz. 320 (8) Sardines, canned in ...

  20. Vitamin D endocrinology

    Energy Technology Data Exchange (ETDEWEB)

    DeLuca, H.F.

    1976-09-01

    Current status of our understanding of the metabolism of vitamin D and its implications in metabolic bone disease is reviewed. The details of metabolism of vitamin D/sub 3/ to 25-hydroxyvitamin D/sub 3/ in the liver and its further conversion in the kidney to either 1,25-dihydroxyvitamin D/sub 3/ or 24,25-dihydroxyvitamin D/sub 3/ are presented. The latter conversions are regulated by the vitamin D status, serum calcium through the parathyroid gland system, and serum inorganic phosphorus concentration. The 1,25-dihydroxyvitamin D/sub 3/ can now be regarded as a calcium- and a phosphate-mobilizing hormone and must be considered as one of the most important serum calcium-regulating hormones. Disruption of the vitamin D metabolic sequence or the signal system for 1,25-dihydroxyvitamin D/sub 3/ results in several bone and calcium metabolism disorders such as renal osteodystrophy, hypoparathyroidism, pseudohypoparathyroidism, and vitamin D-dependency rickets. The use of the synthetic analogs of 1,25-dihydroxyvitamin D/sub 3/ as well as 1,25-dihydroxyvitamin D/sub 3/ itself in the management of these disease states is discussed.

  1. Exploration d'ILIAS

    OpenAIRE

    De Henau, Thierry; Uyttebrouck, Eric

    2004-01-01

    This report provides a in-depth analysis of the ILIAS Learning Management System : functionalities, strengths, weaknesses, etc.; Ce rapport analyse dans le détail la plate-forme d'enseignement ouvert et à distance ILIAS : fonctionnalités détaillées, points forts, points faibles...

  2. Femme d'escrime

    National Research Council Canada - National Science Library

    VERREAULT, CLAIRE

    2002-01-01

      A Chibougamau, mon mari professeur d'education physique dirigeait un club d'escrime et il m' en a confie la direction ainsi que l'entrainement d'une equipe de filles alors qu'il etait alle parfaire ses etudes...

  3. Nonclassical Vitamin D Actions

    Directory of Open Access Journals (Sweden)

    Armin Zittermann

    2010-03-01

    Full Text Available It is becoming increasingly clear that vitamin D has a broad range of actions in the human body. Besides its well-known effects on calcium/phosphate homeostasis, vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and the immune response. Vitamin D deficiency/insufficiency has been associated with muscle weakness and a high incidence of various chronic diseases such as cardiovascular disease, cancer, multiple sclerosis, and type 1 and 2 diabetes. Most importantly, low vitamin D status has been found to be an independent predictor of all-cause mortality. Several recent randomized controlled trials support the assumption that vitamin D can improve muscle strength, glucose homeostasis, and cardiovascular risk markers. In addition, vitamin D may reduce cancer incidence and elevated blood pressure. Since the prevalence of vitamin D deficiency/insufficiency is high throughout the world, there is a need to improve vitamin D status in the general adult population. However, the currently recommended daily vitamin D intake of 5–15 µg is too low to achieve an adequate vitamin D status in individuals with only modest skin synthesis. Thus, there is a need to recommend a vitamin D intake that is effective for achieving adequate circulating 25-hydroxyvitamin D concentrations (>75 nmol/L.

  4. Helix-coil transition of the self-complementary dG-dG-dA-dA-dT-dT-dC-dC duplex.

    Science.gov (United States)

    Patel, D J; Canuel, L L

    1979-05-15

    The helix-coil transition of the octanucleotide self-complementary duplex dG-dG-dA-dA-dT-dT-dC-dC has been monitored at the Watson-Crick protons, the base and sugar nonexchangeable protons and the backbone phosphates by high-resolution nuclear magnetic resonance (NMR) spectroscopy. The melting transition of the octanucleotide monitored by ultraviolet absorbance spectroscopy is characterized by the thermodynamic parameters delta H degree = -216.7 kJ/mol and delta S degree (25 degrees C) = -0.632 KJ mol-1 K-1 in 0.1 M NaCl, 10 mM phosphate solution. Correlation of the transition midpoint values monitored by the ultraviolet absorbance studies at strand concentrations below 0.2 mM and by NMR studies at 5.3 mM suggest that both methods are monitoring the octanucleotide duplex-to-strand transition. The NMR spectra of the Watson-Crick ring NH protons of the octanucleotide duplex have been followed as a function of temperature. The resonance from the terminal dG.dC base pairs broadens out at room temperature while the resonances from the other base pairs broaden simultaneously with the onset of the melting transition. The nonexchangeable base and sugar H-1' protons are resolved in the duplex and strand states and shift as average peaks through the melting transition. The experimental shifts on duplex formation have been compared with calculated values based on ring-current and atomic diamagnetic anisotropy contributions for a B-DNA base-pair-overlap geometry in solution. Several nonexchangeable proton resonances broaden in the fast-exchange region during the duplex-to-strand transition and the excess widths yield a duplex dissociation rate constant for the octanucleotide of 1.9 x 10(3) s-1 at 32 degrees C (fraction of duplex = 0.86) in 0.1 M NaCl, 10 mM phosphate buffer. The 31P resonances of the seven internucleotide phosphates are distributed over 0.6 ppm in the duplex state, shift downfield during the duplex-to-strand transition and undergo additional downfield shifts

  5. Drug: D09054 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available codon root [DR:D06703], Angelica dahurica root [DR:D06779], Perilla herb [DR:D06755], Patchouli [DR:D09125],... [DR:D06778], Poria sclerotium [DR:D06783], Magnolia bark [DR:D06720], Citrus unshiu peel [DR:D06764], Platy

  6. Drug: D07201 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICA...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB07 Flupr...ednidene D07201 Fluprednidene (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderate

  7. Vitamin D supplementation guidelines.

    Science.gov (United States)

    Pludowski, Pawel; Holick, Michael F; Grant, William B; Konstantynowicz, Jerzy; Mascarenhas, Mario R; Haq, Afrozul; Povoroznyuk, Vladyslav; Balatska, Nataliya; Barbosa, Ana Paula; Karonova, Tatiana; Rudenka, Ema; Misiorowski, Waldemar; Zakharova, Irina; Rudenka, Alena; Łukaszkiewicz, Jacek; Marcinowska-Suchowierska, Ewa; Łaszcz, Natalia; Abramowicz, Pawel; Bhattoa, Harjit P; Wimalawansa, Sunil J

    2017-02-12

    Research carried out during the past two-decades extended the understanding of actions of vitamin D, from regulating calcium and phosphate absorption and bone metabolism to many pleiotropic actions in organs and tissues in the body. Most observational and ecological studies report association of higher serum 25-hydroxyvitamin D [25(OH)D] concentrations with improved outcomes for several chronic, communicable and non-communicable diseases. Consequently, numerous agencies and scientific organizations have developed recommendations for vitamin D supplementation and guidance on optimal serum 25(OH)D concentrations. The bone-centric guidelines recommend a target 25(OH)D concentration of 20ng/mL (50nmol/L), and age-dependent daily vitamin D doses of 400-800IU. The guidelines focused on pleiotropic effects of vitamin D recommend a target 25(OH)D concentration of 30ng/mL (75nmol/L), and age-, body weight-, disease-status, and ethnicity dependent vitamin D doses ranging between 400 and 2000IU/day. The wise and balanced choice of the recommendations to follow depends on one's individual health outcome concerns, age, body weight, latitude of residence, dietary and cultural habits, making the regional or nationwide guidelines more applicable in clinical practice. While natural sources of vitamin D can raise 25(OH)D concentrations, relative to dietary preferences and latitude of residence, in the context of general population, these sources are regarded ineffective to maintain the year-round 25(OH)D concentrations in the range of 30-50ng/mL (75-125nmol/L). Vitamin D self-administration related adverse effects, such as hypercalcemia and hypercalciuria are rare, and usually result from taking extremely high doses of vitamin D for a prolonged time. Copyright © 2017 Elsevier Ltd. All rights reserved.

  8. IZDELAVA TISKALNIKA 3D

    OpenAIRE

    Brdnik, Lovro

    2015-01-01

    Diplomsko delo analizira trenutno stanje 3D tiskalnikov na trgu. Prikazan je razvoj in principi delovanja 3D tiskalnikov. Predstavljeni so tipi 3D tiskalnikov, njihove prednosti in slabosti. Podrobneje je predstavljena zgradba in delovanje koračnih motorjev. Opravljene so meritve koračnih motorjev. Opisana je programska oprema za rokovanje s 3D tiskalniki in komponente, ki jih potrebujemo za izdelavo. Diploma se oklepa vprašanja, ali je izdelava 3D tiskalnika bolj ekonomična kot pa naložba v ...

  9. Vitamin D-mangel

    DEFF Research Database (Denmark)

    Hey, Henrik; Schmedes, Anne; Horn, Peer

    2009-01-01

    The importance of vitamin D for osteoporosis and fractures has been known for more than 40 years. Vitamin D deficiency is diagnosed by measuring 25-hydroxyvitamin D (25-OHD), which should be > 50 nmol/l year round. Recent research suggests that a number of severe diseases could be prevented...... by increasing 25-OHD to 80 nmol/l. Despite a strong focus on such increase, recommendations for intake of Vitamin D have not been changed and the present recommendations are too low even to ensure > 50 nmol/l. To achieve optimal concentrations > 80 nmol/l, we estimate that 50-70 microgram of vitamin D per day...

  10. Rediscovering vitamin D

    Directory of Open Access Journals (Sweden)

    Nasr Anaizi

    2010-11-01

    Full Text Available Over the past 2 years there has been a radical change in standard clinical practice with respect to vitamin D. As a result of a growing body of knowledgeable physicians are assessing the vitamin D nutritional status of their patients and prescribing aggressive repletion regimens of a vitamin D supplement. The present paper summarizes some basic information about this essential nutrient and reviews some of the more recent data implicating vitamin D deficiency in disease etiology with an emphasis on cardiovascular disease and cancer. Finally a rational approach to the dosing of vitamin D in different patient populations is provided.

  11. Drug: D07853 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihis...tamines for topical use D04AA13 Dimetindene D07853 Dimetindene (INN) R RESPIRATORY

  12. Drug: D01938 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ode: D11AX12 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGIC...AL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  13. Drug: D08997 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rianal warts ATC code: D06BB12 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGIC...ALS D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D

  14. Drug: D00137 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANT...ISEPTICS AND DISINFECTANTS D08AX Other antiseptics and d

  15. Drug: D01910 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA13 Iodofo...10 Iodoform (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  16. Drug: D05463 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available matologicals D11AX03 Calcium gluconate D05463 Calcium gluconate hydrate (JP16) PubC...RMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  17. Drug: D09053 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09053 Formula, Drug Bukuryotakushato Poria sclerotium [DR:D06783], Alisma rhizome ...:D06712], Ginger [DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  18. Drug: D02583 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tria...zole derivatives D01AC12 Fenticonazole D02583 Fenticonazole nitrate (USAN) G GENITO

  19. Drug: D10300 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07C CORTICOSTERO...inflammatory (tinea) ATC code: D07CC01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D D

  20. Drug: D07801 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...xamethasone phenylpropionate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICO... combinations D07XB05 Dexamethasone D07801 Dexamethasone phenylpropionate D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for trea...tment of acne D10AA03 Dexamethasone D07801 Dexamethasone phenylpropionate H SYSTEMIC HORMONAL PREPARATIONS,

  1. Drug: D09096 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09096 Formula, Drug Keimeisankabukuryo Areca [DR:D06782], Chaenomeles fruit [DR:D09192], Aurantii nobilis pericarpium [DR:D06897], Platycodon root [DR:D06703], Evodia fruit [DR:D00173], Perilla herb [DR:D06755], Dry ginger [DR:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Diuretic formulas D09096 Keimeisankabukuryo PubChem: 96025776 ...

  2. Drug: D09113 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09113 Formula, Drug Shokyoshashinto Pinellia tuber [DR:D06778], Ginseng [DR:D06772], Scutellaria root [DR:D06688], Glycyrrhiza [DR:D04365], Jujube [DR:D06758], Coptis rhizome [DR:D00092], Processed ginger [DR:D06702], Ginger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09113 Shokyoshashinto PubChem: 96025793 ...

  3. D & D screening risk evaluation guidance

    Energy Technology Data Exchange (ETDEWEB)

    Robers, S.K.; Golden, K.M.; Wollert, D.A.

    1995-09-01

    The Screening Risk Evaluation (SRE) guidance document is a set of guidelines provided for the uniform implementation of SREs performed on decontamination and decommissioning (D&D) facilities. Although this method has been developed for D&D facilities, it can be used for transition (EM-60) facilities as well. The SRE guidance produces screening risk scores reflecting levels of risk through the use of risk ranking indices. Five types of possible risk are calculated from the SRE: current releases, worker exposures, future releases, physical hazards, and criticality. The Current Release Index (CRI) calculates the current risk to human health and the environment, exterior to the building, from ongoing or probable releases within a one-year time period. The Worker Exposure Index (WEI) calculates the current risk to workers, occupants and visitors inside contaminated D&D facilities due to contaminant exposure. The Future Release Index (FRI) calculates the hypothetical risk of future releases of contaminants, after one year, to human health and the environment. The Physical Hazards Index (PHI) calculates the risks to human health due to factors other than that of contaminants. Criticality is approached as a modifying factor to the entire SRE, due to the fact that criticality issues are strictly regulated under DOE. Screening risk results will be tabulated in matrix form, and Total Risk will be calculated (weighted equation) to produce a score on which to base early action recommendations. Other recommendations from the screening risk scores will be made based either on individual index scores or from reweighted Total Risk calculations. All recommendations based on the SRE will be made based on a combination of screening risk scores, decision drivers, and other considerations, as determined on a project-by-project basis.

  4. Pragmatic and cost efficient D and D

    Energy Technology Data Exchange (ETDEWEB)

    Morris, M. [Nuclear Fuel Services, Erwin, TN (United States)

    1998-03-01

    A great deal of effort is expended by remediation professionals in the pursuit of new technologies to assist them in performing their tasks more efficiently. These individuals understand the cost savings associated with volume reduction and waste minimization and routinely incorporate these practices into their planning. However, the largest cost component on many D and D projects is labor. Increasing the efficiency of work force utilization is frequently the most overlooked technique that can be instituted and which can easily offer major cost savings. Granted, some D and D jobs require highly specialized tools and equipment which are quite expensive. Decreasing these costs is often not an option or will yield minimal results. Conversely, the increase in worker efficiency can usually decrease costs dramatically. During the performance of the Safe Shutdown Project at the Fernald Environmental Management Project (the Fernald site), a process improvement initiative was instituted in support of the development of the Ten Year Plan. Costs associated with the removal of hundreds of thousands of pounds of nuclear material from formerly utilized equipment piping, and ductwork in nuclear facilities at the Fernald site were analyzed. This analysis indicated that the labor component was large enough to merit further inspection. A new approach to the activities was instituted and the results were significant. A macroscopic overview of all work activities utilized work evolution control (sequencing), building segmentation, and efficient use of engineering controls to streamline the D and D process. Overall costs on the first facility were reduced by over 20%. The increased labor efficiency resulted in decreased Personal Protective Equipment costs for field personnel. This approach will be discussed in detail.

  5. D-Branes and D-Modules

    Science.gov (United States)

    Dijkgraaf, R.

    We study of chiral fermions on a quantum curve by embedding them instring theory as an intersecting D-brane configuration together with a B-field. Mathematically, this system is described by a holonomic D-module. Here we focus on spectral curves, which play a prominant role in the theory of (quantum) integrable hierarchies. We show how to associate a quantum state to the system, and subsequently how to compute quantum invariants. The material of this paper is treated at greater length in the paper [R.~Dijkgraaf, L.~Hollands and P.~Sulkowski, arXiv:0810.4157] that also contains many examples.

  6. 3D and Education

    Science.gov (United States)

    Meulien Ohlmann, Odile

    2013-02-01

    Today the industry offers a chain of 3D products. Learning to "read" and to "create in 3D" becomes an issue of education of primary importance. 25 years professional experience in France, the United States and Germany, Odile Meulien set up a personal method of initiation to 3D creation that entails the spatial/temporal experience of the holographic visual. She will present some different tools and techniques used for this learning, their advantages and disadvantages, programs and issues of educational policies, constraints and expectations related to the development of new techniques for 3D imaging. Although the creation of display holograms is very much reduced compared to the creation of the 90ies, the holographic concept is spreading in all scientific, social, and artistic activities of our present time. She will also raise many questions: What means 3D? Is it communication? Is it perception? How the seeing and none seeing is interferes? What else has to be taken in consideration to communicate in 3D? How to handle the non visible relations of moving objects with subjects? Does this transform our model of exchange with others? What kind of interaction this has with our everyday life? Then come more practical questions: How to learn creating 3D visualization, to learn 3D grammar, 3D language, 3D thinking? What for? At what level? In which matter? for whom?

  7. 4-D Photoacoustic Tomography

    Science.gov (United States)

    Xiang, Liangzhong; Wang, Bo; Ji, Lijun; Jiang, Huabei

    2013-01-01

    Photoacoustic tomography (PAT) offers three-dimensional (3D) structural and functional imaging of living biological tissue with label-free, optical absorption contrast. These attributes lend PAT imaging to a wide variety of applications in clinical medicine and preclinical research. Despite advances in live animal imaging with PAT, there is still a need for 3D imaging at centimeter depths in real-time. We report the development of four dimensional (4D) PAT, which integrates time resolutions with 3D spatial resolution, obtained using spherical arrays of ultrasonic detectors. The 4D PAT technique generates motion pictures of imaged tissue, enabling real time tracking of dynamic physiological and pathological processes at hundred micrometer-millisecond resolutions. The 4D PAT technique is used here to image needle-based drug delivery and pharmacokinetics. We also use this technique to monitor 1) fast hemodynamic changes during inter-ictal epileptic seizures and 2) temperature variations during tumor thermal therapy.

  8. Offshoring R&D

    DEFF Research Database (Denmark)

    Hansen, Zaza Nadja Lee; Rasmussen, Lauge Baungaard

    2010-01-01

    Companies are increasingly offshoring R&D activities. Many firms, however, experience difficulties related to virtual teamwork across cultures and time zones. The research question is: How does increasing R&D offshoring impact transparency of communication structures and knowledge sharing? Using...... case studies from Danish multinational corporations with R&D activities in China, India or Eastern Europe this paper analyses the impact observed in these companies in regard to communication structures and knowledge sharing in management of offshored R&D activities. The findings show that companies...... to the complexity of the R&D activity. This paper shows that management of offshored R&D activities touches upon many key management dilemmas like trust, control and knowledge sharing....

  9. Outsourcing R&D

    DEFF Research Database (Denmark)

    Hsuan, Juliana; Mahnke, Volker

    2011-01-01

    Outsourcing R&D is an increasingly explored corporate practice. Extant research advanced our initial understanding of its increasing importance and benefits. While the associated literature has blossomed, the enthusiasm of R&D managers is tenured by an increasing realization of the possible...... downsides, risks, and costs that come with increasing use of external sources of innovation. Here, we suggest that research on outsourcing R&D has to move towards a balanced view on the profitability of such arrangements. To this end, we offer a review of what we know and need to know about outsourcing R......&D, suggest a simple, yet integrative model on the relation between outsourcing R&D and performance, and offer a research agenda that is instrumental in guiding companies’ process-management and design strategies when seeking to benefit from the outsourcing of R&D....

  10. Outsourcing R&D

    DEFF Research Database (Denmark)

    Hsuan, Juliana; Mahnke, Volker

    2011-01-01

    Outsourcing R&D is an increasingly explored corporate practice. Extant research advanced our initial understanding of its increasing importance and benefits. While the associated literature has blossomed, the enthusiasm of R&D managers is tenured by an increasing realization of the possible...... downsides, risks, and costs that come with increasing use of external sources of innovation. Here, we suggest that research on outsourcing R&D has to move towards a balanced view on the profitability of such arrangements. To this end, we offer a review of what we know and need to know about outsourcing R......&D, suggest a simple, yet integrative model on the relation between outsourcing R&D and performance, and offer a research agenda that is instrumental in guiding companies’ process-management and design strategies when seeking to benefit from the outsourcing of R&D....

  11. Drug: D08407 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08407 Drug Pramocaine (INN) C17H27NO3 293.1991 293.4012 D08407.gif Local anesthetic... TOPICAL USE C05AD Local anesthetics C05AD07 Pramocaine D08407 Pramocaine (INN) D...STAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB07 Pramocaine D08407 Pramocaine (INN) CAS

  12. Drug: D02445 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 6437 D02445.gif ATC code: D08AX04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AX Other antiseptics and d

  13. Drug: D00862 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iinfectives B05CA03 Nitrofural D00862 Nitrofurazone (USP); Nitrofural (INN) D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AF Nitrofuran derivatives D08AF01 Nitrofural D0086

  14. Drug: D09079 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09079 Formula, Drug Dokkatsukakkonto Pueraria root [DR:D06693], Ephedra herb [DR:D...e in Japan [BR:br08304] Formulas Formulas for dampness Antirheumatic formulas D09079 Dokkatsukakkonto PubChem: 96025760 ... ...za [DR:D04365], Araliae cardatae rhizoma [DR:D06909], Rehmannia root [DR:D06736] Traditional Chinese Medicin

  15. Drug: D09063 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09063 Formula, Drug Kigikenchuto Cinnamon bark [DR:D06712], Peony root [DR:D06739], Jujube [DR:D06758], Gin...ger [DR:D06744], Glycyrrhiza [DR:D04365], Japanese angelica root [DR:D06768], Sacch

  16. Drug: D06956 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 3], Cinnamon bark [DR:D06712], Ephedra herb [DR:D06791], Jujube [DR:D06758], Glycyrrhiza [DR:D04365], Ging...er [DR:D06744], Immature orange [DR:D06706], (Atractylodes rhizome [DR:D06780] | At

  17. Drug: D01764 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available alerate (JP16) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOST...EROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III...) D07AC06 Diflucortolone D01764 Diflucortolone valerate (JP16) D07X CORTICOSTEROI

  18. Drug: D07980 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ction Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOST...EROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids,... moderately potent (group II) D07AB07 Fluprednidene D07980 Fluprednidene acetate D07X CORTICOSTEROIDS, OTHER

  19. Drug: D01464 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available utic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTER...OIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (grou...p II) D07AB03 Flumetasone D01464 Flumetasone pivalate (JAN/BAN); Flumethasone pivalate (USP) D07X CORTICOSTE

  20. Drug: D04707 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04707 Mixture, Drug Lithospermum root extract - ethyl aminobenzoate - dibucaine hydrochloride - diphenhydr...amine hydrochloride - cetrimide mixt; Borraginol N (TN) Lithospermum root extract [D...R:D04705], Ethyl aminobenzoate [DR:D00552], Dibucaine hydrochloride [DR:D02220], Diphenhydramine hydrochloride [DR:D00669], Cetrimide [DR:D02164] PubChem: 17398145 ...

  1. TEHNOLOGIJE 3D TISKALNIKOV

    OpenAIRE

    Kolar, Nataša

    2016-01-01

    Diplomsko delo predstavi razvoj tiskanja skozi čas. Podrobneje so opisani 3D tiskalniki, ki uporabljajo različne tehnologije 3D tiskanja. Predstavljene so različne tehnologije 3D tiskanja, njihova uporaba in narejeni prototipi oz. končni izdelki. Diplomsko delo opiše celoten postopek, od zamisli, priprave podatkov in tiskalnika do izdelave prototipa oz. končnega izdelka.

  2. D-brane Bremsstrahlung

    CERN Document Server

    Bachlechner, Thomas C

    2013-01-01

    We study the dynamics of ultrarelativistic D-branes. The dominant phenomenon is bremsstrahlung: mild acceleration induced by closed string interactions triggers extremely rapid energy loss through radiation of massless closed strings. After characterizing bremsstrahlung from a general k-dimensional extended object in a D-dimensional spacetime, we incorporate effects specific to D-branes, including velocity-dependent forces and open string pair creation. We then show that dissipation due to bremsstrahlung can substantially alter the dynamics in DBI inflation.

  3. D-brane bremsstrahlung

    Science.gov (United States)

    Bachlechner, Thomas C.; McAllister, Liam

    2013-10-01

    We study the dynamics of ultrarelativistic D-branes. The dominant phenomenon is bremsstrahlung: mild acceleration induced by closed string interactions triggers extremely rapid energy loss through radiation of massless closed strings. After characterizing bremsstrahlung from a general k-dimensional extended object in a D-dimensional spacetime, we incorporate effects specific to D-branes, including velocity-dependent forces and open string pair creation. We then show that dissipation due to bremsstrahlung can substantially alter the dynamics in DBI inflation.

  4. AE3D

    Energy Technology Data Exchange (ETDEWEB)

    2016-06-20

    AE3D solves for the shear Alfven eigenmodes and eigenfrequencies in a torodal magnetic fusion confinement device. The configuration can be either 2D (e.g. tokamak, reversed field pinch) or 3D (e.g. stellarator, helical reversed field pinch, tokamak with ripple). The equations solved are based on a reduced MHD model and sound wave coupling effects are not currently included.

  5. Vitamin D and psoriasis.

    Science.gov (United States)

    Lowe, K E; Norman, A W

    1992-05-01

    Skin can serve as the source of vitamin D when exposed to sunlight so that cutaneous 7-dehydrocholesterol can be converted to the vitamin. Skin is also a target organ for the hormone form of vitamin D: 1,25-(OH)2D3. Both skin keratinocytes grown in tissue culture and samples of human skin have the nuclear receptor for 1,25(OH)2D3. New results suggest that this hormone or its analogs may be effective in treating some forms of psoriasis.

  6. ‘Den sociale død' - ‘det sociales død'

    DEFF Research Database (Denmark)

    Jacobsen, Michael Hviid

    2009-01-01

    Det er nu snart et kvart århundrede siden, at Norbert Elias udgav sin bog De døendes ensomhed, hvori han fremsætter tesen om de ældres og døendes tiltagende marginalisering og heraf følgende oplevelse af ensomhed i det moderne samfund. Denne artikel fokuserer i forlængelse heraf på en kort præsen...... præsentation af fænomenet ‘social død'....

  7. Drug: D07203 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07203 Drug Methylprednisolone aceponate (INN); Advantan (TN) C27H36O7 472.2461 472...STEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone D07203 Methylprednisolone a...ceponate (INN) D07AC Corticosteroids, potent (group III) D07AC14 Methylprednisolone... aceponate D07203 Methylprednisolone aceponate (INN) D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATION...S FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA02 Methylprednisolone D07203 Methylprednisolone

  8. Measurement of the Branching Ratios Gamma(D_s*+ -> D_s+ pi0)/Gamma(D_s*+ -> D_s+ gamma) and Gamma(D0+ -> D0 pi0)/Gamma(D0* -> D0 gamma)

    CERN Document Server

    Aubert, B; Boutigny, D; Couderc, F; Karyotakis, Yu; Lees, J P; Poireau, V; Tisserand, V; Zghiche, A; Graugès-Pous, E; Palano, A; Pappagallo, M; Pompili, A; Chen, J C; Qi, N D; Rong, G; Wang, P; Zhu, Y S; Eigen, G; Ofte, I; Stugu, B; Abrams, G S; Battaglia, M; Breon, A B; Brown, D N; Button-Shafer, J; Cahn, R N; Charles, E; Day, C T; Gill, M S; Gritsan, A V; Groysman, Y; Jacobsen, R G; Kadel, R W; Kadyk, J; Kerth, L T; Kolomensky, Yu G; Kukartsev, G; Lynch, G; Mir, L M; Oddone, P J; Orimoto, T J; Pripstein, M; Roe, N A; Ronan, M T; Wenzel, W A; Barrett, M; Ford, K E; Harrison, T J; Hart, A J; Hawkes, C M; Morgan, S E; Watson, A T; Fritsch, M; Goetzen, K; Held, T; Koch, H; Lewandowski, B; Pelizaeus, M; Peters, K; Schröder, T; Steinke, M; Boyd, J T; Burke, J P; Chevalier, N; Cottingham, W N; Çuhadar-Dönszelmann, T; Fulsom, B G; Hearty, C; Knecht, N S; Mattison, T S; McKenna, J A; Khan, A; Kyberd, P; Saleem, M; Teodorescu, L; Blinov, A E; Blinov, V E; Bukin, A D; Druzhinin, V P; Golubev, V B; Kravchenko, E A; Onuchin, A P; Serednyakov, S I; Skovpen, Yu I; Solodov, E P; Yushkov, A N; Best, D; Bondioli, M; Bruinsma, M; Chao, M; Curry, S; Eschrich, I; Kirkby, D; Lankford, A J; Lund, P; Mandelkern, M A; Mommsen, R K; Röthel, W; Stoker, D P; Buchanan, C; Hartfiel, B L; Weinstein, A J R; Foulkes, S D; Gary, J W; Long, O; Shen, B C; Wang, K; Zhang, L; Del Re, D; Hadavand, H K; Hill, E J; MacFarlane, D B; Paar, H P; Rahatlou, S; Sharma, V; Berryhill, J W; Campagnari, C; Cunha, A; Dahmes, B; Hong, T M; Mazur, M A; Richman, J D; Verkerke, W; Beck, T W; Eisner, A M; Flacco, C J; Heusch, C A; Kroseberg, J; Lockman, W S; Nesom, G; Schalk, T; Schumm, B A; Seiden, A; Spradlin, P; Williams, D C; Wilson, M G; Albert, J; Chen, E; Dubois-Felsmann, G P; Dvoretskii, A; Hitlin, D G; Minamora, J S; Narsky, I; Piatenko, T; Porter, F C; Ryd, A; Samuel, A; Andreassen, R; Mancinelli, G; Meadows, B T; Sokoloff, M D; Blanc, F; Bloom, P; Chen, S; Ford, W T; Hirschauer, J F; Kreisel, A; Nauenberg, U; Olivas, A; Ruddick, W O; Smith, J G; Ulmer, K A; Wagner, S R; Zhang, J; Chen, A; Eckhart, E A; Soffer, A; Toki, W H; Wilson, R J; Zeng, Q; Altenburg, D; Feltresi, E; Hauke, A; Spaan, B; Brandt, T; Brose, J; Dickopp, M; Klose, V; Lacker, H M; Nogowski, R; Otto, S; Petzold, A; Schubert, J; Schubert, K R; Schwierz, R; Sundermann, J E; Bernard, D; Bonneaud, G R; Grenier, P; Schrenk, S; Thiebaux, C; Vasileiadis, G; Verderi, M; Bard, D J; Clark, P J; Gradl, W; Muheim, F; Playfer, S; Xie, Y; Andreotti, M; Azzolini, V; Bettoni, D; Bozzi, C; Calabrese, R; Cibinetto, G; Luppi, E; Negrini, M; Piemontese, L; Anulli, F; Baldini-Ferroli, R; Calcaterra, A; De Sangro, R; Finocchiaro, G; Patteri, P; Peruzzi, I M; Piccolo, M; Zallo, A; Buzzo, A; Capra, R; Contri, R; Lo Vetere, M; Macri, M; Monge, M R; Passaggio, S; Patrignani, C; Robutti, E; Santroni, A; Tosi, S; Brandenburg, G; Chaisanguanthum, K S; Morii, M; Won, E; Wu, J; Dubitzky, R S; Langenegger, U; Marks, J; Schenk, S; Uwer, U; Schott, G; Bhimji, W; Bowerman, D A; Dauncey, P D; Egede, U; Flack, R L; Gaillard, J R; Nash, J A; Nikolich, M B; Panduro-Vazquez, W; Chai, X; Charles, M J; Mader, W F; Mallik, U; Mohapatra, A K; Ziegler, V; Cochran, J; Crawley, H B; Eyges, V; Meyer, W T; Prell, S; Rosenberg, E I; Rubin, A E; Yi, J; Arnaud, N; Davier, M; Giroux, X; Grosdidier, G; Höcker, A; Le Diberder, F R; Lepeltier, V; Lutz, A M; Oyanguren, A; Petersen, T C; Plaszczynski, S; Rodier, S; Roudeau, P; Schune, M H; Stocchi, A; Wormser, G; Cheng, C H; Lange, D J; Simani, M C; Wright, D M; Bevan, A J; Chavez, C A; Forster, I J; Fry, J R; Gabathuler, E; Gamet, R; George, K A; Hutchcroft, D E; Parry, R J; Payne, D J; Schofield, K C; Touramanis, C; Cormack, C M; Di Lodovico, F; Menges, W; Sacco, R; Brown, C L; Cowan, G; Flächer, H U; Green, M G; Hopkins, D A; Jackson, P S; McMahon, T R; Ricciardi, S; Salvatore, F; Brown, D; Davis, C L; Allison, J; Barlow, N R; Barlow, R J; Edgar, C L; Hodgkinson, M C; Kelly, M P; Lafferty, G D; Naisbit, M T; Williams, J C; Chen, C; Hulsbergen, W D; Jawahery, A; Kovalskyi, D; Lae, C K; Roberts, D A; Simi, G; Blaylock, G; Dallapiccola, C; Hertzbach, S S; Kofler, R; Koptchev, V B; Li, X; Moore, T B; Saremi, S; Stängle, H; Willocq, S; Cowan, R; Koeneke, K; Sciolla, G; Sekula, S J; Spitznagel, M; Taylor, F; Yamamoto, R K; Kim, H; Patel, P M; Robertson, S H; Lazzaro, A; Lombardo, V; Palombo, F; Bauer, J M; Cremaldi, L; Eschenburg, V; Godang, R; Kroeger, R; Reidy, J; Sanders, D A; Summers, D J; Zhao, H W; Brunet, S; Côte, D; Taras, P; Viaud, B; Nicholson, H; Cavallo, N; De Nardo, Gallieno; Fabozzi, F; Gatto, C; Lista, L; Monorchio, D; Paolucci, P; Piccolo, D; Sciacca, C; Baak, M; Bulten, H; Raven, G; Snoek, H L; Wilden, L; Jessop, C P; LoSecco, J M; Allmendinger, T; Benelli, G; Gan, K K; Honscheid, K; Hufnagel, D; Jackson, P D; Kagan, H; Kass, R; Pulliam, T; Rahimi, A M; Ter-Antonian, R; Wong, Q K; Brau, J E; Frey, R; Igonkina, O; Lu, M; Potter, C T; Sinev, N B; Strom, D; Strube, J; Torrence, E; Galeazzi, F; Margoni, M; Morandin, M; Posocco, M; Rotondo, M; Simonetto, F; Stroili, R; Voci, C; Benayoun, M; Briand, H; Chauveau, J; David, P; Del Buono, L; La Vaissière, C de; Hamon, O; John, M J J; Leruste, P; Malcles, J; Ocariz, J; Roos, L; Therin, G; Behera, P K; Gladney, L; Guo, Q H; Panetta, J; Biasini, M; Covarelli, R; Pacetti, S; Pioppi, M; Angelini, C; Batignani, G; Bettarini, S; Bucci, F; Calderini, G; Carpinelli, M; Cenci, R; Forti, F; Giorgi, M A; Lusiani, A; Marchiori, G; Morganti, M; Neri, N; Paoloni, E; Rama, M; Rizzo, G; Walsh, J; Haire, M; Judd, D; Wagoner, D E; Biesiada, J; Danielson, N; Elmer, P; Lau, Y P; Lü, C; Olsen, J; Smith, A J S; Telnov, A V; Bellini, F; Cavoto, G; D'Orazio, A; Di Marco, E; Faccini, R; Ferrarotto, F; Ferroni, F; Gaspero, M; Li Gioi, L; Mazzoni, M A; Morganti, S; Piredda, G; Polci, F; Safai-Tehrani, F; Voena, C; Schröder, H; Wagner, G; Waldi, R; Adye, T; De Groot, N; Franek, B; Gopal, G P; Olaiya, E O; Wilson, F F; Aleksan, Roy; Emery, S; Gaidot, A; Ganzhur, S F; Graziani, G; Hamel de Monchenault, G; Kozanecki, Witold; Legendre, M; London, G W; Mayer, B; Vasseur, G; Yéche, C; Zito, M; Purohit, M V; Weidemann, A W; Wilson, J R; Yumiceva, F X; Abe, T; Allen, M T; Aston, D; Bartoldus, R; Berger, N; Boyarski, A M; Buchmüller, O L; Claus, R; Coleman, J P; Convery, M R; Cristinziani, M; Dingfelder, J C; Dong, D; Dorfan, J; Dujmic, D; Dunwoodie, W M; Fan, S; Field, R C; Glanzman, T; Gowdy, S J; Hadig, T; Halyo, V; Hast, C; Hrynóva, T; Innes, W R; Kelsey, M H; Kim, P; Kocian, M L; Leith, D W G S; Libby, J; Luitz, S; Lüth, V; Lynch, H L; Marsiske, H; Messner, R; Müller, D R; O'Grady, C P; Ozcan, V E; Perazzo, A; Perl, M; Ratcliff, B N; Roodman, A; Salnikov, A A; Schindler, R H; Schwiening, J; Snyder, A; Stelzer, J; Su, D; Sullivan, M K; Suzuki, K; Swain, S K; Thompson, J M; Vavra, J; Van Bakel, N; Weaver, M; Wisniewski, W J; Wittgen, M; Wright, D H; Yarritu, A K; Yi, K; Young, C C; Burchat, P R; Edwards, A J; Majewski, S A; Petersen, B A; Roat, C; Ahmed, M; Ahmed, S; Alam, M S; Bula, R; Ernst, J A; Saeed, M A; Wappler, F R; Zain, S B; Bugg, W; Krishnamurthy, M; Spanier, S M; Eckmann, R; Ritchie, J L; Satpathy, A; Schwitters, R F; Izen, J M; Kitayama, I; Lou, X C; Ye, S; Bianchi, F; Bóna, M; Gallo, F; Gamba, D; Bomben, M; Bosisio, L; Cartaro, C; Cossutti, F; Della Ricca, G; Dittongo, S; Grancagnolo, S; Lanceri, L; Vitale, L; Martínez-Vidal, F; Panvini, R S; Banerjee, S; Bhuyan, B; Brown, C M; Fortin, D; Hamano, K; Kowalewski, R V; Roney, J M; Sobie, R J; Back, J J; Harrison, P F; Latham, T E; Mohanty, G B; Band, H R; Chen, X; Cheng, B; Dasu, S; Datta, M; Eichenbaum, A M; Flood, K T; Graham, M; Hollar, J J; Johnson, J R; Kutter, P E; Li, H; Liu, R; Mellado, B; Mihályi, A; Pan, Y; Pierini, M; Prepost, R; Tan, P; Wu, S L; Yu, Z; Neal, H

    2005-01-01

    Data samples corresponding to the isospin-violating decay $D_s^{*+}\\to D_s^+ \\pi^0$ and the decays $D_s^{*+}\\to D_s^+\\gamma$, $D^{*0}\\to D^0\\pi^0$ and $D^{*0}\\to D^0\\gamma$ are reconstructed using 90.4 ${\\rm fb}^{-1}$ of data recorded by the BaBar detector at the PEP-II asymmetric-energy $e^+e^-$ collider. The following branching ratios are extracted: $\\Gamma(D_s^{*+}\\to D_s^+ \\pi^0)/\\Gamma(D_s^{*+}\\to D_s^+\\gamma) = 0.062\\pm0.005 ({\\rm stat.})\\pm0.006 ({\\rm syst.})$ and $\\Gamma(D^{*0}\\to D^0\\pi^0)/\\Gamma(D^{*0}\\to D^0\\gamma) = 1.74\\pm0.02 ({\\rm stat.})\\pm0.13 ({\\rm syst.})$. Both measurements represent significant improvements over present world averages.

  9. Anatomy of $B\\rightarrow D\\bar{D}$ Decays

    CERN Document Server

    Bel, Lennaert; Fleischer, Robert; Mulder, Mick; Tuning, Niels

    2015-01-01

    The decays $B_d^0\\rightarrow D_d^-D_d^+$ and $B_s^0\\rightarrow D_s^-D_s^+$ probe the CP-violating mixing phases $\\phi_d$ and $\\phi_s$, respectively. The theoretical uncertainty of the corresponding determinations is limited by contributions from penguin topologies, which can be included with the help of the $U$-spin symmetry of the strong interaction. We analyse the currently available data for $B^0_{d,s}\\rightarrow D_{d,s}^-D_{d,s}^+$ decays and those with similar dynamics to constrain the involved non-perturbative parameters. Using further information from semileptonic $B_d^0\\rightarrow D_d^-\\ell^+\

  10. Drug: D06971 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06971 Formula, Drug Jiinshihoto Cyperus rhizome [DR:D06719], Bupleurum root [DR:D06727], Lycium bark [DR:D06737], Peony root [DR:D06739], Anemarrhena rhizome [DR:D06761], Citrus unshiu peel [DR:D06764], Japanese angelica root [DR:D06768], Ophiopogon tuber [DR:D06775], Atractylodes rhizome [DR:D06780], Poria sclerotium [DR:D06783], Fritillaria bulb [DR:D06774], Glycyrrhiza [DR:D04365], Peppermint [DR:D05431] Chronic sputum and cough Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06971 Jiinshihoto Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for replenishing Ying Formulas for replenishing Ying D06971 *Jiinshihoto Formulas for dampness Cough suppressant and expectorant formulas D06971 *Jiinshihoto PubChem: 51091313 ...

  11. ACTINOMYCIN D ANALOGUES

    DEFF Research Database (Denmark)

    1997-01-01

    The present invention relates to new compounds being structurally and functionally similar to Actinomycin D and to combinatorial libraries of such compounds. The Actinomycin D analogues according to the present invention comprise two linear or cyclic peptide moieties constituted by $g...

  12. 3D virtuel udstilling

    DEFF Research Database (Denmark)

    Tournay, Bruno; Rüdiger, Bjarne

    2006-01-01

    3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s.......3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s....

  13. Hypovitaminosis D in Thailand.

    Science.gov (United States)

    Soontrapa, Sukree; Soontrapa, Suppasin; Chailurkit, La-Or

    2009-09-01

    The hypovitaminosis D in the premenopausal women and the postmenopausal elderly women in Thailand was investigated. One hundred and six cases of the elderly women living in the urban area of Khon Kaen province, one hundred and thirty-two cases of the elderly women living in the rural area of Khon Kaen province, ninety-eight cases of the postmenopausal women who attended Menopausal Clinic, Srinagarind Hospital, Khon Kaen province, and 357 premenopausal women from the multicenters in Thailand were the subjects. The serum level of 25(OH)D hypovitaminosis D. The prevalence of hypovitaminosis D in these selected groups of women was 65.4, 15.4, 60.2, and 77.8 percent respectively. The premenopausal female group had the highest prevalence of hypovitaminosis D and the lowest level of 25 (OH) D whereas the group of the postmenopausal elderly women in the rural area had the lowest prevalence of hypovitaminosis D and the highest 25 (OH) D level.

  14. Vitamin D Deficiency

    Science.gov (United States)

    ... body forms vitamin D naturally after exposure to sunlight. But too much sun exposure can lead to skin aging and skin cancer, ... a malabsorption problem) You don't get enough exposure to sunlight. Your liver or kidneys cannot convert vitamin D ...

  15. Beyond Type D personality

    DEFF Research Database (Denmark)

    Pelle, Aline J; Pedersen, Susanne S.; Szabó, Balázs M

    2009-01-01

    Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important.......Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important....

  16. Vitamin D Deficiency

    Science.gov (United States)

    ... and the foods you eat. Foods with natural vitamin D include: • Certain fish: salmon, sardines, mackerel, tuna • Cod liver oil • Shiitake mushrooms • Egg yolks Foods that often have added vitamin D include: • Dairy products • Orange juice • Infant formula • ...

  17. Vitamin D and Cancer

    Science.gov (United States)

    Vuolo, Laura; Di Somma, Carolina; Faggiano, Antongiulio; Colao, Annamaria

    2012-01-01

    Vitamin D system is a complex pathway that includes precursors, active metabolites, enzymes, and receptors. This complex system actives several molecular pathways and mediates a multitude of functions. In addition to the classical role in calcium and bone homeostasis, vitamin D plays “non-calcemic” effects in host defense, inflammation, immunity, and cancer processes as recognized in vitro and in vivo studies. The aim of this review is to highlight the relationship between vitamin D and cancer, summarizing several mechanisms proposed to explain the potential protective effect of vitamin D against the development and progression of cancer. Vitamin D acts like a transcription factor that influences central mechanisms of tumorigenesis: growth, cell differentiation, and apoptosis. In addition to cellular and molecular studies, epidemiological surveys have shown that sunlight exposure and consequent increased circulating levels of vitamin D are associated with reduced reduced occurrence and a reduced mortality in different histological types of cancer. Another recent field of interest concerns polymorphisms of vitamin D receptor (VDR); in this context, preliminary data suggest that VDR polymorphisms more frequently associated with tumorigenesis are Fok1, Bsm1, Taq1, Apa1, EcoRV, Cdx2; although further studies are needed to clarify their role in the cancer. In this review, the relationship between vitamin D and cancer is discussed. PMID:22649423

  18. Beyond Type D personality

    DEFF Research Database (Denmark)

    Pelle, Aline J; Pedersen, Susanne S.; Szabó, Balázs M

    2009-01-01

    Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important.......Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important....

  19. ACTINOMYCIN D ANALOGUES

    DEFF Research Database (Denmark)

    1997-01-01

    The present invention relates to new compounds being structurally and functionally similar to Actinomycin D and to combinatorial libraries of such compounds. The Actinomycin D analogues according to the present invention comprise two linear or cyclic peptide moieties constituted by $g...

  20. Enterovirus D68 Infection

    Directory of Open Access Journals (Sweden)

    Susanna Esposito

    2015-11-01

    Full Text Available First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68 is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many reports from different countries have described an increasing number of patients with respiratory diseases due to EV-D68 associated with relevant clinical severity. In particular, an unexpectedly high number of children have been hospitalized for severe respiratory disease due to EV-D68, requiring intensive care such as intubation and mechanical ventilation. Moreover, EV-D68 has been associated with acute flaccid paralysis and cranial nerve dysfunction in children, which has caused concerns in the community. As no specific antiviral therapy is available, treatment is mainly supportive. Moreover, because no vaccines are available, conventional infection control measures (i.e., standard, for contacts and droplets in both community and healthcare settings are recommended. However, further studies are required to fully understand the real importance of this virus. Prompt diagnosis and continued surveillance of EV-D68 infections are essential to managing and preventing new outbreaks. Moreover, if the association between EV-D68 and severe diseases will be confirmed, the development of adequate preventive and therapeutic approaches are a priority.

  1. 4D Electron Tomography

    Science.gov (United States)

    Kwon, Oh-Hoon; Zewail, Ahmed H.

    2010-06-01

    Electron tomography provides three-dimensional (3D) imaging of noncrystalline and crystalline equilibrium structures, as well as elemental volume composition, of materials and biological specimens, including those of viruses and cells. We report the development of 4D electron tomography by integrating the fourth dimension (time resolution) with the 3D spatial resolution obtained from a complete tilt series of 2D projections of an object. The different time frames of tomograms constitute a movie of the object in motion, thus enabling studies of nonequilibrium structures and transient processes. The method was demonstrated using carbon nanotubes of a bracelet-like ring structure for which 4D tomograms display different modes of motion, such as breathing and wiggling, with resonance frequencies up to 30 megahertz. Applications can now make use of the full space-time range with the nanometer-femtosecond resolution of ultrafast electron tomography.

  2. D-term strings

    CERN Document Server

    Dvali, Gia; Van Proeyen, A; Dvali, Gia; Van Proeyen, Antoine

    2004-01-01

    We study the embedding of cosmic strings, related to the Abrikosov-Nielsen-Olesen vortex solution, into d=4, N=1 supergravity. We find that the local cosmic string solution which saturates the BPS bound of supergravity with the D-term potential for the Higgs field and with the constant Fayet--Iliopoulos term, has 1/2 of supersymmetry unbroken. We observe an interesting relation between the gravitino supersymmetry transformation, positive energy condition and the deficit angle of the cosmic string. We argue that the string solutions with the magnetic flux with F-term potential cannot be supersymmetric, which leads us to a conjecture that D1-strings of string theory in the effective 4d supergravity may be described by the D-term strings, which we study in this paper.

  3. Drug: D07031 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available oria sclerotium [DR:D06783], Moutan bark [DR:D06788], Cinnamon bark [DR:D06712], Processed aconite root [DR:D06784] Nephritis; Diabet...es; Oscheitis; Sciatic pain; High pressure (HP); Geriatr

  4. Drug: D06233 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06233 Mixture, Drug Trikates (USP) Potassium acetate [DR:D01154], Potassium bicarbonate [DR:D02077], Potass...ium citrate [DR:D05578] Replenisher [electrolyte] PubChem: 47207891 ...

  5. Drug: D09062 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09062 Formula, Drug Kanzoshashinto Pinellia tuber [DR:D06778], Scutellaria root [D...ormulas Formulas for stomach Antidiarrheal formulas D09062 Kanzoshashinto PubChem: 96025743 ...

  6. Drug: D02120 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02120 Mixture, Drug Citric acid monohydrate - potassium bicarbonate mixt; K-lyte (...TN) Citric acid monohydrate [DR:D01222], Potassium bicarbonate [DR:D02077] PubChem: 7849181 LigandBox: D02120 ...

  7. Drug: D08432 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available L. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topical use D04AA10 Promethazine D08432 Promet...e Respiratory Tract/Pulmonary Agents Antihistamines Promethazine D08432 Promethazine maleate Target-based cl

  8. Drug: D02419 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available , INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topical use D0... Diphenhydramine D02419 Diphenhydramine salicylate (JAN) Respiratory Tract/Pulmonary Agents Antihistamines D

  9. Drug: D07196 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 12 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D04 ANTIPRURITICS, IN...CL. ANTIHISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Anti

  10. Drug: D00073 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGIC...AL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other dermatologicals

  11. Drug: D00418 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available AR SMOOTH MUSCLE, AGENTS ACTING ON C02DC Pyrimidine derivatives C02DC01 Minoxidil D00418 Minoxidil (JAN/USP/INN) D DERMATOLOGIC...ALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGIC

  12. Drug: D02164 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available PD:C20389]) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AJ Quaternary ammoniu

  13. Drug: D02905 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ed Aminoacridine in INN. Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AA Acrid

  14. Drug: D01730 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available itrate (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AL Silver compo

  15. Drug: D09064 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09064 Formula, Drug Kyukichoketsuindaiichikagen Japanese angelica root [DR:D06768], Cnidium rhizome [DR:D06748], Rehmannia root [DR:D06736], (Atractylodes lancea rhizome [DR:D06752] | Atractylodes rhizome [DR:D06780]), Poria sclerotium [DR:D06783], Citrus unshiu peel [DR:D06764], Lindera root [DR:D06696], Cyperus rhizome [DR:D06719], Moutan bark [DR:D06788], Leonuri herba [DR:D06913], Jujube [DR:D06758], Glycyrrhiza [DR:D04365], (Dry ginger [DR:D06744] | Processed ginger [DR:D06702]), Peony root [DR:D06739], Peach kernel [DR:D06769], Safflower [DR:D06717], Immature orange [DR:D06706], Cinnamon bark [DR:D06712], Achyranthes root [DR:D06722], Saussurea root [DR:D06795], Corydalis tuber [DR:D06686] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formulas for replenishing blood D09064 Kyukichoketsuindaiichikagen PubChem: 96025745 ...

  16. Drug: D03285 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for top...ical use D04AA32 Diphenhydramine D03285 Diphenhydramine tannate (JP16) R RESPIRATOR

  17. Drug: D07197 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topi...cal use D04AA15 Bamipine D07197 Bamipine (INN) R RESPIRATORY SYSTEM R06 ANTIHISTAMI

  18. Drug: D09110 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09110 Formula, Drug Shakosaito; Sammishakosaito Digenea [DR:D06792], Rhubarb [DR:D...elling parasites Anthelmintic formulas D09110 Shakosaito; Sammishakosaito PubChem: 96025790 ...

  19. Drug: D04366 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04366 Mixture, Drug Pipethanate hydrochloride - magnesium aluminometasilicate - liqourice extract... mixt; Geschwur (TN) Pipethanate hydrochloride [DR:D01521], Magunesium aluminometasilicate [DR:D03242], Crude glycyrrhiza extract [DR:D06811] PubChem: 17398077 ...

  20. Drug: D06417 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available N) Cresol [DR:D01960], Vegetable oil, (Potassium hydroxide [DR:D01168] | Sodium hydroxide [DR:D01169]), Wate...D06417 Mixture, Drug Saponated cresol solution (JP16); Saponated cresol solution (T

  1. Drug: D09103 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09103 Formula, Drug Goshitsusan Achyranthes root [DR:D06722], Cinnamon bark [DR:D0...br08304] Formulas Formulas for blood Formulas for removing blood stasis D09103 Goshitsusan PubChem: 96025783 ...

  2. Drug: D10299 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iasis ATC code: D07CB01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOST...EROIDS, DERMATOLOGICAL PREPARATIONS D07C CORTICOSTEROIDS, COMBINATIO

  3. Drug: D00863 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available apeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ... antiinfectives D09AA09 Povidone-iodine D00863 Povidone-Iodine (JP16/USP) D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOG...one-iodine D00863 Povidone-Iodine (JP16/USP) G GENITO URINARY SYSTEM AND SEX HORMONES G01 GYNECOLOGICAL ANTI...A15 Povidone-iodine D00863 Povidone-Iodine (JP16/USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECT...ICAL PREPARATIONS D11AC Medicated shampoos D11AC06 Povid

  4. Drug: D09049 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09049 Formula, Drug Bunshoto (Atractylodes lancea rhizome [DR:D06752] | Atractylod...es rhizome [DR:D06780]), Poria sclerotium [DR:D06783], Citrus unshiu peel [DR:D06764], Magnolia bark [DR:D06720], Cyperu...s rhizome [DR:D06719], Polyporus sclerotium [DR:D06763], Alisma rhizome [DR:D06759], Immature or... [DR:D06795], Ginger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304] Formul

  5. Drug: D04470 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04470 Mixture, Drug Dilute iodine tincture (JP16); Dilute iodine tincture (TN) Iod...ine [DR:D00108], Potassium iodine [DR:D01016], (70 percent Alcohol [DR:D00068] | Isopropanol [DR:D00137] | M...nts 2612 Iodates D04470 Dilute iodine tincture (JP16) Anatomical Therapeutic Chemical (ATC) classification [...ine products D08AG03 Iodine D04470 Dilute iodine tincture (JP16) PubChem: 47206326 ...

  6. Drug: D05000 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05000 Drug Methylprednisolone succinate (JP16); Methylprednisolone hemisuccinate (...RMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone... D05000 Methylprednisolone succinate (JP16); Methylprednisolone hemisuc...ombinations for treatment of acne D10AA02 Methylprednisolone D05000 Methylprednisolone succinate (JP16); Methylprednisolone... Glucocorticoids H02AB04 Methylprednisolone D05000 Methylprednisolone succinate (JP16); Methylprednisolone h

  7. INEL D&D long-range plan

    Energy Technology Data Exchange (ETDEWEB)

    Buckland, R.J.; Kenoyer, D.J.; LaBuy, S.A.

    1995-09-01

    This Long-Range Plan presents the Decontamination and Dismantlement (D&D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D&D Program objectives, management criteria, and policy; discusses current activities; and documents the INEL D&D Program cost and schedule estimate projections for the next 15 years. Appendices are included that provide INEL D&D project historical information, a comprehensive descriptive summary of each current D&D surplus facility, and a summary database of all INEL contaminated facilities awaiting or undergoing the facility transition process.

  8. 3D/2D Registration of medical images

    OpenAIRE

    Tomaževič, D.

    2008-01-01

    The topic of this doctoral dissertation is registration of 3D medical images to corresponding projective 2D images, referred to as 3D/2D registration. There are numerous possible applications of 3D/2D registration in image-aided diagnosis and treatment. In most of the applications, 3D/2D registration provides the location and orientation of the structures in a preoperative 3D CT or MR image with respect to intraoperative 2D X-ray images. The proposed doctoral dissertation tries to find origin...

  9. Drug: D06816 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06816 Mixture, Drug Arsenical paste (JP16) Arsenic trioxide [DR:D02106], Procaine hydrochloride [DR:D00740], Hydrophilic ointment [DR:D05237], Clove oil [DR:D06823], Medicinal carbon [DR:D03251] PubChem: 47208467 ...

  10. Drug: D07213 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 1 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other dermatologicals D11AX...426 ATC code: D11AX02 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D1

  11. Drug: D07211 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available B03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PRE...PARATIONS FOR TOPICAL USE D10AB Preparations containing sulfur D10AB03 Tioxolone D0

  12. Drug: D00056 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available AA Enzymes B06AA07 Trypsin D00056 Trypsin (JAN); Trypsin, crystallized (USP) D DERMATOLOGICALS D03 PREPARA...TIONS FOR TREATMENT OF WOUNDS AND ULCERS D03B ENZYMES D03BA Proteolytic enzymes D03

  13. Drug: D03854 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Tract/Pulmonary Agents Antihistamines Diphenhydramine D03854 Diphenhydramine citrate (USP) Target-based cla...ANTIHISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihi...stamines for topical use D04AA32 Diphenhydramine D03854 Diphenhydramine citrate (US...(USP) Antiparkinson Agents Anticholinergics Diphenhydramine D03854 Diphenhydramine citrate (USP) Respiratory

  14. Drug: D06661 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06661 Drug Dimethisoquin hydrochloride (USAN); Quinisocaine hydrochloride C17H24N2...O. HCl 308.1655 308.8462 D06661.gif ATC code: D04AB05 Dimethisoquin is called Quinisocaine in INN. Anatomica...ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D06661 Dimethisoquin hydrochloride (USAN) CAS: 2

  15. Drug: D03965 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03965 Mixture, Drug Salsocain; Salsocain (TN) Sulpyrine [DR:D01762], Sodium salicy...late [DR:D00566], Allobarbital [DR:D02817], Procaine hydrochloride [DR:D00740], Caffeine [DR:D01453] CAS: 85886-25-5 PubChem: 47205951 ...

  16. Drug: D06139 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ATC code: D01AE08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGI...CAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D0

  17. Drug: D09107 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available root [DR:D06736], Peach kernel [DR:D06769], Peony root [DR:D06739], Immature orange [DR:D06706], Leek, Rhuba...D09107 Formula, Drug Jiketsujunchoto Japanese angelica root [DR:D06768], Rehmannia

  18. Drug: D07209 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available .gif ATC code: D08AK02 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AK Mercurial products D08AK02 Phenylm

  19. Drug: D01905 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 77 ATC code: D08AK03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AK Mercurial products D08AK03 Mercuric

  20. Drug: D03135 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FOR TOPICAL USE D10AB Preparations containing sulfur D10AB01 Bithionol D03135 Bi...l (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS

  1. Drug: D06925 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nseng [DR:D06772], Jujube [DR:D06758], Pinellia tuber [DR:D06778], (Cinnamon bark [DR:D06712] | Cinnamon branch [ED:E00249]), (Proces...sed ginger [DR:D06702] | Ginger [DR:D06744]) Acute gastritis; Hangover; Stomatitis

  2. Drug: D06957 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ed [DR:D05525], Alisma rhizome [DR:D06759], Poria sclerotium [DR:D06783], Moutan bark [DR:D06788], Cinnamon bark [DR:D06712], Process...ed aconite root [DR:D06784] Leg pain; LBP; Numbness; Ger

  3. Drug: D07007 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nidium rhizome [DR:D06748], Processed aconite root [DR:D06784], (Glehnia root [DR...:D06777] | Saposhnikovia root [DR:D06787]), (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]), (Processed

  4. Drug: D00526 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH03 Cromoglicic acid D00526 Sodium cromogli...ation [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARA

  5. Drug: D07214 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available atologicals D11AX08 Tiratricol D07214 Tiratricol (INN) H SYSTEMIC HORMONAL PREPARAT...fication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other derm

  6. Drug: D07540 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tologicals D11AX21 Brimonidine D07540 Brimonidine (INN) S SENSORY ORGANS S01 OPHTHA...ication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other derma

  7. Drug: D02273 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02273 Mixture, Drug Isoproterenol sulfate - dexamethasone - atropine methybromide ...mixt; Stmerin D (TN) Isoproterenol sulfate [DR:D02066], Atropine methylbromide [DR:D03814], Dexamethasone [D...9 Others D02273 Isoproterenol sulfate - dexamethasone - atropine methybromide mixt PubChem: 7849332 ...

  8. Drug: D04875 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04875 Mixture, Drug Zinc sulfate - iodine - sodium iodine - glycerin mixt; Neoglyc...erol (TN) Zinc sulfate [DR:D01081], Iodine [DR:D00108], Sodium iodine [DR:D04874], Glycerin [DR:D00028] Ther...ans 27 Dental preparations 279 Miscellaneous 2790 Miscellaneous D04875 Zinc sulfate - iodine - sodium iodine - glycerin mixt PubChem: 17398205 ...

  9. Drug: D03283 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03283 Mixture, Drug Cadexomer iodine (USAN); Iodine - cadexomer mixt; Iodosorb (TN... Epidermides 269 Miscellaneous 2699 Others D03283 Cadexomer iodine (USAN) Anatomi...OF WOUNDS AND ULCERS D03A CICATRIZANTS D03AX Other cicatrizants D03AX01 Cadexomer iodine D03283 Cadexomer iodine (USAN) CAS: 94820-09-4 PubChem: 17397435 ...

  10. Drug: D09082 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09082 Formula, Drug Tokisan Japanese angelica root [DR:D06768], Peony root [DR:D06...ractylodes lancea rhizome [DR:D06752] | Atractylodes rhizome [DR:D06780]) Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for blood Formulas for replenishing blood D09082 Tokisan PubChem: 96025763 ...

  11. Drug: D09112 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09112 Formula, Drug Jogan'ippo Glycyrrhiza [DR:D04365], Coptis rhizome [DR:D00092]..., Phellodendron bark [DR:D06689], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for external use Formulas for external use D09112 Jogan'ippo PubChem: 96025792 ...

  12. Drug: D09084 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09084 Formula, Drug Chuoko Sesame oil [DR:D03314], Yellow beewax [DR:D04968], Term...eric [DR:D06695], Phellodendron bark [DR:D06689] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for external use Formulas for external use D09084 Chuoko PubChem: 96025765 ...

  13. Drug: D09073 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09073 Formula, Drug Byakkoto Gypsum [DR:D01728], Anemarrhena rhizome [DR:D06761], ...Oryzae semen [DR:D06900], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09073 Byakkoto PubChem: 96025754 ...

  14. Drug: D09111 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09111 Formula, Drug Jashoshito Cnidium monnieri fruit [DR:D06740], Japanese angeli...ca root [DR:D06768], Clematis root [DR:D06694], Sophora root [DR:D06710] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for external use Formulas for external use D09111 Jashoshito PubChem: 96025791 ...

  15. Drug: D09090 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09090 Formula, Drug Sesshoin Japanese angelica root [DR:D06768], Peony root [DR:D0...yranthes root [DR:D06722], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formul...as Formulas for blood Formulas for removing blood stasis D09090 Sesshoin PubChem: 96025770 ...

  16. Drug: D09055 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09055 Formula, Drug Kakkon'oren'ogonto Pueraria root [DR:D06693], Coptis rhizome [...DR:D00092], Scutellaria root [DR:D06688], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09055 Kakkon'oren'ogonto PubChem: 96025736 ...

  17. Drug: D09075 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available icine in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09075 Hachimishoyosan PubChem: 96025756 ... ...[DR:D06780]), Bupleurum root [DR:D06727], Glycyrrhiza [DR:D04365], Ginger [DR:D06744], Peppermint [DR:D05431] Traditional Chinese Med

  18. Drug: D03697 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC03 Desoximetasone D03697 Desoximetas...one (USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07

  19. Drug: D07429 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ATMENT OF WOUNDS AND ULCERS D03A CICATRIZANTS D03AX Other cicatrizants D03AX09 Crilanomer D07429 Crilanomer (INN) PubChem: 51091762 ... ...ylonitrile [CPD:C01998]. Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D03 PREPARATIONS FOR TRE

  20. Drug: D08715 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08715 Mixture, Drug dl-Camphor - dl-menthol - methyl salicylate - diphenhydramine ...mixt; Salymetick S (TN) dl-Camphor [DR:D00098], (dl-Menthol [DR:D04849] | l-Menthol [DR:D00064]), Methyl salicylate [DR:D01087], Diphenhydramine [DR:D00300] PubChem: 96025398 ...

  1. Measurements of $B \\to D_{s^{(*)+}} D^{*(*)}$ Branching Fractions

    CERN Document Server

    Ahmed, S; Athar, S B; Jian, L; Ling, L; Saleem, M; Timm, S; Wappler, F; Anastassov, A; Duboscq, J E; Eckhart, E; Gan, K K; Gwon, C; Hart, T; Honscheid, K; Hufnagel, D; Kagan, H; Kass, R; Pedlar, T K; Schwarthoff, H; Thayer, J B; Von Törne, E; Zoeller, M M; Richichi, S J; Severini, H; Skubic, P L; Undrus, A; Chen, S; Fast, J; Hinson, J W; Lee, J; Miller, D H; Shibata, E I; Shipsey, I P J; Pavlunin, V; Cronin-Hennessy, D; Lyon, A L; Thorndike, E H; Jessop, C P; Marsiske, H; Perl, Martin Lewis; Savinov, V; Zhou, X; Coan, T E; Fadeev, V; Maravin, Y; Narsky, I; Stroynowski, R; Ye, J; Wlodek, T; Artuso, M; Ayad, R; Boulahouache, C; Bukin, K; Dambasuren, E; Karamov, S; Majumder, G; Moneti, G C; Mountain, R; Schuh, S; Skwarnicki, T; Stone, S; Viehhauser, G; Wang, J C; Wolf, A; Wu, J; Kopp, S E; Mahmood, A H; Csorna, S E; Danko, I; McLean, K W; Marka, S; Xu, Z; Godang, R; Kinoshita, K; Lai, I C; Schrenk, S; Bonvicini, G; Cinabro, D; McGee, S A; Perera, L P; Zhou, G J; Lipeles, E; Pappas, S P; Schmidtler, M; Shapiro, A; Sun, W M; Weinstein, A J; Würthwein, F; Jaffe, D E; Masek, G E; Paar, H P; Potter, E M; Prell, S; Sharma, V; Asner, D M; Eppich, A; Hill, T S; Morrison, R J; Nelson, H N; Richman, J D; Witherell, M S; Briere, R A; Chen, G P; Behrens, B H; Ford, W T; Gritsan, A; Roy, J D; Smith, J G; Alexander, J P; Baker, R; Bebek, C; Berger, B E; Berkelman, K; Blanc, F; Boisvert, V; Cassel, David G; Dickson, M; Drell, P S; Ecklund, K M; Ehrlich, R; Foland, A D; Gaidarev, P B; Gibbons, L K; Gittelman, B; Gray, S W; Hartill, D L; Heltsley, B K; Hopman, P I; Jones, C D; Kreinick, D L; Lohner, M; Magerkurth, A; Meyer, T O; Mistry, N B; Nordberg, E; Patterson, J R; Peterson, D; Riley, D; Thayer, J G; Urner, D; Valant-Spaight, B L; Warburton, A; Avery, P; Prescott, C; Rubiera, A I; Yelton, J; Zheng, J; Brandenburg, G; Ershov, A; Gao, Y S; Kim, D Y J; Wilson, R; Browder, T E; Li, Y; Rodríguez, J L; Yamamoto, H; Bergfeld, T; Eisenstein, B I; Ernst, J; Gladding, G E; Gollin, G D; Hans, R M; Johnson, E; Karliner, I; Marsh, M A; Palmer, M; Plager, C; Sedlack, C; Selen, M; Thaler, J J; Williams, J; Edwards, K W; Janicek, R; Patel, P M; Sadoff, A J; Ammar, R; Bean, A; Besson, D; Davis, R; Kwak, N; Zhao, X; Anderson, S; Frolov, V V; Kubota, Y; Lee, S J; Mahapatra, R; O'Neill, J J; Poling, R A; Riehle, T; Smith, A; Stepaniak, C J; Urheim, J

    2000-01-01

    This article describes improved measurements by CLEO of the $B^0 \\to D_s^+ D^{*-}$ and $B^0 \\to D_s^{*+} D^{*-}$ branching fractions, and first evidence for the decay $B^+ \\to D_s^{(*)+} \\bar{D}^{**0}$, where $\\bar{D}^{**0}$ represents the sum of the $\\bar{D}_1(2420)^0$, $\\bar{D}_2^*(2460)^0 $, and $\\bar{D}_1(j=1/2)^0$ L=1 charm meson states. Also reported is the first measurement of the $D_s^{*+}$ polarization in the decay $B^0 \\to D_s^{*+} D^{*-}$. A partial reconstruction technique, employing only the fully reconstructed $D_s^+$ and slow pion $\\pi_s^-$ from the $D^{*-} \\to \\bar{D}^0 \\pi^-_s$ decay, enhances sensitivity. The observed branching fractions are $ {\\mathcal B} (B^0 \\to D_s^+ D^{*-}) = (1.10 \\pm 0.18 \\pm 0.10 \\pm 0.28)%$, $ {\\mathcal B} (B^0 \\to D_s^{*+} D^{*-}) = (1.82 \\pm 0.37 \\pm 0.24 \\pm 0.46)%$, and $ {\\mathcal B} (B^+ \\to D_s^{(*)+} \\bar{D}^{**0}) = (2.73 \\pm 0.78 \\pm 0.48 \\pm 0.68)%$, where the first error is statistical, the second systematic, and the third is due to the uncertainty in th...

  2. Blender 3D cookbook

    CERN Document Server

    Valenza, Enrico

    2015-01-01

    This book is aimed at the professionals that already have good 3D CGI experience with commercial packages and have now decided to try the open source Blender and want to experiment with something more complex than the average tutorials on the web. However, it's also aimed at the intermediate Blender users who simply want to go some steps further.It's taken for granted that you already know how to move inside the Blender interface, that you already have 3D modeling knowledge, and also that of basic 3D modeling and rendering concepts, for example, edge-loops, n-gons, or samples. In any case, it'

  3. X(3872) and Bound State Problem of D~0(D)*~0((D)~0D*~0)

    Institute of Scientific and Technical Information of China (English)

    LIU Tan-rui; LIU Xiang; DENG Wei-zhen

    2009-01-01

    We have performed a dynamical calculation of the bound state problem of D~0(D)~(*0) by considering the pion and sigma meson exchange potential.Our preliminary analysis disfavors the molecular interpretation of X(3872) if we use the experimental D~* Dπ coupling constant g=0.59 and a reasonable cutoff around 1 GeV,which is the typical hadronic scale.In contrast,there probably exists a loosely bound S-wave B (-B)~* molecular state.Such a molecular state would be rather stable since its dominant decay mode is the radiative decay through B~*→Bγ.

  4. Purification of radium-226 for the manufacturing of actinium-225 in a cyclotron for alpha-immunotherapy; Radium-Aufreinigung zur Herstellung von Actinium-225 am Zyklotron fuer die Alpha-Immuntherapie

    Energy Technology Data Exchange (ETDEWEB)

    Marx, Sebastian Markus

    2014-09-23

    The thesis describes the development of methods for the purification of Ra-226. The objective was to obtain the radionuclide in the quality that is needed to be used as starting material in the manufacturing process for Ac-225 via proton-irradiated Ra-226. The radionuclide has been gained efficiently out of huge excesses of impurities. The high purity of the obtained radium affords its use as staring material in a pharmaceutical manufacturing process.

  5. Drug: D02174 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...ne acetate (JAN/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...ations D07XB05 Dexamethasone D02174 Dexamethasone acetate (JAN/USP) D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment ...of acne D10AA03 Dexamethasone D02174 Dexamethasone acetate (JAN/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL.

  6. Drug: D02592 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ssification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...thasone beloxil (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROI...ately potent, other combinations D07XB05 Dexamethasone D02592 Dexamethasone beloxil (USAN) D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of a...cne D10AA03 Dexamethasone D02592 Dexamethasone beloxil (USAN) H SYSTEMIC HORMONAL PREPARATION

  7. Drug: D02500 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02500 Drug Imiquimod (JAN/USAN/INN); Aldara (TN); Zyclara (TN) C14H16N4 240.1375 240.3036 D02500...therapeutics 629 Miscellaneous 6290 Miscellaneous D02500 Imiquimod (JAN/USAN/INN) Anatomical Therapeutic Che...OGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BB Antivirals D06BB10 Imiquimod D02500... Imiquimod (JAN/USAN/INN) USP drug classification [BR:br08302] Dermatological Agents Imiquimod D02500...ll-like receptor 7 [HSA:51284] [KO:K05404] Imiquimod [ATC:D06BB10] D02500 Imiquim

  8. Drug: D00976 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cortisone cypionate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS,... PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00976 Hydrocortisone cypionate D07X CORTICOST...D07XA01 Hydrocortisone D00976 Hydrocortisone cypionate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOS...TEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucoco...ortisone cypionate S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D00976

  9. Drug: D09796 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available AA01 Hydrocortisone D09796 Hydrocortisone caproate (JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGIC...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D09...796 Hydrocortisone caproate (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, othe...EMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOST...3 Hydrocortisone D09796 Hydrocortisone caproate (JAN) S02 OTOLOGICALS S02B CORTICOST

  10. Drug: D04467 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Hydrocortisone D04467 Hydrocortisone hemisuccinate (USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGIC...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D04...467 Hydrocortisone hemisuccinate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D...SP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOST...2 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D04467 Hydrocortisone hemisu

  11. Drug: D01948 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroid... TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethasone D01948 Dexamethasone valerate (JAN) D DERMATOLOGICA...LS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids... D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combinations D07XB...10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA03

  12. $X(3872)$ production from reactions involving $D$ and $D^*$ mesons

    CERN Document Server

    Torres, A Martinez; Navarra, F S; Nielsen, M; Abreu, Luciano M

    2014-01-01

    In this proceeding we show the results found for the cross sections of the processes $\\bar D D\\to\\pi X(3872)$, $\\bar D^* D\\to \\pi X(3872)$ and $\\bar D^* D^*\\to\\pi X(3872)$, information needed for calculations of the $X(3872)$ abundance in heavy ion collisions. Our formalism is based on the generation of $X(3872)$ from the interaction of the hadrons $\\bar D^0 D^{*0} - \\textrm{c.c}$, $D^- D^{*+} - \\textrm{c.c}$ and $D^-_s D^{*+}_s - \\textrm{c.c}$. The evaluation of the cross section associated with processes having $D^*$ meson(s) involves an anomalous vertex, $X\\bar D^* D^*$, which we have determined by considering triangular loops motivated by the molecular nature of $X(3872)$. We find that the contribution of this vertex is important. Encouraged by this finding we estimate the $X\\bar D^* D^*$ coupling, which turns out to be $1.95\\pm 0.22$. We then use it to obtain the cross section for the reaction $\\bar D^* D^*\\to\\pi X$ and find that the $X\\bar D^* D^*$ vertex is also relevant in this case. We also discuss t...

  13. Donato D'Urbino

    Index Scriptorium Estoniae

    2005-01-01

    Itaalia arhitektide-disainerite Jonathan De Pasi, Donato D'Urbino, Paolo Lomazzi ja Carla Scolari kavandatud ning Itaalia firmas Zanotta S.p.A. toodetud täispuhutavast plastikust tugitoolist "Blow" (1967)

  14. 3D Digital Modelling

    DEFF Research Database (Denmark)

    Hundebøl, Jesper

    wave of new building information modelling tools demands further investigation, not least because of industry representatives' somewhat coarse parlance: Now the word is spreading -3D digital modelling is nothing less than a revolution, a shift of paradigm, a new alphabet... Research qeustions. Based...... on empirical probes (interviews, observations, written inscriptions) within the Danish construction industry this paper explores the organizational and managerial dynamics of 3D Digital Modelling. The paper intends to - Illustrate how the network of (non-)human actors engaged in the promotion (and arrest) of 3......D Modelling (in Denmark) stabilizes - Examine how 3D Modelling manifests itself in the early design phases of a construction project with a view to discuss the effects hereof for i.a. the management of the building process. Structure. The paper introduces a few, basic methodological concepts...

  15. Calcium and Vitamin D

    Science.gov (United States)

    ... Pizza, cheese, frozen 1 serving 115 mg Pudding, chocolate, prepared with 2% milk 4 oz 160 mg ... Treatment Medication and Treatment Adherence Calcium/Vitamin D Nutrition Overall Health Fractures/Fall Prevention Exercise/Safe Movement ...

  16. DELTA 3D PRINTER

    Directory of Open Access Journals (Sweden)

    ȘOVĂILĂ Florin

    2016-07-01

    Full Text Available 3D printing is a very used process in industry, the generic name being “rapid prototyping”. The essential advantage of a 3D printer is that it allows the designers to produce a prototype in a very short time, which is tested and quickly remodeled, considerably reducing the required time to get from the prototype phase to the final product. At the same time, through this technique we can achieve components with very precise forms, complex pieces that, through classical methods, could have been accomplished only in a large amount of time. In this paper, there are presented the stages of a 3D model execution, also the physical achievement after of a Delta 3D printer after the model.

  17. D and C

    Science.gov (United States)

    Dilatation and curettage; Uterus scraping; Vaginal bleeding - dilation; Uterine bleeding - dilation; Menopause - dilation ... D and C, also called uterine scraping, may be performed in the ... are under general or local anesthesia. The health care provider ...

  18. Donato D'Urbino

    Index Scriptorium Estoniae

    2005-01-01

    Itaalia arhitektide-disainerite Jonathan De Pasi, Donato D'Urbino, Paolo Lomazzi ja Carla Scolari kavandatud ning Itaalia firmas Zanotta S.p.A. toodetud täispuhutavast plastikust tugitoolist "Blow" (1967)

  19. Harmonic d-tensors

    Energy Technology Data Exchange (ETDEWEB)

    Hohmann, Manuel [Physikalisches Institut, Universitaet Tartu (Estonia)

    2016-07-01

    Tensor harmonics are a useful mathematical tool for finding solutions to differential equations which transform under a particular representation of the rotation group SO(3). In order to make use of this tool also in the setting of Finsler geometry, where the objects of relevance are d-tensors instead of tensors, we construct a set of d-tensor harmonics for both SO(3) and SO(4) symmetries and show how these can be used for calculations in Finsler geometry and gravity.

  20. Fokker D.VII

    Science.gov (United States)

    1923-01-01

    Fokker D.VII: The Fokker D.VII was one of the best fighter aircraft of World War I, and was the only weapon used by the Central Powers specifically mentioned in the Versailles Treaty. The Central Powers surrendered 142 at the close of the war, and the Fokker company sold even more to the U. S. Air Service. Several were flown at Langley Field, but this one was the sole example operated by the NACA.

  1. M.A.D

    DEFF Research Database (Denmark)

    Kacunko, Slavko

    2009-01-01

    concepts related to media art in its widest sense. In this context, the author presents the M.A.D. Media Art Database project as an information system at the disposal of media art and its history and theory, and as a network interface between archived material and knowledge. With its bottom-up structure......, the M.A.D. database is proposed as a decisive motive force in assembling potent aggregates of knowledge and expertise....

  2. Professional Papervision3D

    CERN Document Server

    Lively, Michael

    2010-01-01

    Professional Papervision3D describes how Papervision3D works and how real world applications are built, with a clear look at essential topics such as building websites and games, creating virtual tours, and Adobe's Flash 10. Readers learn important techniques through hands-on applications, and build on those skills as the book progresses. The companion website contains all code examples, video step-by-step explanations, and a collada repository.

  3. Reflectometry on D17

    Energy Technology Data Exchange (ETDEWEB)

    Cubitt, R. [Institut Max von Laue - Paul Langevin (ILL), 38 - Grenoble (France)

    1997-04-01

    As part of the package of instrument upgrades planned over the next few years, D17 is based on a straightened cold neutron-guide and converted into a dedicated and versatile reflectometer. In the meantime, in order for ILL to become as fully involved as possible in this growing area of activity, the current D17 has been optimised for reflectometry. Results of this project are presented. (author).

  4. Pediatric Hypovitaminosis D

    Directory of Open Access Journals (Sweden)

    Rafiu Ariganjoye MD, MBA, FAAP, FAIHQ, CPE, CHCQM

    2017-01-01

    Full Text Available Vitamin D, a secosteroid, is essential for the development and maintenance of healthy bone in both the adult and pediatric populations. Low level of 25-hydroxy vitamin D (25-(OH-D is highly prevalent in children worldwide and has been linked to various adverse health outcomes including rickets, osteomalacia, osteomalacic myopathy, sarcopenia, and weakness, growth retardation, hypocalcemia, seizure and tetany, autism, cardiovascular diseases, diabetes mellitus, cancers (prostate, colon, breast, infectious diseases (viral, tuberculosis, and autoimmune diseases, such as multiple sclerosis and Hashimoto’s thyroiditis. Risk factors for hypovitaminosis D are people with darker skin pigmentation, use of sunscreen, insufficient ultraviolet B exposure, prematurity, living in northern latitudes, malnutrition, obesity, exclusive breastfeeding, low maternal vitamin D level, certain medications, drinking unfortified cow’s milk, liver failure, chronic renal insufficiency, cystic fibrosis, asthma, and sickle cell hemoglobinopathy. This review highlights and summarizes the molecular perspectives of vitamin D deficiency and its potential adverse health outcomes in pediatric age groups. The recommended treatment regimen is beyond the scope of this review.

  5. Pediatric Hypovitaminosis D

    Science.gov (United States)

    Ariganjoye, Rafiu

    2017-01-01

    Vitamin D, a secosteroid, is essential for the development and maintenance of healthy bone in both the adult and pediatric populations. Low level of 25-hydroxy vitamin D (25-(OH)-D) is highly prevalent in children worldwide and has been linked to various adverse health outcomes including rickets, osteomalacia, osteomalacic myopathy, sarcopenia, and weakness, growth retardation, hypocalcemia, seizure and tetany, autism, cardiovascular diseases, diabetes mellitus, cancers (prostate, colon, breast), infectious diseases (viral, tuberculosis), and autoimmune diseases, such as multiple sclerosis and Hashimoto’s thyroiditis. Risk factors for hypovitaminosis D are people with darker skin pigmentation, use of sunscreen, insufficient ultraviolet B exposure, prematurity, living in northern latitudes, malnutrition, obesity, exclusive breastfeeding, low maternal vitamin D level, certain medications, drinking unfortified cow’s milk, liver failure, chronic renal insufficiency, cystic fibrosis, asthma, and sickle cell hemoglobinopathy. This review highlights and summarizes the molecular perspectives of vitamin D deficiency and its potential adverse health outcomes in pediatric age groups. The recommended treatment regimen is beyond the scope of this review. PMID:28229097

  6. VITAMIN D IMMUNOMODULATORY EFFECT

    Directory of Open Access Journals (Sweden)

    Jelena Radović

    2012-01-01

    Full Text Available In addition to the classical role in the homeostasis of calcium and phosphorus, vitamin D shows a regulatory effect on a number of different cells, especially its antiproliferative and pro-differential biological function. Through its own receptor in the immune cells, vitamin D increases the phagocytic activity of macrophages and NK cells. Also, by binding to the regulatory sequences of antimicrobial peptides genes, vitamin D increases the microbicidal activity of phagocytes. Inhibition of differentiation and maturation of antigen-presenting dendritic cells, as well as direct influence on their contact with T lymphocytes, it significantlly influences the type of immune response. Dendritic cells under the influence of vitamin D induce a suppressor T cells, which can inhibit Th1 cell response and are critical in the regulation of immune tolerance. Vitamin D inhibits proliferation of Th1 and Th17 cells, as well their cytokine production, and suppresses the differentiation and maturation of B lymphocytes. Due to all these functions, vitamin D has shown beneficial effects in the prevention and modification of a number of autoimmune diseases. On the other hand, immunity disorders with predominant Th2 response (asthma, allergies did not show such good results after the use of hypocalcemic VDR agonists.

  7. Cosmic D--term Strings as Wrapped D3 Branes

    CERN Document Server

    Halyo, E

    2004-01-01

    We describe cosmic D--term strings as D3 branes wrapped on a resolved conifold. The matter content that gives rise to D--term strings is shown to describe the world--volume theory of a space--filling D3 brane transverse to the conifold which itself is a wrapped D5 brane. We show that, in this brane theory, the tension of the wrapped D3 brane mathces that of the D--term string. We argue that there is a new type of cosmic string which arises from fractional D1 branes on the world--volume of a fractional D3 brane.

  8. Drug: D02476 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02476 Drug Meclocycline (USAN/INN) C22H21ClN2O8 476.0986 476.8637 D02476.gif Antib... of acne D10AF04 Meclocycline D02476 Meclocycline (USAN/INN) Antiinfectives [BR:b...] Tetracyclines Meclocycline [ATC:D10AF04] D02476 Meclocycline (USAN/INN) CAS: 2013-58-3 PubChem: 7849531 LigandBox: D0247

  9. Drug: D01720 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01720 Drug Amorolfine hydrochloride (JAN); Pekiron (TN) C21H35NO. HCl 353.2485 353...is agents 2659 Others D01720 Amorolfine hydrochloride (JAN) Anatomical Therapeutic Chemical (ATC) classifica...D01AE Other antifungals for topical use D01AE16 Amorolfine D01720 Amorolfine hydr... inhibitor [KO:K00511] Morpholines Amorolfine [ATC:D01AE16] D01720 Amorolfine hydrochloride (JAN) CAS: 78613

  10. Drug: D09047 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09047 Formula, Drug En'nenhangeto Pinellia tuber [DR:D06778], Bupleurum root [DR:D... ginger [DR:D06744], Immature orange [DR:D06706], Evodia fruit [DR:D00173] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for stomach Formulas for calming stomachache D09047 En'nenhangeto PubChem: 96025728 ...

  11. Drug: D00165 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tisone D00165 Hydrocortisone acetate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST...cortisone acetate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corti...MIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOST... S01CB03 Hydrocortisone D00165 Hydrocortisone acetate (JP16/USP) S02 OTOLOGICALS S02B CORTICOST

  12. Drug: D02288 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e D02288 Hydrocortisone valerate (USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST... valerate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, w...ARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYST...on S01CB03 Hydrocortisone D02288 Hydrocortisone valerate (USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Co

  13. Drug: D03325 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids... OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC03 Mometasone D03325 Mometasone f...TS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD09 Mometasone D03325 Mometasone f...l) Mometasone D03325 Mometasone furoate hydrate (JAN) Respiratory Tract/Pulmonary Agents Anti-inflammatories, Inhaled Corticosteroids

  14. Drug: D04819 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04819 Mixture, Drug Arsenic trioxide - dibucaine hydrochloride - dl-methylephedrine hydr...ochloride - p-butylaminobenzoyldiethylaminoethyl hydrochloride - benzyl alcohol mixt; Neoarsen black (...TN) Arsenic trioxide [DR:D02106], Dibucaine hydrochloridide [DR:D02220], dl-Methylephedrine hydrochloride [D...R:D02109], p-Butylaminobenzoyldiethylaminoethyl hydrochloride [DR:D01967], Benzyl alcohol [DR:D00077] PubChem: 17398187 ...

  15. D&D TECHNOLOGIES FOR POLLUTION PREVENTION

    Energy Technology Data Exchange (ETDEWEB)

    Tripp, Julia L.

    2003-02-27

    A new Accelerated Site Technology Deployment (ASTD) project was awarded in FY 2002 to the Idaho National Engineering and Environmental Laboratory (INEEL) to deploy technologies that decrease pollution and waste in the areas of facility characterization, sludge treatment, dust and contamination control, and concrete demolition. This project was called ''D&D Technologies for Pollution Prevention'' and planned to deploy four different technologies. To reduce protective equipment requirements, waste generation, and risk of radiation exposure during facility characterization, the Russian Gamma Locater Device (GLD) and Isotopic Identification Device (IID) for remote characterization was investigated. The GLD detects gamma ray readings and video images remotely and uses radio communication to transmit the readings to personnel located a safe distance from the contaminated area. The IID, an integral part of the GLD, provides real-time spectrometric analysis of radiation sources for remotely identifying the specific radioactive isotopes present in the facility. At the INEEL, sludge has accumulated in the bottom of a fuel storage pool and the presence of heavy metals in the sludge makes it a mixed waste. This project planned to use LEADX{reg_sign} to treat sludge in place to effectively make all heavy metals in the sludge insoluble. LEADX{reg_sign} is a dry granular chemical additive (apatite) used for in-situ treatment of heavy-metal-contaminated material. LEADX{reg_sign} chemically bonds to any free heavy metals that it contacts and forms a stable, non-leachable molecule. After treating the sludge with LEADX{reg_sign}, it was to be left in the basin and the pool filled with grout. The successful treatment of the sludge with LEADX{reg_sign} will reduce the amount of waste to be disposed at the burial ground by eliminating the need to remove the sludge from the basin. Many off-gas and duct systems being dismantled contain dust and lint that has been

  16. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody

    Energy Technology Data Exchange (ETDEWEB)

    Schwartz, J; O' Donoghue, J A; Humm, J L [Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 (United States); Jaggi, J S [Bristol-Myers Squibb, Plainsboro, NJ (United States); Ruan, S; Larson, S M [Nuclear Medicine Service Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 (United States); McDevitt, M; Scheinberg, D A, E-mail: schwarj1@mskcc.org [Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10065 (United States)

    2011-02-07

    Clinical therapeutic studies using {sup 225}Ac-labeled antibodies have begun. Of major concern is renal toxicity that may result from the three alpha-emitting progeny generated following the decay of {sup 225}Ac. The purpose of this study was to determine the amount of {sup 225}Ac and non-equilibrium progeny in the mouse kidney after the injection of {sup 225}Ac-huM195 antibody and examine the dosimetric consequences. Groups of mice were sacrificed at 24, 96 and 144 h after injection with {sup 225}Ac-huM195 antibody and kidneys excised. One kidney was used for gamma ray spectroscopic measurements by a high-purity germanium (HPGe) detector. The second kidney was used to generate frozen tissue sections which were examined by digital autoradiography (DAR). Two measurements were performed on each kidney specimen: (1) immediately post-resection and (2) after sufficient time for any non-equilibrium excess {sup 213}Bi to decay completely. Comparison of these measurements enabled estimation of the amount of excess {sup 213}Bi reaching the kidney ({gamma}-ray spectroscopy) and its sub-regional distribution (DAR). The average absorbed dose to whole kidney, determined by spectroscopy, was 0.77 (SD 0.21) Gy kBq{sup -1}, of which 0.46 (SD 0.16) Gy kBq{sup -1} (i.e. 60%) was due to non-equilibrium excess {sup 213}Bi. The relative contributions to renal cortex and medulla were determined by DAR. The estimated dose to the cortex from non-equilibrium excess {sup 213}Bi (0.31 (SD 0.11) Gy kBq{sup -1}) represented {approx}46% of the total. For the medulla the dose contribution from excess {sup 213}Bi (0.81 (SD 0.28) Gy kBq{sup -1}) was {approx}80% of the total. Based on these estimates, for human patients we project a kidney-absorbed dose of 0.28 Gy MBq{sup -1} following administration of {sup 225}Ac-huM195 with non-equilibrium excess {sup 213}Bi responsible for approximately 60% of the total. Methods to reduce renal accumulation of radioactive progeny appear to be necessary for the success of {sup 225}Ac radioimmunotherapy.

  17. Drug: D07800 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...21-valerate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D...Dexamethasone D07800 Dexamethasone 21-valerate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATION...ethasone D07800 Dexamethasone 21-valerate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS ... H02AB Glucocorticoids H02AB02 Dexamethasone D07800 Dexamethasone 21-valerate R RESPIRATORY SYSTEM R01 NASAL PREPARATION

  18. Drug: D00193 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00193 Drug Panthenol (JAN); Dexpanthenol (USP/INN); Ilopan (TN) C9H19NO4 205.1314 ... preparations 3133 Pantothenic acids D00193 Panthenol (JAN); Dexpanthenol (USP/IN...ITAMINS A11H OTHER PLAIN VITAMIN PREPARATIONS A11HA Other plain vitamin preparations A11HA30 Dexpanthenol D0...0193 Panthenol (JAN); Dexpanthenol (USP/INN) D DERMATOLOGICALS D03 PREPARATIONS F...OR TREATMENT OF WOUNDS AND ULCERS D03A CICATRIZANTS D03AX Other cicatrizants D03AX03 Dexpanthenol D00193 Panthenol (JAN); Dexpantheno

  19. Drug: D04798 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04798 Mixture, Drug Zinc oxide oil (JP16); Zinc oxide oil (TN) Zinc oxide [DR:D01170], (Soybean oil... [DR:D04962] | Sesame oil [DR:D03314] | Rape seed oil | Camellia oil [DR:D05289] | Olive oil... [DR:D03311] | Rice bran oil | Castor oil [DR:D06462]) Therapeutic category: 2621 2649 Component of Acrinol and zinc oxide oil...1] 2 Agents affecting individual organs 26 Epidermides 262 Skin protectants 2621 Zinc oxides D04798 Zinc oxide oil... (JP16) 264 Analgesics, anti-itchings, astringents, anti-inflammatory agents 2649 Others D04798 Zinc oxide oil (JP16) PubChem: 17398167 ...

  20. Drug: D00751 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00751 Drug Methylprednisolone sodium succinate (JAN/USP); A-methapred (TN); Solu-m...2 Agents affecting individual organs 24 Hormones 245 Adrenal hormone preparations 2456 Prednisolones D00751 Methylprednisolone...COSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone D00751 Methylprednisolone...S FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA02 Methylprednisolone D00751 Methylprednisolone...one D00751 Methylprednisolone sodium succinate (JAN/USP)

  1. Drug: D05001 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05001 Drug Methylprednisolone sodium phosphate (USAN) C22H29O8P. 2Na 498.1395 498.... PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone D05001 Methylprednisolone sodium pho...USE D10AA Corticosteroids, combinations for treatment of acne D10AA02 Methylprednisolone D05001 Methylprednisolone...ocorticoids H02AB04 Methylprednisolone D05001 Methylprednisolone sodium phosphate (USAN) USP drug classifica...tion [BR:br08302] Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Methylprednisolone D05001 Methylprednisolone

  2. Drug: D05002 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05002 Drug Methylprednisolone suleptanate (USAN/INN) C33H48NO10S. Na 673.2897 673....DS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone D05002 Methylprednisolone sulepta...L USE D10AA Corticosteroids, combinations for treatment of acne D10AA02 Methylprednisolone D05002 Methylprednisolone...cocorticoids H02AB04 Methylprednisolone D05002 Methylprednisolone suleptanate (USAN/INN) USP drug classifica...tion [BR:br08302] Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Methylprednisolone D05002 Methylprednisolone

  3. Drug: D00407 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00407 Drug Methylprednisolone (JP16/USP/INN); Medrol (TN) C22H30O5 374.2093 374.47... Hormones 245 Adrenal hormone preparations 2456 Prednisolones D00407 Methylprednisolone (JP16/USP/INN) Anato...solone D00407 Methylprednisolone (JP16/USP/INN) D10 ANTI-ACNE PREPARATIONS D10A ANT...ment of acne D10AA02 Methylprednisolone D00407 Methylprednisolone (JP16/USP/INN) H SYSTEMIC HORMONAL PREPARA...C USE, PLAIN H02AB Glucocorticoids H02AB04 Methylprednisolone D00407 Methylprednisolone (JP16/USP/INN) USP d

  4. Drug: D01662 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01662 Drug Falecalcitriol (JAN/INN); Hornel (TN) C27H38F6O3 524.2725 524.5792 D016...cting metabolism 31 Vitamins 311 Vitamins A and D preparations 3112 Synthetic vitamin D preparations D01662 Falecalcitriol... like receptors Vitamin D3 like receptor vitamin D receptor [HSA:7421] [KO:K08539] Falecalcitriol... D01662 Falecalcitriol (JAN/INN) CAS: 83805-11-2 PubChem: 7848725 LigandBox: D01662 NIKKAJI:

  5. Drug: D06876 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drocortisone D06876 Hydrocortisone aceponate (INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST...drocortisone aceponate D06876 Hydrocortisone aceponate (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA ...TEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS ...FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB09 Hydrocortisone D...driatics in combination S01CB03 Hydrocortisone D06876 Hydrocortisone aceponate (INN) S02 OTOLOGICALS S02B CORTICOST

  6. Drug: D01468 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01468 Drug Nemonapride (JAN/INN); Emilace (TN) C21H26ClN3O2 387.1714 387.903 D0146...ting central nervous system 117 Psychotropics 1179 Others D01468 Nemonapride (JAN...e dopamine D2-receptor [HSA:1813] [KO:K04145] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D3-receptor ...[HSA:1814] [KO:K04146] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D4-recep...tor [HSA:1815] [KO:K04147] Nemonapride D01468 Nemonapride (JAN/INN) CAS: 75272-39-8 PubChem: 7848531 LigandB

  7. Drug: D05720 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05720 Drug Retapamulin (USAN/INN); Altabax (TN) C30H47NO4S 517.3226 517.7635 D0572...S FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX13 Retapamulin D05720 Retapa...bacterials Antibacterials, Other Retapamulin D05720 Retapamulin (USAN/INN) Antiinfectives [BR:br08307] Antib...acterials Protein biosynthesis inhibitor 23S rRNA of 50S ribosomal subunit inhibitor [KO:K01980] Pleuromutilin derivatives Retapa...mulin [ATC:D06AX13] D05720 Retapamulin (USAN/INN) CAS: 22445

  8. Drug: D04221 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available S FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA06 Fluorometholo...ERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D...07AB06 Fluorometholone D04221 Fluorometholone acetate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids...4221 Fluorometholone acetate (USAN) D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids...ate (USAN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain

  9. Drug: D01367 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA06 Fl...EPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (...group II) D07AB06 Fluorometholone D01367 Fluorometholone (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroid...lone (JP16/USP/INN) D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids...holone (JP16/USP/INN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids

  10. Drug: D00385 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available EMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA12 Triamcinolone D00385 Triamcinolon...e (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids.../INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately ...FOR TOPICAL USE R01AD Corticosteroids R01AD11 Triamcinolone D00385 Triamcinolone (JP16/USP/INN) R03 DRUGS FO...1 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain S01BA05 Triamcinolone D00385 T

  11. Drug: D00980 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...D ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D00980 Prednisolone acetate (JP16.../USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids...te (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D...R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  12. Drug: D08731 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08731 Mixture, Drug Methyl salicylate - diphenhydramine mixt; Air salonpas (TN) Me...thyl salicylate [DR:D01087], Diphenhydramine [DR:D00300], Glycol salicylate [DR:D01557], l-Menthol [DR:D0006...4], d-Camphor [DR:D06392], Benzyl nicotinate [DR:D01419] Therapeutic category: 2649 Therapeutic category of dr...64 Analgesics, anti-itchings, astringents, anti-inflammatory agents 2649 Others D08731 Methyl salicylate - diphenhydramine mixt PubChem: 96025414 ...

  13. Vitamin D and Cancer*

    Directory of Open Access Journals (Sweden)

    Doré Jean-François

    2014-05-01

    Full Text Available Epidemiological studies, mostly ecological but also case-control and prospective studies show a negative association between residential sun exposure and incidence (or fatality of major cancers: colon, breast, and prostate cancer, and non-Hodgkin lymphoma. And it has been suggested that this reduction in risk could be influenced by vitamin D synthesized in the skin as a result of sun exposure. Low serum vitamin D levels are linked to an increase in risk of colon cancer, and to a lesser extent to risk of breast cancer, but not to risk of prostate cancer or non-Hodgkin lymphoma. Intervention trials consisting in daily supplementation in vitamin D for several years have all failed to demonstrate an effect on cancer incidence. Hence, it is not clear whether the reduction in cancer risk associated with sun exposure is mediated by vitamin D or by another factor influenced by sun exposure such as inflammation or immunosuppression, or whether a low vitamin D status is simply a consequence of ill health.

  14. Drug: D04956 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04956 Mixture, Drug Ferric chloride - manganese chloride - zinc sulfate - cupric sulfate - potassium iodide... [DR:D01081], Cupric sulfate [DR:D03613], Potassium iodide [DR:D01016] Therapeutic category: 3229 Therapeuti...nts, tonics 322 Mineral preparations 3229 Others D04956 Ferric chloride - manganese chloride - zinc sulfate - cupric sulfate - potassium iodide mixt PubChem: 17398230 ...

  15. Drug: D08835 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08835 Mixture, Drug Zinc oxide - lard - hardened oil - white beeswax mixt; Wilson'...s (TN) Zinc oxide [DR:D01170], Lard [DR:D05301], Hardened oil, White beeswax [DR:D04969] Therapeutic categor...ers D08835 Zinc oxide - lard - hardened oil - white beeswax mixt PubChem: 96025518 ...

  16. Drug: D08462 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08462 Drug Quinisocaine (INN); Dimethisoquin C17H24N2O 272.1889 272.3853 D08462.gif Local anesthetic...INES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D0

  17. Drug: D09100 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09100 Formula, Drug Koshayoito Ginseng [DR:D06772], Atractylodes rhizome [DR:D0678...omum seed [DR:D06743] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Formulas for resolving dampness D09100 Koshayoito PubChem: 96025780 ...

  18. Drug: D09119 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09119 Formula, Drug Shojokito Rhubarb [DR:D06756], Immature orange [DR:D06706], Ma...gnolia bark [DR:D06720] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Purgative formulas Purgative formulas D09119 Shojokito PubChem: 96025799 ...

  19. Drug: D01076 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5 500.6222 D01076.gif Pseudomonas fluorescens [TAX:294] Antibacterial [topical] Same as: C11758 ATC code: D0... ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX09 Mupirocin D01076 Mupirocin (USP

  20. Drug: D02845 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02845 Drug Aluminum chloride (USP) AlCl3. 6H2O 239.9515 241.4322 D02845.gif Astringent [topica...LOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AX Other anti-acne preparations for topica

  1. Drug: D00551 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 264.3633 D00551.gif Anesthetic [topical] Same as: C07526 ATC code: C05AD02 D04AB06 N01BA03 S01HA03 voltage-... INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB06 Tetracaine D00551 Tetraca

  2. Drug: D04723 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ], Potassium iodine [DR:D01016], (Ethanol [DR:D00068] | Isopropanol [DR:D00137]) Therapeutic category: 2612 ATC code: D08AG03 Therape...6 Epidermides 261 Antimicrobial agents 2612 Iodates D04723 Iodine tincture (JP16) Anatomical Therapeutic...utic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 2

  3. Drug: D03418 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03418 Drug Aromatic castor oil (JP16); Aromatic castor oil (TN) Therapeutic catego...ry: 2356 ATC code: A06AB05 contains: Castor oil [DR:D06462], Orange oil [DR:D05186], Mentha oil [DR:D06461] Therapeutic...agents 235 Purgatives, clysters 2356 Oils and fats D03418 Aromatic castor oil (JP16) Anatomical Therapeuti

  4. Drug: D04967 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (TN) Carbazochrome [DR:D01864], Phytonadione [DR:D00148], Ascorbic acid [DR:D00018] Hemostatics Therapeutic ...d body fluid agents 332 Hemostatics 3329 Others D04967 Carbazochrome - phytonadione - ascorbic acid mixt PubChem: 17398238 ...

  5. Drug: D03290 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nction 44 Allergic agents 441 Antihistamines 4413 Phenothiazines D03290 Promethazine methylenedisalicylate (... ANESTHETICS, ETC. D04AA Antihistamines for topical use D04AA10 Promethazine D03290 Promethazine methylenedi...90 Promethazine methylenedisalicylate (JAN) Respiratory Tract/Pulmonary Agents Antihistamines Promethazine D

  6. Drug: D07215 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iinflammatory ATC code: D11AX09 M01AX24 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGIC...ALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  7. Drug: D05072 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gif Depigmentor Same as: C14244 ATC code: D11AX13 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGIC...ALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX

  8. Drug: D07200 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available C code: D06BB08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTI...BIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BB Antivirals

  9. Drug: D03454 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available SEPTICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AJ Quaternary ammon...ame as: C11275 ATC code: D08AJ02 R02AA17 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTI

  10. Drug: D07205 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available AC03 S01AX15 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AC Biguanides and amidines D08AC03 Propamidine

  11. Drug: D08399 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available gif Antiseptic ATC code: D08AC05 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AC Biguanides and amidines

  12. Drug: D02798 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e: D08AX08 V03AB16 V03AZ01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AX Other antiseptics and disinfec

  13. Drug: D07204 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available septic ATC code: D08AC01 S01AX14 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTIC...S AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AC Biguanides and amidines

  14. Drug: D07747 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07747 Mixture, Drug alpha, beta-Pinene - borneol - anetholtrithion - d-camphene - cine...11], Anetholtrithion [DR:D02377], d-Camphene [CPD:C06304], Cineole [DR:D04115], Fenchone [CPD:C09859] PubChem: 96024466 ...

  15. Drug: D07035 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07035 Formula, Drug Byakkokaninjinto Gypsum [DR:D01728], Anemarrhena rhizome [DR:D...hinese Medicine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D07035 *Byakkokaninjinto Formula...s for replenishing Ying Formulas for replenishing Ying D07035 *Byakkokaninjinto PubChem: 51091377 ...

  16. Drug: D09085 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09085 Formula, Drug Daihangeto Pinellia tuber [DR:D06778], Ginseng [DR:D06772], Ho...ney [DR:D06776] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09085 Daihangeto PubChem: 96025766 ...

  17. Drug: D09076 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09076 Formula, Drug Hainoto Glycyrrhiza [DR:D04365], Platycodon root [DR:D06703], ...Ginger [DR:D06744], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formula

  18. Drug: D09097 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09097 Formula, Drug Kenchuto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D067...ycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09097 Kenchuto PubChem: 96025777 ...

  19. Drug: D09040 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09040 Formula, Drug Ryokeikansoto Poria sclerotium [DR:D06783], Cinnamon bark [DR:...D06712], Glycyrrhiza [DR:D04365], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  20. Drug: D09056 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09056 Formula, Drug Kakkonkokato Pueraria root [DR:D06693], Peony root [DR:D06739]... Glycyrrhiza [DR:D04365], Rhubarb [DR:D06756] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formula

  1. Drug: D09109 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09109 Formula, Drug Shiteito Clove [DR:D03570], Persimmon calyx [DR:D07154], Ginge...r [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09109 Shiteito PubChem: 96025789 ...

  2. Drug: D09098 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09098 Formula, Drug Kojito Cinnamon bark [DR:D06712], Poria sclerotium [DR:D06783]...nger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formulas for removing blood stasis D09098 Kojito PubChem: 96025778 ...

  3. Drug: D09108 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ature orange [DR:D06706], Areca peel [DR:D09184], Amomum seed [DR:D06743], Saussurea root [DR:D06795], Gin...ger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304

  4. Drug: D09091 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ese angelica root [DR:D06768], (Cnidium rhizome [DR:D06748] | Chinese cnidium rhizome [ED:E00321]), Angeli...ca dahurica root [DR:D06779], Vitex fruit [DR:D09191], Asiasarum root [DR:D06728],

  5. Drug: D08723 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08723 Mixture, Drug dl-Camphor - capsicum extract - methyl salicylate mixt; Rakool... (TN) dl-Camphor [DR:D00098], Capsicum extract [DR:D06455], Methyl salicylate [DR:D01087] Therapeutic catego...hers D08723 dl-Camphor - capsicum extract - methyl salicylate mixt PubChem: 96025406 ...

  6. Drug: D08707 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08707 Mixture, Drug l-Menthol - gentian - scopolia extract powder - sodium bicarbo...nate mixt; Bellsan (TN) l-Menthol [DR:D00064], Gentian [DR:D06716], Scopolia extract powder [DR:D06875], Sod...digestives 2339 Others D08707 l-Menthol - gentian - scopolia extract powder - sodium bicarbonate mixt PubChem: 96025390 ...

  7. Drug: D02154 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02154 Mixture, Drug Aspirin - oxycodone hydrochloride - oxycodone terephthalate mi...xt; Percodan (TN) Oxycodone hydrochloride [DR:D00847], Oxycodone terephthalate [DR:D03783], Aspirin [DR:D001... and derivatives N02BA51 Acetylsalicylic acid, combinations excl. psycholeptics D02154 Aspirin - oxycodone hydrochloride - oxycodone terephthalate mixt PubChem: 7849215 ...

  8. Drug: D02155 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02155 Mixture, Drug Aspirin - caffeine - propoxyphene hydrochloride mixt; Darvon c...ompound-65 (TN) Propoxyphene hydrochloride [DR:D00482], Aspirin [DR:D00109], Caffeine [DR:D00528] ATC code: ... Acetylsalicylic acid, combinations excl. psycholeptics D02155 Aspirin - caffeine - propoxyphene hydrochloride mixt PubChem: 7849216 ...

  9. Drug: D08789 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08789 Drug Freeze-dried human anti-D (Rho) immunoglobulin; Anti D globulin (TN) Th...anisms and parasites 63 Biological preparations 634 Human blood preparations 6343 Plasma preparations D08789 Freeze-dried human anti-D (Rho) immunoglobulin PubChem: 96025472 ...

  10. Drug: D08708 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08708 Mixture, Drug Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium...e) [DR:D02831], Aluminum hydroxide, dried [DR:D02416], Magnesium carbonate [DR:D01446], Sodium bicarbonate [...2339 Others D08708 Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium carbonate - sodium bicarbonate - precipitated calcium carbonate mixt PubChem: 96025391 ...

  11. Drug: D08694 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08694 Mixture, Drug dl-Methylephedrine hydrochloride - chlorpheniramine maleate mi...xt; Neoas (TN) dl-Methylephedrine hydrochloride [DR:D02109], (Chlorpheniramine maleate [DR:D00665] | d-Chlorpheniramine maleate [DR:D00668]) PubChem: 96025377 ...

  12. Drug: D10273 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10273 Mixture, Drug Metoprolol - hydrochlorothiazide mixt; Dutoprol (TN); Lopresso...r hct (TN) (Metoprolol tartrate [DR:D00601] | Metoprolol succinate [DR:D00635]), Hydrochlorothiazide [DR:D00...ZIDES C07BB Beta blocking agents, selective, and thiazides C07BB02 Metoprolol and thiazides D10273 Metoprolol - hydrochlorothiazide mixt PubChem: 163312304 ...

  13. Drug: D10280 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10280 Mixture, Drug Fosinopril - hydrochlorothiazide mixt; Fosinopril sodium and hydrochlorot...hiazide (TN) (Fosinopril sodium [DR:D00622] | Fosinopril [DR:D07992]), Hydrochlorothiazide [DR:D0... INHIBITORS, COMBINATIONS C09BA ACE inhibitors and diuretics C09BA09 Fosinopril and diuretics D10280 Fosinopril - hydrochlorothiazide mixt PubChem: 163312311 ...

  14. Drug: D02863 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02863 Drug Aluminum sesquichlorohydrate (USP) Aly(OH)3y-zClz. H2O Anhidrotic ATC c...ED DRESSINGS D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02863 Aluminum sesquichlorohydrate (USP) PubChem: 17397020 ...

  15. Drug: D10301 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available exidine gluconate [DR:D00858], (Isopropanol [DR:D00137] | Anhydrous ethanol [DR:D00068] | Ethanol for disinfection [DR:D04855]) Antis...eptic ATC code: D08AC52 Anatomical Therapeutic Chemical (ATC) classification [BR:br

  16. Drug: D04219 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 08 Fluocortolone D04219 Fluocortolone caproate (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL ...MONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB G...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III

  17. Drug: D04218 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ocortolone D04218 Fluocortolone (USAN/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST...luocortolone D04218 Fluocortolone (USAN/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOST...EROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H

  18. Drug: D10267 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10267 Mixture, Drug Methyldopa - hydrochlorothiazide mixt; Methyldopa and hydrochl...orothiazide (TN) (Methyldopa hydrate [DR:D00405] | Methyldopa [DR:D08205]), Hydrochlorothiazide [DR:D00340] ...MBINATION C02LB Methyldopa and diuretics in combination C02LB01 Methyldopa (levorotatory) and diuretics D10267 Methyldopa - hydrochlorothiazide mixt PubChem: 163312298 ...

  19. Drug: D09117 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 752]), Bupleurum root [DR:D06727], Glycyrrhiza [DR:D04365], Dry ginger [DR:D06744], Peppermint [DR:D05431] Traditional Chinese Medici...ne in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09117 Shoyosan PubChem: 96025797 ...

  20. Drug: D06392 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06392 Drug d-Camphor (JP16); d-Camphor (TN) C10H16O 152.1201 152.2334 D06392.gif Cinnamomum...phenic (TN), Sulfur and camphor [DR:D04811] In case of crude: Lauraceae (laurel family) Cinnamomum camphora

  1. Drug: D10286 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10286 Mixture, Drug Amlodipine - valsartan -hydrochlorothiazide mixt; Exforge hct ...(TN) Amlodipine besilate [DR:D00615], Hydrochlorothiazide [DR:D00340], Valsartan [DR:D00400] Antihypertensiv...TS, COMBINATIONS C09DX Angiotensin II antagonists, other combinations C09DX01 Valsartan, amlodipine and hydr...ochlorothiazide D10286 Amlodipine - valsartan -hydrochlorothiazide mixt PubChem: 163312317 ...

  2. Drug: D09077 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09077 Formula, Drug Hainosan Immature orange [DR:D06706], Peony root [DR:D06739], ...Platycodon root [DR:D06703] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formulas for pus discharge D09077 Hainosan PubChem: 96025758 ...

  3. Drug: D10295 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10295 Mixture, Drug Mometasone furoate - formoterol fumarate mixt; Dulera (TN) (Mometas...one furoate [DR:D00690] | Mometasone furoate hydrate [DR:D03325]), (Formoterol fumarate [DR:D01373] | F... drugs, excl. anticholinergics R03AK09 Formoterol and mometasone D10295 Mometasone furoate - formoterol fumarate mixt PubChem: 163312326 ...

  4. Drug: D04921 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics ...ATIONS WITH CORTICOSTEROIDS G01AA Antibiotics G01AA09 Mepartricin D04921 Mepartricin (USAN/INN) G04 UROLOGIC

  5. Drug: D01458 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Paecilomyces varioti var. antibioticus Antibiotics Same as: C12905 ATC code: D01AA04 natural product Anatomi...CAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics D01AA04 Pecilocin D014

  6. Drug: D07116 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain S01BA10 Alcl...OLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroi...ds, moderately potent (group II) D07AB10 Alclometasone D07116 Alclometasone (INN) S

  7. Drug: D04930 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04930 Mixture, Drug Benfotiamine - pyridoxine hydrochloride - Hydroxocobalamin hydr...ochloride mixt; Vitamedin-S (TN) Benfotiamine [DR:D01255], Pyridoxine hydrochloride [DR:D02179], Hydroxocobalamin hydrochloride [DR:D04929] See [DR:D04911] PubChem: 17398222 ...

  8. Drug: D02856 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02856 Drug Aluminum dichlorohydrate (USP) Aly(OH)3y-zClz. nH2O Anhidrotic ATC code...DRESSINGS D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02856 Aluminum dichlorohydrate (USP) PubChem: 17397013 ...

  9. Drug: D04844 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04844 Mixture, Drug Paraformaldehyde - dibucaine hydrochloride mixt; Periodon (TN)... Paraformaldehyde [DR:D01494], Dibucaine hydrochloride [DR:D02220] Therapeutic category: 2730 Therapeutic category of dr...sics and sedatives 2730 Analgesics and sedatives D04844 Paraformaldehyde - dibucaine hydrochloride mixt CAS: 617-48-1 PubChem: 17398192 NIKKAJI: J237.180D ...

  10. Drug: D05239 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04969], Sorbitan sesquioleate [DR:D05282], White petrolatum [DR:D05304] Pharmaceutic aid [ointment base, Ol...eaginous] Therapeutic category: 7121 Mixture of White beewax [DR:D04969], Sorbitan sesquioleate [DR:D05282] and White petrolatum

  11. 3D Projection Installations

    DEFF Research Database (Denmark)

    Halskov, Kim; Johansen, Stine Liv; Bach Mikkelsen, Michelle

    2014-01-01

    Three-dimensional projection installations are particular kinds of augmented spaces in which a digital 3-D model is projected onto a physical three-dimensional object, thereby fusing the digital content and the physical object. Based on interaction design research and media studies, this article...... contributes to the understanding of the distinctive characteristics of such a new medium, and identifies three strategies for designing 3-D projection installations: establishing space; interplay between the digital and the physical; and transformation of materiality. The principal empirical case, From...... Fingerplan to Loop City, is a 3-D projection installation presenting the history and future of city planning for the Copenhagen area in Denmark. The installation was presented as part of the 12th Architecture Biennale in Venice in 2010....

  12. Vitamin D metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Deluca, H.F.

    1977-01-01

    During the past decade, an explosion of information has become available on the metabolism and function of vitamin D which is of great importance to clinicians in the treatment of metabolic bone disease. We have learned that vitamin D is the precursor of at least one hormone and that this hormone carries out functions in calcium and phosphorus metabolism bringing about mineralization of bone on one hand, and the prevention of hypocalcaemic tetany on the other. It may also function in the prevention of such degenerative bone diseases as osteoporosis. An important analogue of this hormone, 1..cap alpha..-hydroxyvitamin D/sub 3/ has been prepared and is used successfully in the treatment of a variety of clinical conditions. This presentation will summarize these findings and their possible implications in these metabolic bone diseases.

  13. 3D Spectroscopic Instrumentation

    CERN Document Server

    Bershady, Matthew A

    2009-01-01

    In this Chapter we review the challenges of, and opportunities for, 3D spectroscopy, and how these have lead to new and different approaches to sampling astronomical information. We describe and categorize existing instruments on 4m and 10m telescopes. Our primary focus is on grating-dispersed spectrographs. We discuss how to optimize dispersive elements, such as VPH gratings, to achieve adequate spectral resolution, high throughput, and efficient data packing to maximize spatial sampling for 3D spectroscopy. We review and compare the various coupling methods that make these spectrographs ``3D,'' including fibers, lenslets, slicers, and filtered multi-slits. We also describe Fabry-Perot and spatial-heterodyne interferometers, pointing out their advantages as field-widened systems relative to conventional, grating-dispersed spectrographs. We explore the parameter space all these instruments sample, highlighting regimes open for exploitation. Present instruments provide a foil for future development. We give an...

  14. Radiochromic 3D Detectors

    Science.gov (United States)

    Oldham, Mark

    2015-01-01

    Radiochromic materials exhibit a colour change when exposed to ionising radiation. Radiochromic film has been used for clinical dosimetry for many years and increasingly so recently, as films of higher sensitivities have become available. The two principle advantages of radiochromic dosimetry include greater tissue equivalence (radiologically) and the lack of requirement for development of the colour change. In a radiochromic material, the colour change arises direct from ionising interactions affecting dye molecules, without requiring any latent chemical, optical or thermal development, with important implications for increased accuracy and convenience. It is only relatively recently however, that 3D radiochromic dosimetry has become possible. In this article we review recent developments and the current state-of-the-art of 3D radiochromic dosimetry, and the potential for a more comprehensive solution for the verification of complex radiation therapy treatments, and 3D dose measurement in general.

  15. D2-tree

    DEFF Research Database (Denmark)

    Brodal, Gerth Stølting; Sioutas, Spyros; Pantazos, Kostas;

    2015-01-01

    We present a new overlay, called the Deterministic Decentralized tree (D2-tree). The D2-tree compares favorably to other overlays for the following reasons: (a) it provides matching and better complexities, which are deterministic for the supported operations; (b) the management of nodes (peers......-balancing scheme of elements into nodes is deterministic and general enough to be applied to other hierarchical tree-based overlays. This load-balancing mechanism is based on an innovative lazy weight-balancing mechanism, which is interesting in its own right....

  16. Interaktiv 3D design

    DEFF Research Database (Denmark)

    Villaume, René Domine; Ørstrup, Finn Rude

    2002-01-01

    Projektet undersøger potentialet for interaktiv 3D design via Internettet. Arkitekt Jørn Utzons projekt til Espansiva blev udviklet som et byggesystem med det mål, at kunne skabe mangfoldige planmuligheder og mangfoldige facade- og rumudformninger. Systemets bygningskomponenter er digitaliseret som...... 3D elementer og gjort tilgængelige. Via Internettet er det nu muligt at sammenstille og afprøve en uendelig  række bygningstyper som  systemet blev tænkt og udviklet til....

  17. β-d-Gulose

    Directory of Open Access Journals (Sweden)

    Tomohiko Ishii

    2014-05-01

    Full Text Available The title compound, C6H12O6, a C-3 position epimer of d-galactose, crystallized from an aqueous solution, was confirmed as β-d-pyranose with a 4C1 (C1 conformation. In the crystal, O—H...O hydrogen bonds between the hydroxy groups at the C-1 and C-6 positions connect molecules into a tape structure with an R33(11 ring motif running along the a-axis direction. The tapes are connected by further O—H...O hydrogen bonds, forming a three-dimensional network.

  18. GridAPPS-D

    Energy Technology Data Exchange (ETDEWEB)

    2017-03-28

    GridAPPS-D is an open-source, open architecture, standards based platform for development of advanced electric power system planning and operations applications. GridAPPS-D provides a documented data abstraction for the application developer enabling creation of applications that can be run in any compliant system or platform. This enables development of applications that are platform vendor independent applications and applications that take advantage of the possibility of data rich and data driven applications based on deployment of smart grid devices and systems.

  19. Drug: D06920 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ark [DR:D06689], Coptis rhizome [DR:D00092], Gardenia fruit [DR:D06731] Disorder of menstruation; Dysmenorrhea; Climacteric disturban...ce; Nervous disease Therapeutic category: 5200 Therapeut

  20. Drug: D04249 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04249 Mixture, Drug Oxytetracycline hydrochloride - hydrocortisone acetate mixt; T...erra-cortril (TN); Tetrazol (TN) Oxytetracycline hydrochloride [DR:D01596], Hydrocortisone acetate [DR:D00165] combination adrenocorticoid and antibiotic PubChem: 17398033 ...

  1. Drug: D04867 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04867 Mixture, Drug Fradiomycin sulfate - hydrocortisone acetate mixt; Fradiomycin... celludent (TN) Fradiomycin sulfate [DR:D01618], Hydrocortisone acetate [DR:D00165] PubChem: 17398202 ...

  2. Drug: D04801 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04801 Mixture, Drug Hydrocortisone - crotamiton mixt; Eurax H (TN) Crotamiton [DR:D01381], Hydrocortisone...inflammatory agents 2649 Others D04801 Hydrocortisone - crotamiton mixt PubChem: 17398170 ...

  3. Drug: D07875 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available epin D07875 Doxepin (INN) Dermatological Agents Doxepin D07875 Doxepin (INN) Sleep Disorder... Agents Sleep Disorders, Other Doxepin D07875 Doxepin (INN) CAS: 1668-19-5 PubChem: 96024571 DrugB

  4. Drug: D10210 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cin [DR:D00211], Isoniazid [DR:D00346], Pyrazinamide [DR:D00144] Antibacterial, Treatment of pulmonary tuberculosis [DS:H00342] Genomic biomarker: NAT [HSA:9 10] PubChem: 163312241 ...

  5. Drug: D04769 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS D07CA Corticosteroids, weak, combinations with antibiotics... D07CA03 Prednisolone and antibiotics D04769 Fradiomycin sulfate - prednisolone mixt PubChem: 17398159 ...

  6. Drug: D04753 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available COMBINATIONS WITH ANTIBIOTICS D07CA Corticosteroids, weak, combinations with antibiotics... D07CA03 Prednisolone and antibiotics D04753 Chloramphenicol - fradiomycin sulfate - prednisolone mixt PubChem: 17398155 ...

  7. Drug: D04250 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NS WITH ANTIBIOTICS D07CA Corticosteroids, weak, combinations with antibiotics D0...7CA02 Methylprednisolone and antibiotics D04250 Fradiomycin sulfate - methylprednisolone mixt S SENSORY ORGA

  8. Vitamin D and Disease Prevention

    Science.gov (United States)

    ... a hormone. The skin makes vitamin D after exposure to sunlight. We also absorb vitamin D from certain foods, ... people do not make enough vitamin D by exposure to sunlight* or get enough through their diets. They may ...

  9. Drug: D09093 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ea [DR:D06792], Ophiopogon tuber [DR:D06775] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for expelling paras...ites Anthelmintic formulas D09093 Seikiankaito PubChem: 96025773 ...

  10. Drug: D00494 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamine...Antiemetics, Other Promethazine D00494 Promethazine (JAN/INN) Respiratory Tract/Pulmonary Agents Antihistamine

  11. Drug: D01242 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamine...Respiratory Tract/Pulmonary Agents Antihistamines Promethazine D01242 Promethazine teoclate (JAN/INN) Target

  12. Drug: D06311 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available X10 J01FG01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS... FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE

  13. Drug: D05840 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D...05840 Silver nitrate, toughened (USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECTIVES S01AX Other

  14. Drug: D03332 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available P16) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTIBIOTICS AND... CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE

  15. Drug: D00133 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREP...in (JAN); Resorcinol (USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECT

  16. Drug: D07069 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fication [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL ...4 Benzoxonium chloride D07069 Benzoxonium chloride (INN) D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS

  17. Drug: D01364 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available peutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D... olamine (JAN/USP) G GENITO URINARY SYSTEM AND SEX HORMONES G01 GYNECOLOGICAL ANT

  18. Drug: D03538 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available omical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANTISEPTIC...S G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS G01A ANTIINFECTIVES AND ANTISEPTIC

  19. Drug: D10292 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10292 Mixture, Drug Niacin - lovastatin mixt; Advicor (TN) Nicotinic acid [DR:D000...er lipid modifying agents C10BA01 Lovastatin and nicotinic acid D10292 Niacin - lovastatin mixt PubChem: 163312323 ...

  20. Drug: D02135 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available pa [DR:D00059], Benserazide hydrochloride [DR:D01653] Antiparkinsonian [DS:H00057] Therapeutic category: 116...d sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian

  1. Drug: D09039 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :D06783], Cinnamon bark [DR:D06712], Millet Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09039 Ifuto PubChem: 96025722 ...

  2. Drug: D06988 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available as D06988 *Shohangekabukuryoto Formulas for dampness Diuretic formulas D06988 *Shohangekabukuryoto PubChem: 51091330 ... ...dicines D06988 Shohangekabukuryoto Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formul

  3. Drug: D09061 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :D06772], Pinellia tuber [DR:D06778] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic form...ulas D09061 Kankyoninjinhangegan PubChem: 96025742 ...

  4. Drug: D09052 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09052 Kashokuyohito PubChem: 96025733 ...

  5. Drug: D09116 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available R:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09116 Bukuryukanto PubChem: 96025796 ...

  6. Drug: D08828 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08828 Mixture, Drug Eksalb; Eksalb (TN) Hydrocortisone [DR:D00088], Killed bacillus coli [DR:D08826], Kill...ed staphylococcal, Killed chain cocci, Killed pseudomonad aeruginosa Therapeutic cat

  7. Drug: D08748 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e hydrochloride - choline bitartrate - inositol - cyanocobalamin mixt PubChem: 96025431 ... ...D08748 Mixture, Drug Liver hydrolysate - cysteine hydrochloride - choline bitartrate - inositol - cyanocobal...amin mixt; Proheparum (TN) Liver hydrolysate [DR:D04994], Cysteine hydrochloride [D

  8. Drug: D00292 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available lammatory Bowel Disease Agents Glucocorticoids Dexamethasone D00292 Dexamethasone (...placement/Modifying (Adrenal) Dexamethasone D00292 Dexamethasone (JP16/USP/INN) Dexamethasone D00292 Dexamethasone (JP16/USP/INN) Inf

  9. Drug: D09070 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09070 Formula, Drug Keishikashakuyakushokyoninjinto Cinnamon bark [DR:D06712], Peo...aditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09070 Keishikashakuyakushokyoninjinto PubChem: 96025751 ...

  10. Drug: D09099 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09099 Formula, Drug Koshaheiisan (Atractylodes lancea rhizome [DR:D06752] | Atract... [DR:D09125] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Formula

  11. Drug: D09048 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09048 Formula, Drug Boibukuryoto Sinomenium stem [DR:D06785], Astragalus root [DR:...e Medicine in Japan [BR:br08304] Formulas Formulas for dampness Diuretic formulas D09048 Boibukuryoto PubChem: 96025729 ...

  12. Drug: D09102 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09102 Formula, Drug Kobokushokyohangeninjinkanzoto Magnolia bark [DR:D06720], Ging... Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09102 Kobokushokyohangeninjinkanzoto PubChem: 96025782 ...

  13. Drug: D09059 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09059 Formula, Drug Kamishoyosangoshimotsuto Japanese angelica root [DR:D06768], P...cine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D09059 *Kamishoyosangoshimotsuto Formula

  14. Drug: D09071 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09071 Formula, Drug Bukuryoinkahange Poria sclerotium [DR:D06783], (Atractylodes l...ese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09071 Bukuryoinkahange PubChem: 96025752 ...

  15. Drug: D09118 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09118 Formula, Drug Shobaito Prunus mume fruit [DR:D09233], Zanthoxylum fruit [DR:...edicine in Japan [BR:br08304] Formulas Formulas for expelling parasites Anthelmintic formulas D09118 Shobaito PubChem: 96025798 ...

  16. Drug: D09105 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09105 Formula, Drug Saishakurikkunshito Ginseng [DR:D06772], (Atractylodes lancea ...pan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09105 Saishakurikkunshito PubChem: 96025785 ...

  17. Drug: D08696 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08696 Mixture, Drug Acetaminophen - ephedra herb - scopolia extract - caffeine and... sodium benzoate - magnesium oxide mixt; Asgen (TN) Acetaminophen [DR:D00217], Ephedra herb [DR:D06791], Scopolia extract

  18. Drug: D10513 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10513 Mixture, Drug Clopidogrel sulfate - aspirin mixt; Complavin (TN) Clopidogrel sulfate [DR:D00769], Asp...irin [DR:D00109] Therapeutic category: 3399 Therapeutic category of drugs in Japan

  19. Drug: D08623 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available dol D08623 Tramadol (INN) USP drug classification [BR:br08302] Analgesics Opioid Analgesics, Long-acting Tra...madol D08623 Tramadol (INN) Opioid Analgesics, Short-acting Tramadol D08623 Trama

  20. Drug: D04311 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04311 Mixture, Drug dl-Methylephedrine hydrochloride - diphenhydramine hydrochlori...de mixt; Asdrin (TN) dl-Methylephedrine hydrochloride [DR:D02109], Diphenhydramine hydrochloride [DR:D00669] PubChem: 17398049 ...

  1. Drug: D02153 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02153 Mixture, Drug Acetaminophen - oxycodone hydrochloride mixt; Percocet (TN); R...oxicet 5/500 (TN); Tylox (TN) Oxycodone hydrochloride [DR:D00847], Acetaminophen [DR:D00217] Analgesic PubChem: 7849214 ...

  2. Drug: D09095 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09095 Formula, Drug Keibohaidokusan Schizonepeta spike [DR:D06711], Saposhnikovia ...Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formulas for pus discharge D09095 Keibohaidokusan PubChem: 96025775 ...

  3. Drug: D09094 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09094 Formula, Drug Jinreibyakujutsusan Ginseng [DR:D06772], Poria sclerotium [DR:...ine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09094 Jinreibyakujutsusan PubChem: 96025774 ...

  4. Drug: D09088 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09088 Formula, Drug Senshibyakujutsusan (Atractylodes lancea rhizome [DR:D06752] |...e in Japan [BR:br08304] Formulas Formulas for dampness Formulas for resolving dampness D09088 Senshibyakujutsusan PubChem: 96025768 ...

  5. Drug: D10274 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10274 Mixture, Drug Propranolol hydrochloride - hydrochlorothiazide mixt; Inderide... (TN); Propranolol hydrochloride and hydrochlorothiazide (TN) Propranolol hydrochloride [DR:D00483], Hydrochlorot...hiazides D10274 Propranolol hydrochloride - hydrochlorothiazide mixt PubChem: 163312305 ...

  6. Drug: D03162 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03162 Drug Bromelain (JAN); Bromelains (USAN/INN); Edemase D (TN) Ananas comosus [TAX:4615] Anti-inflammato...ry Therapeutic category: 3959 ATC code: D03BA03 cysteine protease fibrin depolymeri

  7. Drug: D08054 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CYP3A5 [HSA:1577] CYP inhibition: CYP2D6 [HSA:1565] map07030 Anxiolytics map0703...ics Antiemetics, Other Hydroxyzine D08054 Hydroxyzine (INN) Anxiolytics Anxiolytics, Other Hydroxyzine D0805

  8. Drug: D03935 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03935 Mixture, Drug Galactose - palmitic acid mixt; Levovist (TN) Alfa-D-galactopy...s 729 Miscellaneous 7290 Miscellaneous D03935 Galactose - palmitic acid mixt PubChem: 47205923 ...

  9. Drug: D09067 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09067 Formula, Drug Kujinto Sophora root [DR:D06710] Traditional Chinese Medicine ...in Japan [BR:br08304] Formulas Formulas for external use Formulas for external use D09067 Kujinto PubChem: 96025748 ...

  10. Drug: D01275 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ng cellular function 42 Antineoplastics 423 Antibiotics 4235 Anthracycline antibiotics D01275 Doxorubicin hy...tics [BR:br08308] Natural products Antibiotics Doxorubicin [ATC:L01DB01] D01275 D

  11. Drug: D09121 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09121 Formula, Drug Shoseiryutogomakyokansekito Ephedra herb [DR:D06791], Peony ro...as for dampness Cough suppressant and expectorant formulas D09121 Shoseiryutogomakyokansekito PubChem: 96025801 ...

  12. Drug: D07049 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Insomnia; Night cry in childhood Therapeutic category: 5200 Therapeutic category...a [DR:D04365], (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]) Nervous disease;

  13. Drug: D06965 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available adenoiditis; Ecozema in childhood Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08...Trichosanthes root [DR:D06701], Burdock fruit [DR:D06723], Glycyrrhiza [DR:D04365] Nervous disease; Chronic

  14. Drug: D08753 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08753 Mixture, Drug Bromelain - trypsin, crystallized mixt; Bromelains - trypsin, crystal...lized mixt; Kimotab (TN) Bromelain [DR:D03162], Trypsin, crystallized [DR:D00056] PubChem: 96025436 ...

  15. Drug: D04818 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04818 Mixture, Drug Propitocaine hydrochloride - Epinephrine bitartrate mixt; Cita...nest (TN) Propitocaine hydrochloride [DR:D01243], Epinephrine bitartrate [DR:D02149] PubChem: 17398186 ...

  16. Drug: D09080 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09080 Formula, Drug Tokibaimokujinganryo Japanese angelica root [DR:D06768], Friti...s Formulas for clearing heat Formulas for clearing heat D09080 Tokibaimokujinganryo PubChem: 96025761 ...

  17. Drug: D00280 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00280.gif Anticonvulsant Therapeutic category: 1139 ATC code: N03AE01 Benzodiazepines GABAA-receptor (benz...Agents Clonazepam D00280 Clonazepam (JP16/USP/INN) Anxiolytics Benzodiazepines Clonazepam D00280 Clonazepam

  18. Drug: D08319 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetic...CALS S01H LOCAL ANESTHETICS S01HA Local anesthetics S01HA02 Oxybuprocaine D08319 Oxybuprocaine (INN) CAS: 99...4158 D08319.gif Local anesthetic ATC code: D04AB03 S01HA02 map07015 Local analgesics Anatomical Therapeutic ...D08319 Drug Oxybuprocaine (INN); Monofree oxybuprocaine (TN) C17H28N2O3 308.21 308.

  19. Drug: D08477 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available onate D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FO...ATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AX Other ...R TOPICAL USE D10AD Retinoids for topical use in acne D10AD02 Retinol D08477 Retinol propionate R RESPIRATORY SYSTEM R01 NASAL PREPAR

  20. Drug: D07207 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 1AX03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANTI...Policresulen (INN) G GENITO URINARY SYSTEM AND SEX HORMONES G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTI...CS G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS G01...SEPTICS AND DISINFECTANTS D08AE Phenol and derivatives D08AE02 Policresulen D07207

  1. Drug: D00540 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00540 Drug Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP); Robinul (TN); S...an agents 225 Bronchodilators 2259 Others D00540 Glycopyrronium bromide (JAN/INN)...02 Glycopyrronium D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) R RESPIRATORY SYSTEM R03 DRU...linergics R03BB06 Glycopyrronium bromide D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) USP d...estinal Glycopyrrolate D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) Target-based classifica

  2. Drug: D00977 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drocortisone sodium phosphate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOST...ne sodium phosphate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Cor...SP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOST... phosphate (JP16/USP) S02 OTOLOGICALS S02B CORTICOSTEROIDS S02BA Corticosteroids S02BA01 Hydrocortisone D009

  3. Drug: D07880 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07880 Drug Duloxetine (INN); Yentreve (TN) C18H19NOS 297.1187 297.4146 D07880.gif Antidepress...A:1544], CYP2D6 [HSA:1565] CYP inhibition: CYP2D6 [HSA:1565] map07027 Antidepress...BR:br08303] N NERVOUS SYSTEM N06 PSYCHOANALEPTICS N06A ANTIDEPRESSANTS N06AX Other antidepressants N06AX21 D...uloxetine D07880 Duloxetine (INN) USP drug classification [BR:br08302] Antidepress

  4. Drug: D08288 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08288 Drug Nortriptyline (INN); Nortrilen (TN) C19H21N 263.1674 263.3767 D08288.gif Antidepress...ant, tricyclic Same as: C07274 ATC code: N06AA10 Tricyclic antidepressants serotonin transporte... Serotonergic synapse Enzyme: CYP2D6 [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07027 Antidepress... D08288 Nortriptyline (INN) USP drug classification [BR:br08302] Antidepressants Tricyclics Nortriptyline D0

  5. Drug: D09197 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09197 Mixture, Drug Valsartan - hydrochlorothiazide mixt; Co-dio (TN) Valsartan [D...R:D00400], Hydrochlorothiazide [DR:D00340] Therapeutic category: 2149 ATC code: C09DA03 The target of Valsartan...s 21 Cardiovascular agents 214 Antihypertensives 2149 Others D09197 Valsartan - h...Angiotensin II antagonists and diuretics C09DA03 Valsartan and diuretics D09197 Valsartan - hydrochlorothiazide mixt PubChem: 96025877 ...

  6. Drug: D08067 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08067 Drug Azilsartan medoxomil (USAN); Edarbi (TN) C30H24N4O8 568.1594 568.5336 D...ists, plain C09CA09 Azilsartan medoxomil D08067 Azilsartan medoxomil (USAN) USP d...rug classification [BR:br08302] Cardiovascular Agents Angiotensin II Receptor Antagonists Azilsartan D08067 Azilsartan...receptor [HSA:185] [KO:K04166] Azilsartan medoxomil [ATC:C09CA09] D08067 Azilsartan medoxomil (USAN) CAS: 86

  7. Drug: D02143 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics...EPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS G01AA Antibiotics G01AA06 Hachimycin D02143 Trichomycin (JP1...ibiotics J02AA02 Hachimycin D02143 Trichomycin (JP16); H...6); Hachimycin (INN) J ANTIINFECTIVES FOR SYSTEMIC USE J02 ANTIMYCOTICS FOR SYSTEMIC USE J02A ANTIMYCOTICS FOR SYSTEMIC USE J02AA Ant

  8. Drug: D04265 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04265 Mixture, Drug Reserpine - hydralazine hydrochloride - hydrochlorothiazide mi...xt Reserpine [DR:D00197], Hydralazine hydrochloride [DR:D01302], Hydrochlorothiazide [DR:D00340] ATC code: C...lkaloids C02AA52 Reserpine, combinations D04265 Reserpine - hydralazine hydrochloride - hydrochlorothiazide ...ion C02LA51 Reserpine and diuretics, combinations with other drugs D04265 Reserpine - hydralazine hydr...ochloride - hydrochlorothiazide mixt PubChem: 17398039 ...

  9. Drug: D05332 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05332 Mixture, Drug Hydrophilic petrolatum (JP16); Petrolatum, hydrophilic (USP) W...hite beewax [DR:D04969], Stearyl alcohol [DR:D01924], Cholesterol [DR:D00040], White petrolatum [DR:D05304] ...71 Dispensing medicines 712 Ointment bases 7121 Oil bases D05332 Hydrophilic petrolatum (JP16); Petrolatum, hydrophilic (USP) CAS: 8027-64-3 PubChem: 17398285 ...

  10. Drug: D01600 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01600 Drug Diphenylpiperidinomethyldioxolan iodide (JAN); Anacolin; Gastrophyllin-...iperidinomethyldioxolan D01600 Diphenylpiperidinomethyldioxolan iodide (JAN) CAS: 21216-78-4 PubChem: 784866

  11. Drug: D10519 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10519 Mixture, Drug Rabeprazole - amoxicillin - clarithromycin mixt; Rabecure (TN)...tibiotics 619 Miscellaneous 6199 Miscellaneous D10519 Rabeprazole - amoxicillin - clarithromycin mixt ...

  12. Drug: D07796 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatme...steroids C05AA09 Dexamethasone D07796 Dexamethasone 21-acetate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATION...one 21-acetate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids,... combinations for treatment of acne D10AA03 Dexamethasone D07796 Dexamethasone 21-acetate H SYSTEMIC HORMONAL PREPARATION...asone 21-acetate R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS

  13. Drug: D07802 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...hate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Co...sone D07802 Dexamethasone phosphate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATION...7802 Dexamethasone phosphate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOST...orticoids H02AB02 Dexamethasone D07802 Dexamethasone phosphate R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R

  14. Drug: D07585 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07585 Mixture, Drug Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine...ers D07585 Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine mixt PubChem: 96024447 ...

  15. Drug: D04814 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04814 Mixture, Drug Ethyl aminobenzoate - p-butylaminobenzoyldiethylaminoethyl hyd...rochloride mixt; Neozalocaine (TN) Ethyl aminobenzoate [DR:D00552], p-Butylaminobenzoyldiethylaminoethyl hyd

  16. Drug: D01327 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01327 Drug Diflorasone diacetate (JAN/USP); Florone (TN); Psorcon (TN) C26H32F2O7 ...A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC10 Diflorasone D01327 Diflorasone di...acetate (JAN/USP) USP drug classification [BR:br08302] Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Diflor...asone D01327 Diflorasone diacetate (JAN/USP) Diflorasone D01327 Diflor... receptors 3-Ketosteroid receptor glucocorticoid receptor [HSA:2908] [KO:K05771] Diflorasone [ATC:D07AC10] D01327 Diflor

  17. Drug: D10520 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10520 Mixture, Drug Rabeprazole - amoxicillin - metronidazole mixt; Rabefine (TN) ...1 Antibiotics 619 Miscellaneous 6199 Miscellaneous D10520 Rabeprazole - amoxicillin - metronidazole mixt ...

  18. Drug: D04913 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04913 Mixture, Drug Thiamine chloride hydrochloride - pyridoxine hydrochloride - cyanocobalamin...3179 Others D04913 Thiamine chloride hydrochloride - pyridoxine hydrochloride - cyanocobalamin mixt PubChem: 17398216 ...

  19. Drug: D04917 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04917 Mixture, Drug Octotiamine - riboflavin - pyridoxine hydrochloride - cyanocobalamin...9 Others D04917 Octotiamine - riboflavin - pyridoxine hydrochloride - cyanocobalamin mixt PubChem: 17398219 ...

  20. Drug: D00985 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available mmatory Bowel Disease Agents Glucocorticoids Triamcinolone D00985 Triamcinolone hex...00985 Triamcinolone hexacetonide (USP/INN) Triamcinolone D00985 Triamcinolone hexacetonide (USP/INN) Infla

  1. Drug: D00979 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00979 Drug Methylprednisolone acetate (JAN/USP); Depo-medrol (TN) C24H32O6 416.219...ing individual organs 24 Hormones 245 Adrenal hormone preparations 2456 Prednisolones D00979 Methylprednisolone...Corticosteroids, weak (group I) D07AA01 Methylprednisolone D00979 Methylprednisolone acetate (JAN/USP) D10 A...eroids, combinations for treatment of acne D10AA02 Methylprednisolone D00979 Methylprednisolone acetate (JAN... H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H02AB04 Methylprednisolone D00979 Methylprednisolone

  2. Drug: D04418 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04418 Mixture, Drug Pipethanate hydrochloride - mallotus japonics extract; Irricol... 239 Miscellaneous 2399 Others D04418 Pipethanate hydrochloride - mallotus japonics extract PubChem: 17398100 ...

  3. Drug: D03034 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03034 Drug Azelaic acid (USAN/INN); Azelex (TN); Finacea (TN) C9H16O4 188.1049 188.2209 D0303...0240(K00384) Pyrimidine metabolism Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMA... D10AX Other anti-acne preparations for topical use D10AX03 Azelaic acid D03034 Azelaic acid (USAN/INN) USP ...drug classification [BR:br08302] Dermatological Agents Azelaic acid D03034 Azelaic acid (USAN/INN) CAS: 123-...99-9 PubChem: 17397189 DrugBank: DB00548 PDB-CCD: AZ1 LigandBox: D03034 NIKKAJI:

  4. Drug: D03362 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03362 Drug Trafermin (genetical recombination) (JAN); Trafermin (USAN/INN); Fiblas...rmides 269 Miscellaneous 2699 Others D03362 Trafermin (genetical recombination) (JAN); Trafermi

  5. Drug: D08485 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08485 Drug Rizatriptan (INN); Maxalt (TN) C15H19N5 269.164 269.3449 D08485.gif Ant...OUS SYSTEM N02 ANALGESICS N02C ANTIMIGRAINE PREPARATIONS N02CC Selective serotonin (5HT1) agonists N02CC04 Rizatriptan D08485 Rizatri...) 1b/1d Receptor Agonists Rizatriptan D08485 Rizatriptan (INN) Target-based class...ptan [ATC:N02CC04] D08485 Rizatriptan (INN) 5-HT1D-receptor [HSA:3352] [KO:K04153] Rizatriptan... [ATC:N02CC04] D08485 Rizatriptan (INN) CAS: 144034-80-0 PubChem: 9602

  6. Drug: D10291 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10291 Mixture, Drug Aliskiren hemifumarate - amlodipine besylate - hydrochlorothia... amlodipine and hydrochlorothiazide D10291 Aliskiren hemifumarate - amlodipine besylate - hydrochlorothiazide mixt PubChem: 163312322 ...

  7. Drug: D00978 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rocortisone D00978 Hydrocortisone sodium succinate (JP16/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATO...LOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortison...e D00978 Hydrocortisone sodium succinate (JP16/USP) D07X CORTICOSTEROIDS, OTHER C...ium succinate (JP16/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROI...DS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorti

  8. Drug: D06315 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06315 Drug Fluticasone furoate (JAN/USAN/INN); Veramyst (TN) C27H29F3O6S 538.1637 ... nasal agents 1329 Others D06315 Fluticasone furoate (JAN/USAN/INN) Anatomical Th...REPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC17 Fluticasone D06315 Fluticaso...01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD12 Fluticasone furoate D06315 Fluticaso...R OBSTRUCTIVE AIRWAY DISEASES, INHALANTS R03BA Glucocorticoids R03BA05 Fluticasone D06315 Fluticasone furoat

  9. Drug: D07981 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07981 Drug Fluticasone (INN); Fluticaps (TN) C22H27F3O4S 444.1582 444.5076 D07981....TICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC17 Fluticaso...ne D07981 Fluticasone (INN) R RESPIRATORY SYSTEM R01 NASAL P...REPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD08 Fluticasone D07981 Fluticas...E AIRWAY DISEASES, INHALANTS R03BA Glucocorticoids R03BA05 Fluticasone D07981 Fluticaso

  10. Drug: D08413 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D08413 Prednis...RHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolo...TIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D08413 Predniso...lone sodium metazoate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other com...THER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Prednisolone D08413 Prednisolone sodiu

  11. Drug: D00982 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available INFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D00... HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D00982 Prednisolon...ATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D00982 Prednis...olone tebutate (JAN/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combina... RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  12. Drug: D01357 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA04 Betamethasone D01...OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D01357 Betameth...ROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D013...57 Betamethasone valerate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent,...NS FOR TOPICAL USE R01AD Corticosteroids R01AD06 Betamethasone D01357 Betamethaso

  13. Drug: D02156 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D0215...S C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 P...) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids...nate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 ...REPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Pr

  14. Drug: D02032 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...SURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D02032 Betamethasone butyrate propionate (...JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids...rate propionate (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinat...FOR TOPICAL USE R01AD Corticosteroids R01AD06 Betamethasone D02032 Betamethasone

  15. Drug: D02286 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D02286 Betamethasone benzoate (US...OSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D02286 Betamethasone benzoa...te (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC01 ...M R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids...MATORY AGENTS S01BA Corticosteroids, plain S01BA06 Betamethasone D02286 Betametha

  16. Drug: D01510 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC02 Dexamethasone D01510 Dexamethasone m...ENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethas...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately pote..., OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combinations D07XB05 Dexamethasone D015...NTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA03 Dexa

  17. Drug: D01402 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...SSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D01402 Betamethasone acetate (JAN/USP) D ...OIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D01402 Betamethasone acetate (JA...N/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC01 Be...YSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  18. Drug: D03301 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...URES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D03301 Prednisolone valerate acetate (JAN) D... DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids... (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 Pred...RY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  19. Drug: D06700 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 4], (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]) Cold constitution...; Weak constitution; Disorder of menstruation; Dysmenorrhea; Climacteric disturbance Therap

  20. 3D Wire 2015

    DEFF Research Database (Denmark)

    Jordi, Moréton; F, Escribano; J. L., Farias

    This document is a general report on the implementation of gamification in 3D Wire 2015 event. As the second gamification experience in this event, we have delved deeply in the previous objectives (attracting public areas less frequented exhibition in previous years and enhance networking) and ha......, improves socialization and networking, improves media impact, improves fun factor and improves encouragement of the production team....

  1. 3D terrestrisk laserscanning

    DEFF Research Database (Denmark)

    Christoffersen, Morten Thoft

    2004-01-01

    Forfatteren til denne artikel er pr. juni 2004 påbegyndt et ph.d.-studie i terrestrisk laserscanning ved Aalborg Universitet, Institut for Samfundsudvikling og Planlægning. De næste 3 år skal derfor benyttes til forskning inden for dette fagfelt....

  2. Shaping 3-D boxes

    DEFF Research Database (Denmark)

    Stenholt, Rasmus; Madsen, Claus B.

    2011-01-01

    Enabling users to shape 3-D boxes in immersive virtual environments is a non-trivial problem. In this paper, a new family of techniques for creating rectangular boxes of arbitrary position, orientation, and size is presented and evaluated. These new techniques are based solely on position data...

  3. Vann on 3D

    Index Scriptorium Estoniae

    2006-01-01

    Aivar Habakukest, kes on 2005. aastast AS Balteco peadisainer. A. Habakukk AS Balteco tootegruppidest, tööstusdisainist. A. Habakuke projektid, objektid ja tööd. Ill.: värv. foto A. Habakukest, tema disainitud AS Balteco vann Metro

  4. Hybrid R&D

    NARCIS (Netherlands)

    S. Goyal (Sanjeev); A. Konovalov; J.L. Moraga-Gonzalez (José Luis)

    2003-01-01

    textabstractWe develop a model of R&D competition and collaboration in which individual firms carry out independent in-house research and also undertake joint research projects with other firms. We examine the impact of collaboration on in-house research and explore the circumstances under which a h

  5. Vitamin D and Influenza

    Science.gov (United States)

    2008-07-01

    ozone easily filters out Ultra Violet B radiation unless the sun is high enough in the sky. Seasonal variation of 25(OH)D levels Cannell JJ, Vieth R...could be easily measured, and such measurement could guide therapy using UV light or through diet. Acknowledgements Cannell JJ Vieth R Holick MF

  6. Bruno D'Amicis

    Index Scriptorium Estoniae

    2008-01-01

    Bioloogist ja loodusemehest itaalia fotograafist Bruno D'Amicist, kes vaatamata oma noorusele (28), on võtnud ette suuri projekte - Berliini metropolis elutsevate loomade jäädvustamine, Kesk-Euroopa viimase metsiku mägismaa päästmine Slovakkias. Fotod, õigemini keskkonnaportreed on pärit seeriast "Intimate landscapes"

  7. Bruno D'Amicis

    Index Scriptorium Estoniae

    2008-01-01

    Bioloogist ja loodusemehest itaalia fotograafist Bruno D'Amicist, kes vaatamata oma noorusele (28), on võtnud ette suuri projekte - Berliini metropolis elutsevate loomade jäädvustamine, Kesk-Euroopa viimase metsiku mägismaa päästmine Slovakkias. Fotod, õigemini keskkonnaportreed on pärit seeriast "Intimate landscapes"

  8. Course d'Orientation

    CERN Multimedia

    Course d'Orientation

    2012-01-01

      Coupe de printemps La deuxième étape de la coupe de printemps organisée par le club d’orientation du CERN s’est déroulée le samedi 21 avril dans la forêt de Pougny-Challex. étant donné le temps très humide qui domine depuis début avril, les coureurs ne pouvaient trouver qu’un terrain gras et trempé, mais cela fait partie des défis de la course d’orientation. Le parcours technique long a été remporté par Yvan Balliot, CO Annecy en 51:18 devant Jean-Charles Baritaux en 56:21 et Bruno Barge, CO CERN en 59:39. La prochaine CO populaire se courra à Vulbens le samedi 28 avril. Les inscriptions et les départs se feront entre 13h et 15h. A noter les courses en mai : • Samedi 5 mai : Trelex • Samedi 12 mai : Chancy / Valleiry • Samedi 19 mai : Lausan...

  9. Tangible 3D Modelling

    DEFF Research Database (Denmark)

    Hejlesen, Aske K.; Ovesen, Nis

    2012-01-01

    This paper presents an experimental approach to teaching 3D modelling techniques in an Industrial Design programme. The approach includes the use of tangible free form models as tools for improving the overall learning. The paper is based on lecturer and student experiences obtained through facil...

  10. 3D photoacoustic imaging

    Science.gov (United States)

    Carson, Jeffrey J. L.; Roumeliotis, Michael; Chaudhary, Govind; Stodilka, Robert Z.; Anastasio, Mark A.

    2010-06-01

    Our group has concentrated on development of a 3D photoacoustic imaging system for biomedical imaging research. The technology employs a sparse parallel detection scheme and specialized reconstruction software to obtain 3D optical images using a single laser pulse. With the technology we have been able to capture 3D movies of translating point targets and rotating line targets. The current limitation of our 3D photoacoustic imaging approach is its inability ability to reconstruct complex objects in the field of view. This is primarily due to the relatively small number of projections used to reconstruct objects. However, in many photoacoustic imaging situations, only a few objects may be present in the field of view and these objects may have very high contrast compared to background. That is, the objects have sparse properties. Therefore, our work had two objectives: (i) to utilize mathematical tools to evaluate 3D photoacoustic imaging performance, and (ii) to test image reconstruction algorithms that prefer sparseness in the reconstructed images. Our approach was to utilize singular value decomposition techniques to study the imaging operator of the system and evaluate the complexity of objects that could potentially be reconstructed. We also compared the performance of two image reconstruction algorithms (algebraic reconstruction and l1-norm techniques) at reconstructing objects of increasing sparseness. We observed that for a 15-element detection scheme, the number of measureable singular vectors representative of the imaging operator was consistent with the demonstrated ability to reconstruct point and line targets in the field of view. We also observed that the l1-norm reconstruction technique, which is known to prefer sparseness in reconstructed images, was superior to the algebraic reconstruction technique. Based on these findings, we concluded (i) that singular value decomposition of the imaging operator provides valuable insight into the capabilities of

  11. 3D/4D ultrasound registration of bone

    CERN Document Server

    Schers, Jonathan; Daanen, Vincent; Fouard, Céline; Plaskos, Christopher; Kilian, Pascal

    2008-01-01

    This paper presents a method to reduce the invasiveness of Computer Assisted Orthopaedic Surgery (CAOS) using ultrasound. In this goal, we need to develop a method for 3D/4D ultrasound registration. The premilinary results of this study suggest that the development of a robust and ``realtime'' 3D/4D ultrasound registration is feasible.

  12. Energy Efficiency of D2D Multi-User Cooperation.

    Science.gov (United States)

    Zhang, Zufan; Wang, Lu; Zhang, Jie

    2017-03-28

    The Device-to-Device (D2D) communication system is an important part of heterogeneous networks. It has great potential to improve spectrum efficiency, throughput and energy efficiency cooperation of multiple D2D users with the advantage of direct communication. When cooperating, D2D users expend extraordinary energy to relay data to other D2D users. Hence, the remaining energy of D2D users determines the life of the system. This paper proposes a cooperation scheme for multiple D2D users who reuse the orthogonal spectrum and are interested in the same data by aiming to solve the energy problem of D2D users. Considering both energy availability and the Signal to Noise Ratio (SNR) of each D2D user, the Kuhn-Munkres algorithm is introduced in the cooperation scheme to solve relay selection problems. Thus, the cooperation issue is transformed into a maximum weighted matching (MWM) problem. In order to enhance energy efficiency without the deterioration of Quality of Service (QoS), the link outage probability is derived according to the Shannon Equation by considering the data rate and delay. The simulation studies the relationships among the number of cooperative users, the length of shared data, the number of data packets and energy efficiency.

  13. The population genetics of dN/dS.

    Science.gov (United States)

    Kryazhimskiy, Sergey; Plotkin, Joshua B

    2008-12-01

    Evolutionary pressures on proteins are often quantified by the ratio of substitution rates at non-synonymous and synonymous sites. The dN/dS ratio was originally developed for application to distantly diverged sequences, the differences among which represent substitutions that have fixed along independent lineages. Nevertheless, the dN/dS measure is often applied to sequences sampled from a single population, the differences among which represent segregating polymorphisms. Here, we study the expected dN/dS ratio for samples drawn from a single population under selection, and we find that in this context, dN/dS is relatively insensitive to the selection coefficient. Moreover, the hallmark signature of positive selection over divergent lineages, dN/dS>1, is violated within a population. For population samples, the relationship between selection and dN/dS does not follow a monotonic function, and so it may be impossible to infer selection pressures from dN/dS. These results have significant implications for the interpretation of dN/dS measurements among population-genetic samples.

  14. Substitutional 4d and 5d impurities in graphene.

    Science.gov (United States)

    Alonso-Lanza, Tomás; Ayuela, Andrés; Aguilera-Granja, Faustino

    2016-08-21

    We describe the structural and electronic properties of graphene doped with substitutional impurities of 4d and 5d transition metals. The adsorption energies and distances for 4d and 5d metals in graphene show similar trends for the later groups in the periodic table, which are also well-known characteristics of 3d elements. However, along earlier groups the 4d impurities in graphene show very similar adsorption energies, distances and magnetic moments to the 5d ones, which can be related to the influence of the 4d and 5d lanthanide contraction. Surprisingly, within the manganese group, the total magnetic moment of 3 μB for manganese is reduced to 1 μB for technetium and rhenium. We find that compared with 3d elements, the larger size of the 4d and 5d elements causes a high degree of hybridization with the neighbouring carbon atoms, reducing spin splitting in the d levels. It seems that the magnetic adjustment of graphene could be significantly different if 4d or 5d impurities are used instead of 3d impurities.

  15. Drug: D06944 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06944 Formula, Drug Keishikajutsubuto Cinnamon bark [DR:D06712], Peony root [DR:D06739], Jujube [DR:D06758], Atractylodes lancea rhizome [DR:D06752], Glycyrrhiza [DR:D04365], Ginger [DR:D06744], Processed aconite root [DR:D06784] Arthralgia; Neuralgic Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs and Chinese medicine formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06944 Keishikajutsubuto Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for warming the interior Formulas for warming the interior D06944 *Keishikajutsubuto Formulas for dampness Antirheumatic formulas D06944 *Keishikajutsubuto PubChem: 51091286 ...

  16. Exclusive initial-state-radiation production of the D Dmacr , D* Dmacr , and D* Dmacr * systems

    Science.gov (United States)

    Aubert, B.; Karyotakis, Y.; Lees, J. P.; Poireau, V.; Prencipe, E.; Prudent, X.; Tisserand, V.; Garra Tico, J.; Grauges, E.; Lopez, L.; Palano, A.; Pappagallo, M.; Eigen, G.; Stugu, B.; Sun, L.; Battaglia, M.; Brown, D. N.; Kerth, L. T.; Kolomensky, Yu. G.; Lynch, G.; Osipenkov, I. L.; Tackmann, K.; Tanabe, T.; Hawkes, C. M.; Soni, N.; Watson, A. T.; Koch, H.; Schroeder, T.; Asgeirsson, D. J.; Fulsom, B. G.; Hearty, C.; Mattison, T. S.; McKenna, J. A.; Barrett, M.; Khan, A.; Randle-Conde, A.; Blinov, V. E.; Bukin, A. D.; Buzykaev, A. R.; Druzhinin, V. P.; Golubev, V. B.; Onuchin, A. P.; Serednyakov, S. I.; Skovpen, Yu. I.; Solodov, E. P.; Todyshev, K. Yu.; Bondioli, M.; Curry, S.; Eschrich, I.; Kirkby, D.; Lankford, A. J.; Lund, P.; Mandelkern, M.; Martin, E. C.; Stoker, D. P.; Abachi, S.; Buchanan, C.; Atmacan, H.; Gary, J. W.; Liu, F.; Long, O.; Vitug, G. M.; Yasin, Z.; Zhang, L.; Sharma, V.; Campagnari, C.; Hong, T. M.; Kovalskyi, D.; Mazur, M. A.; Richman, J. D.; Beck, T. W.; Eisner, A. M.; Heusch, C. A.; Kroseberg, J.; Lockman, W. S.; Martinez, A. J.; Schalk, T.; Schumm, B. A.; Seiden, A.; Winstrom, L. O.; Cheng, C. H.; Doll, D. A.; Echenard, B.; Fang, F.; Hitlin, D. G.; Narsky, I.; Piatenko, T.; Porter, F. C.; Andreassen, R.; Mancinelli, G.; Meadows, B. T.; Mishra, K.; Sokoloff, M. D.; Bloom, P. C.; Ford, W. T.; Gaz, A.; Hirschauer, J. F.; Nagel, M.; Nauenberg, U.; Smith, J. G.; Wagner, S. R.; Ayad, R.; Soffer, A.; Toki, W. H.; Wilson, R. J.; Feltresi, E.; Hauke, A.; Jasper, H.; Karbach, M.; Merkel, J.; Petzold, A.; Spaan, B.; Wacker, K.; Kobel, M. J.; Nogowski, R.; Schubert, K. R.; Schwierz, R.; Volk, A.; Bernard, D.; Bonneaud, G. R.; Latour, E.; Verderi, M.; Clark, P. J.; Playfer, S.; Watson, J. E.; Andreotti, M.; Bettoni, D.; Bozzi, C.; Calabrese, R.; Cecchi, A.; Cibinetto, G.; Franchini, P.; Luppi, E.; Negrini, M.; Petrella, A.; Piemontese, L.; Santoro, V.; Baldini-Ferroli, R.; Calcaterra, A.; de Sangro, R.; Finocchiaro, G.; Pacetti, S.; Patteri, P.; Peruzzi, I. M.; Piccolo, M.; Rama, M.; Zallo, A.; Contri, R.; Guido, E.; Lo Vetere, M.; Monge, M. R.; Passaggio, S.; Patrignani, C.; Robutti, E.; Tosi, S.; Chaisanguanthum, K. S.; Morii, M.; Adametz, A.; Marks, J.; Schenk, S.; Uwer, U.; Bernlochner, F. U.; Klose, V.; Lacker, H. M.; Bard, D. J.; Dauncey, P. D.; Tibbetts, M.; Behera, P. K.; Chai, X.; Charles, M. J.; Mallik, U.; Cochran, J.; Crawley, H. B.; Dong, L.; Meyer, W. T.; Prell, S.; Rosenberg, E. I.; Rubin, A. E.; Gao, Y. Y.; Gritsan, A. V.; Guo, Z. J.; Arnaud, N.; Béquilleux, J.; D'Orazio, A.; Davier, M.; da Costa, J. Firmino; Grosdidier, G.; Le Diberder, F.; Lepeltier, V.; Lutz, A. M.; Pruvot, S.; Roudeau, P.; Schune, M. H.; Serrano, J.; Sordini, V.; Stocchi, A.; Wormser, G.; Lange, D. J.; Wright, D. M.; Bingham, I.; Burke, J. P.; Chavez, C. A.; Fry, J. R.; Gabathuler, E.; Gamet, R.; Hutchcroft, D. E.; Payne, D. J.; Touramanis, C.; Bevan, A. J.; Clarke, C. K.; di Lodovico, F.; Sacco, R.; Sigamani, M.; Cowan, G.; Paramesvaran, S.; Wren, A. C.; Brown, D. N.; Davis, C. L.; Denig, A. G.; Fritsch, M.; Gradl, W.; Hafner, A.; Alwyn, K. E.; Bailey, D.; Barlow, R. J.; Jackson, G.; Lafferty, G. D.; West, T. J.; Yi, J. I.; Anderson, J.; Chen, C.; Jawahery, A.; Roberts, D. A.; Simi, G.; Tuggle, J. M.; Dallapiccola, C.; Salvati, E.; Saremi, S.; Cowan, R.; Dujmic, D.; Fisher, P. H.; Henderson, S. W.; Sciolla, G.; Spitznagel, M.; Yamamoto, R. K.; Zhao, M.; Patel, P. M.; Robertson, S. H.; Schram, M.; Lazzaro, A.; Lombardo, V.; Palombo, F.; Stracka, S.; Bauer, J. M.; Cremaldi, L.; Godang, R.; Kroeger, R.; Summers, D. J.; Zhao, H. W.; Simard, M.; Taras, P.; Nicholson, H.; de Nardo, G.; Lista, L.; Monorchio, D.; Onorato, G.; Sciacca, C.; Raven, G.; Snoek, H. L.; Jessop, C. P.; Knoepfel, K. J.; Losecco, J. M.; Wang, W. F.; Corwin, L. A.; Honscheid, K.; Kagan, H.; Kass, R.; Morris, J. P.; Rahimi, A. M.; Regensburger, J. J.; Sekula, S. J.; Wong, Q. K.; Blount, N. L.; Brau, J.; Frey, R.; Igonkina, O.; Kolb, J. A.; Lu, M.; Rahmat, R.; Sinev, N. B.; Strom, D.; Strube, J.; Torrence, E.; Castelli, G.; Gagliardi, N.; Margoni, M.; Morandin, M.; Posocco, M.; Rotondo, M.; Simonetto, F.; Stroili, R.; Voci, C.; Del Amo Sanchez, P.; Ben-Haim, E.; Briand, H.; Chauveau, J.; Hamon, O.; Leruste, Ph.; Ocariz, J.; Perez, A.; Prendki, J.; Sitt, S.; Gladney, L.; Biasini, M.; Manoni, E.; Angelini, C.; Batignani, G.; Bettarini, S.; Calderini, G.; Carpinelli, M.; Cervelli, A.; Forti, F.; Giorgi, M. A.; Lusiani, A.; Marchiori, G.; Morganti, M.; Neri, N.; Paoloni, E.; Rizzo, G.; Walsh, J. J.; Pegna, D. Lopes; Lu, C.; Olsen, J.; Smith, A. J. S.; Telnov, A. V.; Anulli, F.; Baracchini, E.; Cavoto, G.; Faccini, R.; Ferrarotto, F.; Ferroni, F.; Gaspero, M.; Jackson, P. D.; Gioi, L. Li; Mazzoni, M. A.; Morganti, S.; Piredda, G.; Renga, F.

    2009-05-01

    We perform a study of the exclusive production of D Dmacr , D* Dmacr , and D* Dmacr * in initial-state-radiation events, from e+e- annihilations at a center-of-mass energy near 10.58 GeV, to search for charmonium and possible new resonances. The data sample corresponds to an integrated luminosity of 384fb-1 and was recorded by the BABAR experiment at the PEP-II storage rings. The D Dmacr , D* Dmacr , and D* Dmacr * mass spectra show clear evidence of several ψ resonances. However, there is no evidence for Y(4260)→D* Dmacr or Y(4260)→D* Dmacr *.

  17. D and D Knowledge Management Information Tool - 2012 - 12106

    Energy Technology Data Exchange (ETDEWEB)

    Upadhyay, H.; Lagos, L.; Quintero, W.; Shoffner, P. [Applied Research Center, Florida International University, Miami. FL 33174 (United States); DeGregory, J. [Office of D and D and Facility Engineering, Environmental Management, Department of Energy (United States)

    2012-07-01

    Deactivation and decommissioning (D and D) work is a high priority activity across the Department of Energy (DOE) complex. Subject matter specialists (SMS) associated with the different ALARA (As-Low-As-Reasonably-Achievable) Centers, DOE sites, Energy Facility Contractors Group (EFCOG) and the D and D community have gained extensive knowledge and experience over the years in the cleanup of the legacy waste from the Manhattan Project. To prevent the D and D knowledge and expertise from being lost over time from the evolving and aging workforce, DOE and the Applied Research Center (ARC) at Florida International University (FIU) proposed to capture and maintain this valuable information in a universally available and easily usable system. D and D KM-IT provides single point access to all D and D related activities through its knowledge base. It is a community driven system. D and D KM-IT makes D and D knowledge available to the people who need it at the time they need it and in a readily usable format. It uses the World Wide Web as the primary source for content in addition to information collected from subject matter specialists and the D and D community. It brings information in real time through web based custom search processes and its dynamic knowledge repository. Future developments include developing a document library, providing D and D information access on mobile devices for the Technology module and Hotline, and coordinating multiple subject matter specialists to support the Hotline. The goal is to deploy a high-end sophisticated and secured system to serve as a single large knowledge base for all the D and D activities. The system consolidates a large amount of information available on the web and presents it to users in the simplest way possible. (authors)

  18. 2D vs. 3D mammography observer study

    Science.gov (United States)

    Fernandez, James Reza F.; Hovanessian-Larsen, Linda; Liu, Brent

    2011-03-01

    Breast cancer is the most common type of non-skin cancer in women. 2D mammography is a screening tool to aid in the early detection of breast cancer, but has diagnostic limitations of overlapping tissues, especially in dense breasts. 3D mammography has the potential to improve detection outcomes by increasing specificity, and a new 3D screening tool with a 3D display for mammography aims to improve performance and efficiency as compared to 2D mammography. An observer study using a mammography phantom was performed to compare traditional 2D mammography with this ne 3D mammography technique. In comparing 3D and 2D mammography there was no difference in calcification detection, and mass detection was better in 2D as compared to 3D. There was a significant decrease in reading time for masses, calcifications, and normals in 3D compared to 2D, however, as well as more favorable confidence levels in reading normal cases. Given the limitations of the mammography phantom used, however, a clearer picture in comparing 3D and 2D mammography may be better acquired with the incorporation of human studies in the future.

  19. O Poeta D. Dinis

    OpenAIRE

    Esteves, Elisa

    2011-01-01

    D. Dinis foi um poeta tardio dentro da tradição trovadoresca galego – portuguesa, mas essa condição não implica que a sua poesia apresente marcas de decadência ou esgotamento dos respectivos códigos poéticos. Pelo contrário, o que constatamos é uma capacidade de renovação do cânone e uma recepção muito criativa de temas e formas poéticas da poesia trovadoresca extra-peninsular, que ele também conhecia. Entre a tradição e a renovação, o poeta D. Dinis avulta como o grande representante por...

  20. Sony D-Eight

    CERN Multimedia

    1987-01-01

    The 8mm backup format is a format for storing magnetic tape data used in computer systems, launched by Exabyte Corporation. It is also known as Data8, often abbreviated to D8 and writes D-Eight on some Sony brand media. The company was formed in order to take the 8 mm video format and make it suitable for data storage. They did this by building a mechanism and a reliable data format that used the common 8 mm video tape technology that was available at the time. This was the first form of helical scanning used commercially for data storage. The ribbon was made vertically and has a length of 112 meters. It was designed to withstand heat and high temperatures. It has been introduced in at CERN in 1994.

  1. D-Moduli Stabilization

    CERN Document Server

    Giedt, J

    2002-01-01

    The matter sector of four-dimensional effective supergravity models obtained from the weakly coupled heterotic string contains many moduli. In particular, flat directions of the D-term part of the scalar potential in the presence of an anomalous U(1) give rise to massless chiral multiplets which have been referred to elsewhere as D-moduli. The stabilization of these moduli is necessary for the determination of the large vacuum expectation values of complex scalar fields induced by the corresponding Fayet-Illiopoulos term. This stabilization is of phenomenological importance since these background values determine the effective theory below the scale of the anomalous U(1) symmetry breaking. In some simple models we illustrate the stabilization of these moduli due to the nonperturbative dynamics associated with gaugino condensation in a hidden sector. We find that background field configurations which are stable above the condensation scale no longer represent global minima once dynamical supersymmetry breaking...

  2. Drug: D01583 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01583 Drug Pirfenidone (JAN/USAN/INN); Esbriet (TN) C12H11NO 185.0841 185.2218 D01...ts affecting metabolism 399 Miscellaneous 3999 Others D01583 Pirfenidone (JAN/USA...NG AGENTS L04 IMMUNOSUPPRESSANTS L04A IMMUNOSUPPRESSANTS L04AX Other immunosuppressants L04AX05 Pirfenidone D01583 Pirfenidone

  3. Drug: D06970 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06970 Formula, Drug Jiinkokato Japanese angelica root [DR:D06768], Peony root [DR:...ormulas Formulas for replenishing Ying Formulas for replenishing Ying D06970 Jiinkokato PubChem: 51091312 ... ... medicines D06970 Jiinkokato Traditional Chinese Medicine in Japan [BR:br08304] F...ine formulations 52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese

  4. Drug: D08137 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08137 Drug Lithium sulfate; Lithionit (TN) SO4. 2Li 109.9837 109.9446 D08137.gif A...SYSTEM N05 PSYCHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D08137 Lithium sulfate USP drug c...lassification [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D08137 Lithium

  5. Drug: D04750 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04750 Drug Lithium hydroxide (USP) LiHO. H2O 42.0293 41.9636 D04750.gif Antimanic ...CHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D04750 Lithium hydroxide (USP) USP drug classif...ication [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D04750 Lithium hydro

  6. Drug: D08136 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08136 Drug Lithium gluconate; Lithioderm (TN) C6H11O7. Li 202.0665 202.0883 D08136...RVOUS SYSTEM N05 PSYCHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D08136 Lithium gluconate US...P drug classification [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D08136 Lithium

  7. Drug: D02740 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available la (TN); Oraqix (TN); Lidocaine and prilocaine (TN) Lidocaine [DR:D00358], Prilocaine [DR:D00553] Anesthetic...ripheral nervous system 121 Local anesthetics 1219 Others D02740 Lidocaine - prilocaine mixt Anatomical Ther...01BB54 Prilocaine, combinations D02740 Lidocaine - prilocaine mixt USP drug classification [BR:br08302] Anesthetics Local Anesthetic

  8. Drug: D00545 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00545 Drug Isoflurane (JP16/USP/INN); Forane (TN) C3H2ClF5O 183.9714 184.4924 D00545.gif Anesthetic...l nervous system 111 General anesthetics 1114 Ethers D00545 Isoflurane (JP16/USP/INN) 1119 Others D00545 Iso

  9. Drug: D00102 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00102 Drug Nitrous oxide (JP16/USP); Nitrous oxide (TN) N2O 44.0011 44.0128 D00102.gif Anesthetic...entral nervous system 111 General anesthetics 1116 Nitrous oxides D00102 Nitrous ...THETICS N01A ANESTHETICS, GENERAL N01AX Other general anesthetics N01AX13 Nitrous oxide D00102 Nitrous oxide

  10. Drug: D10195 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10195 Drug Luseogliflozin hydrate (JAN) C23H30O6S. xH2O D10195.gif Antidiabetic [D...get-based classification of drugs [BR:br08310] Transporters Solute carrier family SLC5 SLC5A2 [HSA:6524] [KO:K14382] Luseogliflozin... D10195 Luseogliflozin hydrate (JAN) PubChem: 135626913 Li

  11. Drug: D04699 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04699 Mixture, Drug Hydrocortisone - fradiomycin sulfate - dibucaine hydrochloride... - esculoside mixt; Proctosedyl (TN) Hydrocortisone [DR:D00088], Fradiomycin sulfate [DR:D01618], Dibucaine ...organ agents 255 Hemorrhoidal preparations 2559 Others D04699 Hydrocortisone - fradiomycin sulfate - dibucaine hydrochloride - esculoside mixt PubChem: 17398142 ...

  12. Drug: D04776 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04776 Mixture, Drug Oxytetracycline hydrochloride - hydrocortisone mixt; Terra Cor...tril (TN) Oxytetracycline hydrochloride [DR:D01596], Hydrocortisone [DR:D00088] Therapeutic category: 2647 T...and adrenocorticotropic hormone mixtures D04776 Oxytetracycline hydrochloride - hydrocortisone mixt PubChem: 17398163 ...

  13. Drug: D07053 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07053 Formula, Drug Ryutanshakanto Japanese angelica root [DR:D06768], Rehmannia r... medicines D07053 Ryutanshakanto Traditional Chinese Medicine in Japan [BR:br0830...4] Formulas Formulas for clearing heat Formulas for clearing heat D07053 Ryutanshakanto PubChem: 51091395 ...

  14. Drug: D00104 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ing sensory organs 131 Ophthalmic agents 1317 Ophthalmic antibiotics D00104 Chloramphenicol (JP16/USP/INN) 1...32 Otic and nasal agents 1325 Otolaryngologic antibiotics D00104 Chloramphenicol ...ERAPEUTICS FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiotics

  15. Drug: D02204 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02204 Drug Hexamethonium bromide (JAN/INN); Hexamethonium bromide (TN) C12H30N2. 2Br 360.0776 362.188 D0220...1139 55584 57053 1141 1142 1143] Hexamethonium D02204 Hexamethonium bromide (JAN/INN) CAS: 55-97-0 PubChem: 7849264 LigandBox: D0220

  16. Drug: D05165 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tozoal [Histomonas, for poultry] CAS: 5579-89-5 PubChem: 47206889 LigandBox: D05165 NIKKAJI: J8.000D ATOM 16...D05165 Drug Nifursemizone (USAN/INN) C8H10N4O4 226.0702 226.1894 D05165.gif Antipro

  17. Drug: D01046 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available aniline chloride; Crystal violet; Genapax (TN) C25H30N3. Cl 407.2128 407.9788 D01046.gif Anti-infective, topica...TOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D01AE02 Methylrosanil

  18. Drug: D00739 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ) C17H27NO3. HCl 329.1758 329.8621 D00739.gif Anesthetic [topical] ATC code: C05AD07 D04AB07 Anatomical Ther...HISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topica

  19. Drug: D01768 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available oxil (TN) C17H28N2O3. HCl 344.1867 344.8768 D01768.gif Anesthetic [topical] Therapeutic category: 1313 ATC c...ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB03 Oxybuprocaine D01768 Oxybuprocai

  20. Drug: D05352 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 515], Water [DR:D00001] Therapeutic category: 3311 0.9% Sodium chloride [DR:D02056] solution Therapeutic cat...JP16) USP drug classification [BR:br08302] Therapeutic Nutrients/Minerals/Electrolytes Electrolyte/Mineral R...D05352 Mixture, Drug Isotonic sodium chloride solution (JP16) Nitroglycerin [DR:D00

  1. Drug: D00669 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cellular function 44 Allergic agents 441 Antihistamines 4411 Diphenhydramines D00...TIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topical use D04AA32 Diph...ticholinergics Diphenhydramine D00669 Diphenhydramine hydrochloride (JP16/USP) Respiratory Tract/Pulmonary Agents Antihistamine

  2. Drug: D03535 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topical use D04AA14 Cl...(USAN) USP drug classification [BR:br08302] Respiratory Tract/Pulmonary Agents Antihistamines Clemastine D03

  3. Drug: D03360 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 26 Epidermides 264 Analgesics, anti-itchings, astringents, anti-inflammatory agents 2642 Antihistamine...ICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamine... Tract/Pulmonary Agents Antihistamines Diphenhydramine D03360 Diphenhydramine laurylsulfate (JAN) Target-bas...Antiparkinson Agents Anticholinergics Diphenhydramine D03360 Diphenhydramine laurylsulfate (JAN) Respiratory

  4. Drug: D04810 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04810 Drug Potash soap (JP16); Potash soap (TN) Therapeutic category: 2359 2662 26...an agents 235 Purgatives, clysters 2359 Others D04810 Potash soap (JP16) 26 Epidermides 266 Emollients 2662 ...Alkaline agents D04810 Potash soap (JP16) 269 Miscellaneous 2699 Others D04810 Potash soap (JP16) PubChem: 17398179 ...

  5. Drug: D04692 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04692 Mixture, Drug Diflucortolone valerate - Lidocaine mixt; Neriproct (TN) Diflu...cortolone valerate [DR:D01764], Lidocaine [DR:D00358] Therapeutic category: 2559 Therapeutic category of dru...hoidal preparations 2559 Others D04692 Diflucortolone valerate - Lidocaine mixt PubChem: 17398140 ...

  6. Drug: D04934 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available utic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANT...e D04934 Mercury, ammoniated (USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECTIVES S01AX Other an

  7. Drug: D02393 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available l (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS...cinol D02393 Resorcinol monoacetate (USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECTIVES S01AX O

  8. Drug: D08152 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e [EC:3.2.1.17] Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D06 ANTI...BIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BB Antivirals

  9. Drug: D00036 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00036 Drug Nicotinamide (JP16/INN); Niacinamide (USP) C6H6N2O 122.048 122.1246 D00... 3132 Nicotinic acids D00036 Nicotinamide (JP16/INN); Niacinamide (USP) Anatomica... OTHER PLAIN VITAMIN PREPARATIONS A11HA Other plain vitamin preparations A11HA01 Nicotinamide D00036 Nicotinamide (JP16/INN); Niacin

  10. Drug: D08582 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08582 Drug Thiamphenicol glycinate acetylcysteinate; Fluimucil antibiotic (TN) C19...CTERIALS FOR SYSTEMIC USE J01B AMPHENICOLS J01BA Amphenicols J01BA02 Thiamphenicol D08582 Thiamphenicol glycinate acetylcystein...02] D08582 Thiamphenicol glycinate acetylcysteinate CAS: 75639-30-4 PubChem: 96025266 LigandBox: D08582 NIKK

  11. Drug: D08698 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08698 Mixture, Drug Platycodon fluidextract - plantago herb extract - peony root e...xtract mixt; Opisezol A (TN) Platycodon fluidextract [DR:D06812], Plantago herb extract [DR:D04333], Peony r...expectorants 2249 Others D08698 Platycodon fluidextract - plantago herb extract - peony root extract mixt PubChem: 96025381 ...

  12. Drug: D09393 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available sification [BR:br08302] Dermatological Agents Ingenol mebutate D09393 Ingenol mebutate (USAN) CAS: 75567-37-...ICAL USE D06BX Other chemotherapeutics D06BX02 Ingenol mebutate D09393 Ingenol mebutate (USAN) USP drug clas

  13. Drug: D08302 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08302 Drug Ornithine (INN) C5H12N2O2 132.0899 132.161 D08302.gif Hepatic protectan...t Same as: C00077 CAS: 70-26-8 PubChem: 96024989 PDB-CCD: ORN LigandBox: D08302 NIKKAJI: J9.177D ATOM 9 1 C1

  14. Drug: D08304 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08304 Drug Orotic acid calcium salt; Calciumorotat (TN) (C5H3N2O4)2. Ca 349.9812 350.2546 D0830...4.gif Hepatic protectant; Uricosuric See Orotic acid [DR:D00055] CAS: 22454-86-0 PubChem: 96024991 LigandBox: D0830

  15. Drug: D01277 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01277 Drug Droxidopa (JP16/INN); Dops (TN) C9H11NO5 213.0637 213.1873 D01277.gif Antiparkinson...ian [DS:H00057] Therapeutic category: 1169 precursor of Norepinephrine [DR:D00076] map07057 Antiparkinson...d sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian

  16. Drug: D04406 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04406 Mixture, Drug Dioctyl sodium sulfosuccinate - casanthranol mixt; Vemas S (TN...) Dioctyl sodium sulfosuccinate [DR:D00305], Casanthranol [DR:D03417] Therapeutic category: 2359 Therapeutic...Purgatives, clysters 2359 Others D04406 Dioctyl sodium sulfosuccinate - casanthranol mixt PubChem: 17398095 ...

  17. Drug: D02263 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available idin NR (TN) Codeine phosphate [DR:D02101], Guaifenesin [DR:D00337] Expectorant ATC code: R05FA02 Mixture of... Codeine phosphate [DR:D02101] and Guaifenesin [DR:D00337] Anatomical Therapeutic Chemical (ATC) classificat

  18. Drug: D04466 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04466 Mixture, Drug Mestranol - lynestrenol mixt; Lo-Lyndiol (TN) Mestranol [DR:D00575], Lynestren..., fixed combinations G03FA07 Lynestrenol and estrogen D04466 Mestranol - lynestrenol mixt G03FB Progestogens... and estrogens, sequential preparations G03FB02 Lynestrenol and estrogen D04466 Mestranol - lynestrenol mixt PubChem: 17398119 ...

  19. Drug: D03369 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03369 Drug Capobenic acid (USAN/INN) C16H23NO6 325.1525 325.3569 D03369.gif Cardiac depressant [anti-arrhyt...hmic] CAS: 21434-91-3 PubChem: 17397518 LigandBox: D03369 NIKKAJI: J10.782D ATOM 23

  20. Drug: D07894 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07894 Drug Encainide (INN) C22H28N2O2 352.2151 352.4699 D07894.gif Antiarrhythmic ...1] Enzyme: CYP2D6 [HSA:1565] map07037 Antiarrhythmic drugs Anatomical Therapeutic..., CLASS I AND III C01BC Antiarrhythmics, class Ic C01BC08 Encainide D07894 Encainide (INN) Target-based clas

  1. Drug: D07081 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07081 Drug Penthienate bromide (NF XIII) C18H30NO3S. Br 419.113 420.4047 D07081.gi...Penthienate D07081 Penthienate bromide (NF XIII) CAS: 60-44-6 PubChem: 51091423 LigandBox: D07081 NIKKAJI: J

  2. Drug: D10256 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10256 Mixture, Drug Albuterol sulfate - ipratropium bromide mixt; Combivent (TN) S...albutamol sulfate [DR:D00683], Ipratropium bromide hydrate [DR:D02212] Treatment of COPD (Chronic obstructiv...ALANTS R03AL Adrenergics in combination with anticholinergics R03AL02 Salbutamol and ipratropium bromide D10256 Albuterol sulfate - ipratropium bromide mixt PubChem: 163312287 ...

  3. Drug: D10208 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10208 Mixture, Drug Dextromethorphan hydrobromide and quinidine sulfate; Nuedexta ...(TN) Dextromethorphan hydrobromide hydrate [DR:D00848], Quinidine sulfate hydrate [DR:D02272] ATC code: N07X...ons D10208 Dextromethorphan hydrobromide and quinidine sulfate USP drug classific...0208 Dextromethorphan hydrobromide and quinidine sulfate PubChem: 163312239 ...

  4. Drug: D05730 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05730 Drug Rimiterol hydrobromide (USAN) C12H17NO3. HBr 303.047 304.1802 D05730.gi...terol D05730 Rimiterol hydrobromide (USAN) Target-based classification of drugs [...K04142] Rimiterol [ATC:R03AC05] D05730 Rimiterol hydrobromide (USAN) CAS: 31842-61-2 PubChem: 47207391 Ligan

  5. Drug: D08769 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08769 Mixture, Drug Diphenhydramine hydrochloride - calcium bromide mixt; Rescalmi...n (TN) Diphenhydramine hydrochloride [DR:D00669], Calcium bromide [DR:D01723] Therapeutic category: 4419 The... Antihistamines 4419 Others D08769 Diphenhydramine hydrochloride - calcium bromide mixt PubChem: 96025452 ...

  6. Drug: D10298 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available S01ED Beta blocking agents S01ED51 Timolol, combinations D10298 Brimonidine tartrate - timolol maleate mixt PubChem: 163312329 ... ...D10298 Mixture, Drug Brimonidine tartrate - timolol maleate mixt; Combigan (TN) Bri...monidine tartrate [DR:D02076], Timolol maleate [DR:D00603] Treatment of glaucoma, ocular hypertension ATC co

  7. Drug: D03620 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available staminic CAS: 5781-37-3 PubChem: 47205874 LigandBox: D03620 NIKKAJI: J244.730D ATOM...D03620 Drug Cycliramine maleate (USAN); Prolergic (TN) C18H19ClN2. C4H4O4 414.1346 414.882 D03620.gif Antihi

  8. Drug: D05246 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05246 Drug Olmesartan (USAN/INN) C24H26N6O3 446.2066 446.5016 D05246.gif Treatment...vascular Agents Angiotensin II Receptor Antagonists Olmesartan D05246 Olmesartan ...giotensin angiotensin II stimulates angiotensin subtype 1 (AT1) receptor [HSA:185] [KO:K04166] Olmesartan D05246 Olmesa

  9. Drug: D00122 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available H2O 418.3447 418.6523 D00122.gif Regulator [calcium] ATC code: A11CC06 Vitamin D analogue Anatomical Therap... A AND D, INCL. COMBINATIONS OF THE TWO A11CC Vitamin D and analogues A11CC06 Cal

  10. Drug: D04412 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04412 Mixture, Drug Compound iodine glycerin (JP16); Lugol (TN) Iodine [DR:D00108]...s 2399 Others D04412 Compound iodine glycerin (JP16) 27 Dental preparations 279 M...iscellaneous 2790 Miscellaneous D04412 Compound iodine glycerin (JP16) PubChem: 17398098 ...

  11. Drug: D09046 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09046 Formula, Drug Hokikenchuto Ginseng [DR:D06772], (Atractylodes lancea rhizome...R:D06775] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09046 Hokikenchuto PubChem: 96025727 ...

  12. Drug: D09060 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09060 Formula, Drug Kamiheiisan (Atractylodes lancea rhizome [DR:D06752] | Atracty...10], Crataegi fructus [DR:D06904] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for dampness Formulas for resolving dampness D09060 Kamiheiisan PubChem: 96025741 ...

  13. Drug: D09057 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09057 Formula, Drug Kamiuntanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D... Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09057 Kamiuntanto PubChem: 96025738 ...

  14. Drug: D09042 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09042 Formula, Drug Untanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D0678...tional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09042 Untanto PubChem: 96025724 ...

  15. Drug: D09044 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09044 Formula, Drug Hohaito Ophiopogon tuber [DR:D06775], Schisandra fruit [DR:D06...ssilago farfara flower bud [ED:E00345], Ginger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  16. Drug: D06951 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06951 Formula, Drug Keishakuchimoto Cinnamon bark [DR:D06712], Anemarrhena rhizome...tional Chinese medicines 5200 Traditional Chinese medicines D06951 Keishakuchimoto Traditional Chinese Medic...ine in Japan [BR:br08304] Formulas Formulas for dampness Antirheumatic formulas D06951 Keishakuchimoto PubChem: 51091293 ...

  17. Drug: D06500 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06500 Crude, Drug Orange peel tincture (JP16); Orange peel tincture, sweet (NF); D...estives 2333 Bitter agents D06500 Orange peel tincture (JP16); Orange peel tincture, sweet (NF) Crude drugs ...[BR:br08305] Dicot plants: rosids Rutaceae (rue family) D06500 Orange peel tincture PubChem: 47208156 ...

  18. Drug: D09051 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09051 Formula, Drug Oren'akyoto Coptis rhizome [DR:D00092], Peony root [DR:D06739]...08304] Formulas Formulas for replenishing Ying Formulas for replenishing Ying D09051 Oren'akyoto PubChem: 96025732 ...

  19. Drug: D00196 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00196 Drug Physostigmine (USP); Eserine (TN) C15H21N3O2 275.1634 275.3461 D00196.g... D00196 Physostigmine (USP) CAS: 57-47-6 PubChem: 7847264 DrugBank: DB00981 LigandBox: D00196 NIKKAJI: J4.57

  20. Drug: D05074 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05074 Drug Monoethanolamine (NF) C2H7NO 61.0528 61.0831 D05074.gif Pharmaceutic ai...d [surfactant] Same as: C00189 CAS: 141-43-5 PubChem: 47206801 DrugBank: DB03994 PDB-CCD: ETA LigandBox: D05